Page last updated: 2024-11-04

thioridazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Thioridazine: A phenothiazine antipsychotic used in the management of PHYCOSES, including SCHIZOPHRENIA. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

thioridazine : A phenothiazine derivative having a methylsulfanyl subsitituent at the 2-position and a (1-methylpiperidin-2-yl)ethyl] group at the N-10 position. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID5452
CHEMBL ID479
CHEBI ID9566
SCHEMBL ID9566
SCHEMBL ID12434241
MeSH IDM0021377

Synonyms (166)

Synonym
gtpl100
10h-phenothiazine, 10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylthio)-
phenothiazine, 10-[2-(1-methyl-2-piperidyl)ethyl]-2-(methylthio)-
DIVK1C_000066
KBIO1_000066
tp-21
mellaril
melleril
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylthio)-10h-phenothiazine
SPECTRUM_001066
BSPBIO_002030
BPBIO1_000325
thioridazinum [inn-latin]
phenothiazine, 10-((1-methyl-2-piperidyl)ethyl)-2-(methylthio)-
melleryl
einecs 200-044-2
hsdb 3189
ai3-51923
10-(2-(1-methyl-2-piperidyl)ethyl)-2-(methylthio)phenothiazine
tioridazina [inn-spanish]
melleril (liquid)
dl-thioridazine
(+-)-thioridazine
thioridazine prolongatum
BPBIO1_001175
PRESTWICK2_000078
IDI1_000066
CMAP_000015
BIOMOL-NT_000017
PRESTWICK3_000078
BSPBIO_000295
SPECTRUM5_001062
LOPAC0_001252
AB00053553
10h-phenothiazine, 10-(2-(1-methyl-2-piperidinyl)ethyl)-2-(methylthio)-
10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine
mellaril (*hydrochloride*)
thioridazine
50-52-2
thioxidazine
3-methylmercapto-n-(2'-(n-methyl-2-piperidyl)ethyl)phenothiazine
2-methylmercapto-10-(2-(n-methyl-2-piperidyl)ethyl)phenothiazine
DB00679
thioridazin
thioridazine (usp/inn)
mellaril-s (tn)
D00373
NCGC00089809-03
KBIO2_004876
KBIO3_001530
KBIO2_004114
KBIO2_006682
KBIOGR_000791
KBIOGR_002308
KBIO2_002308
KBIO2_001546
KBIO3_002788
KBIOSS_002310
KBIO2_007444
KBIOSS_001546
SPECTRUM2_001332
PRESTWICK0_000078
SPBIO_002216
SPECTRUM3_000585
SPECTRUM4_000356
SPBIO_001483
NINDS_000066
PRESTWICK1_000078
NCGC00089809-02
thiozine
sonapax
melleretten
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10h-phenothiazine
mellerets
malloryl
tioridazina
CHEBI:9566 ,
thioridazinum
orsanil
mellerette
mellaril-s
meleril
mallorol
HMS2090J04
NCGC00016059-10
L001321
novoridazine
thioril
CHEMBL479 ,
(thioridazine)10-[2-(1-methyl-piperidin-2-yl)-ethyl]-2-methylsulfanyl-10h-phenothiazine
10-[2-(1-methyl-piperidin-2-yl)-ethyl]-2-methylsulfanyl-10h-phenothiazine
bdbm50002338
10-(2-(1-methylpiperidin-2-yl)ethyl)-2-(methylthio)-10h-phenothiazine
10-[2-(1-methyl-piperidin-2-yl)-ethyl]-2-methylsulfanyl-10h-phenothiazine (thioridazine)
10-[2-(1-methylpiperidin-2-yl)ethyl]-2-methylsulfanylphenothiazine
NCGC00016059-05
dtxsid6023656 ,
tox21_110294
dtxcid403656
cas-50-52-2
CCG-205326
NCGC00016059-04
NCGC00016059-08
NCGC00016059-09
NCGC00016059-07
NCGC00016059-11
NCGC00016059-03
mellarit
thioridazine, prolongatum
unii-n3d6tg58ni
n3d6tg58ni ,
thioridazine [usan:usp:inn:ban]
NCGC00016059-14
thioridazine [orange book]
thioridazine [mart.]
(+/-)-thioridazine
thioridazine [hsdb]
10-[2-(1-methyl-2-piperidyl)ethyl]-2-(methylthio)phenothiazine
thioridazine [mi]
thioridazine [ep monograph]
thioridazine [usp monograph]
thioridazine [inn]
thioridazine [usan]
thioridazine [usp-rs]
thioridazine [who-dd]
thioridazine [vandf]
NS-835
SCHEMBL9566
NCGC00016059-13
tox21_110294_1
AB00053553-16
mellaril (salt/mix)
(.+/-.)-thioridazine
10h-phenothiazine, 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylthio-
KLBQZWRITKRQQV-UHFFFAOYSA-N
10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylsulfanyl)-10h-phenothiazine #
SCHEMBL12434241
AB00053553_17
AB00053553_18
10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylsulfanyl)-10h-phenothiazine
SBI-0051219.P004
BCP19922
107388-89-6
Q58375
BRD-A84481105-003-17-2
SDCCGSBI-0051219.P005
NCGC00016059-24
malloryl; meleril; mellaril s; mellerets
10-[2-(1-methyl-2-piperidinyl)ethyl]-2-(methylthio)-10h-phenothiazine
D94995
AS-77485
CS-0013830
EN300-708788
HY-B0965A
ps13 - thioridazine
thioridazine (usp-rs)
thioridazine (ep monograph)
10-(2-(1-methyl-2-piperidyl)ethyl)-2-methylsulfanyl-phenothiazine
thioridazine (usp monograph)
tp 21
thioridazine (mart.)
phenothiazine, 10-(2-(1-methyl-2-piperidyl)ethyl)-2-(methylthio)-
10-(2-(1-methylpiperidin-2-yl)ethyl)-2-(methylsulfanyl)-10h-phenothiazine
3-methylmercapto-n-
n05ac02
2-methylmercapto-10-(2-n-methyl-2-piperidyl)ethyl)phenothiazine

Research Excerpts

Overview

Thioridazine is an antipsychotic that has been shown to induce cell death and inhibit self-renewal in a broad spectrum of cancer cells. It is a well-known dopamine-antagonist drug with a wide range of pharmacological properties ranging from neuroleptic to antimicrobial.

ExcerptReferenceRelevance
"Thioridazine (THIO) is a phenothiazine derivative that is mainly used for the treatment of psychotic disorders. "( Thioridazine Induces Cardiotoxicity via Reactive Oxygen Species-Mediated hERG Channel Deficiency and L-Type Calcium Channel Activation.
Ding, Y; Fan, P; Guo, J; Li, B; Li, M; Li, Y; Liu, Y; Wang, F; Xu, X; Yan, C; Zhang, Y, 2020
)
3.44
"Thioridazine is an antipsychotic that has been shown to induce cell death and inhibit self-renewal in a broad spectrum of cancer cells. "( Thioridazine inhibits self-renewal in breast cancer cells via DRD2-dependent STAT3 inhibition, but induces a G
Baldwin, AS; Fan, C; Tegowski, M, 2018
)
3.37
"Thioridazine (THD) is a common phenothiazine antipsychotic drug reported to suppress growth in several types of cancer cells. "( Thioridazine Enhances P62-Mediated Autophagy and Apoptosis Through Wnt/β-Catenin Signaling Pathway in Glioma Cells.
Cheng, HW; Cheng, JT; Cheng, TS; Chiou, SJ; Chou, CH; Chu, CW; Hong, YR; Huang, CF; Ko, HJ; Lai, YL; Liang, YH; Lin, CY; Loh, JK; Su, CL; Wang, C, 2019
)
3.4
"Thioridazine is a well-known dopamine-antagonist drug with a wide range of pharmacological properties ranging from neuroleptic to antimicrobial and even anticancer activity. "( Reinforcing the membrane-mediated mechanism of action of the anti-tuberculosis candidate drug thioridazine with molecular simulations.
Khandelia, H; Kopec, W, 2014
)
2.06
"Thioridazine (TDZ) is a phenothiazine that has been shown to be one of the most potent phenothiazines to inhibit trypanothione reductase irreversibly. "( Trypanothione reductase inhibitors: Overview of the action of thioridazine in different stages of Chagas disease.
Báez, AL; Bazán, PC; Lo Presti, MS; Paglini-Oliva, PA; Rivarola, HW; Strauss, M, 2015
)
2.1
"Thioridazine is an orally administered antipsychotic drug with potential for treatment of drug-resistant tuberculosis (TB). "( In vitro evaluation of novel inhalable dry powders consisting of thioridazine and rifapentine for rapid tuberculosis treatment.
Britton, WJ; Chan, HK; Chan, JG; Pang, A; Parumasivam, T; Quan, DH; Triccas, JA, 2016
)
2.11
"Thioridazine (THD) is a commonly prescribed phenotiazine neuroleptic drug, which is extensively biotransformed in the organism producing as main metabolites sulfoxides and a sulfone by sulfur oxidation. "( Assignment of the absolute configuration at the sulfur atom of thioridazine metabolites by the analysis of their chiroptical properties: the case of thioridazine 2-sulfoxide.
Bertucci, C; Bonato, PS; Borges, KB; Guimarães, LF; Mazzeo, G; Okano, LT; Rosini, C, 2010
)
2.04
"Thioridazine (THZ) is a candidate for the therapy of multidrug and extensively drug-resistant TB."( A Mycobacterium tuberculosis sigma factor network responds to cell-envelope damage by the promising anti-mycobacterial thioridazine.
Dutta, NK; Kaushal, D; Mehra, S, 2010
)
1.29
"Thioridazine is a phenothiazine drug which has previously been extensively used for its antipsychotic properties as it is associated with a low risk of extra-pyramidal side-effects. "( Thioridazine: the good and the bad.
Thanacoody, RH, 2011
)
3.25
"Thioridazine is a first-generation antipsychotic drug that was withdrawn from the market worldwide in 2005. "( Outcome of patients after market withdrawal of thioridazine: a retrospective analysis in a nationwide cohort.
Koponen, H; Purhonen, M; Tanskanen, A; Tiihonen, J, 2012
)
2.08
"Thioridazine is a type of anti-psychotic drug that also includes anti-tumor activity. "( Anti-angiogenic effects of thioridazine involving the FAK-mTOR pathway.
Byun, HJ; Dong, SM; Kang, S; Kim, BR; Lee, JH; Lee, SH; Park, MS; Park, SH; Rho, SB, 2012
)
2.12
"Thioridazine (THD) is a phenothiazine neuroleptic drug used for the treatment of psychiatric disorders. "( Degradation and configurational changes of thioridazine 2-sulfoxide.
Bonato, PS; de Gaitani, CM; Martinez, AS, 2004
)
2.03
"Thioridazine is a phenothiazine derivative that has been used as an antipsychotic; it rarely causes photosensitization. "( Thioridazine induces immediate and delayed erythema in photopatch test.
Fujita, M; Miyaoka, Y; Takiwaki, H; Tsuchiya, K,
)
3.02
"Thioridazine is an antipsychotic that can still be used for schizophrenia although it is associated with the cardiac arrhythmia, torsades de pointe."( Thioridazine for schizophrenia.
Fenton, M; Rathbone, J; Reilly, J; Sultana, A, 2007
)
3.23
"Thioridazine is a phenothiazine antipsychotic drug with well-recognized antimicrobial activity, but this property has not been harnessed for clinical use as a result of its central nervous system and cardiac side-effects."( Thioridazine: resurrection as an antimicrobial agent?
Thanacoody, HK, 2007
)
2.5
"Thioridazine is a member of the class of phenothiazines that act, in part, by inhibiting respiration."( Nitrate enhances the survival of Mycobacterium tuberculosis during inhibition of respiration.
Sohaskey, CD, 2008
)
1.07
"Thioridazine is a commonly prescribed phenothiazine drug administered as a racemate and it is believed that its antipsychotic effect is mainly associated with (R)-thioridazine. "( Determination of the enantiomers of thioridazine, thioridazine 2-sulfone, and of the isomeric pairs of thioridazine 2-sulfoxide and thioridazine 5-sulfoxide in human plasma.
Baumann, P; Eap, CB; Koeb, L; Powell, K, 1995
)
2.01
"Thioridazine (THI) is a tricyclic drug that belongs to the phenothiazine series. "( Structural, ultrastructural studies and evolution of Trypanosoma cruzi-infected mice treated with thioridazine.
Fernández, AR; Fretes, R; Paglini-Oliva, P; Peslman, A, 1998
)
1.96
"Thioridazine is a piperidine phenothiazine used for the treatment of people with schizophrenia. "( Thioridazine for schizophrenia.
Fenton, M; Reilly, J; Sultana, A, 2000
)
3.19

Effects

Thioridazine (TZ) has been shown by us to have in vitro and ex vivo activity against antibiotic-susceptible and multidrug-resistant Mycobacterium tuberculosis (MDRTB) It also has prominent anticholinergic effects, whereas mezilamine does not. Thioridazines toxicity has been described as a 'progressive chorioretinopathy'

ExcerptReferenceRelevance
"Thioridazine has shown good anti-TB properties both in vitro and in vivo, likely due to its capacity to inhibit efflux mechanisms."( Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
Azzali, E; Costantino, G; Couto, I; Machado, D; Pieroni, M; Santos Costa, S; Viveiros, M, 2015
)
1.42
"Thioridazine has limited bactericidal activity against extracellular bacilli within necrotic granulomas. "( Thioridazine lacks bactericidal activity in an animal model of extracellular tuberculosis.
Dutta, NK; Karakousis, PC; Pinn, ML; Rudek, MA; Zhao, M, 2013
)
3.28
"Thioridazine has been known as an antipsychotic agent, but it also has anticancer activity. "( Antipsychotic agent thioridazine sensitizes renal carcinoma Caki cells to TRAIL-induced apoptosis through reactive oxygen species-mediated inhibition of Akt signaling and downregulation of Mcl-1 and c-FLIP(L).
Bae, YC; Kwon, TK; Min, KJ; Seo, BR; Yoo, YH, 2014
)
2.17
"Thioridazine has been shown to reverse oxacillin resistance in methicillin-resistant Staphylococcus aureus (MRSA) in vitro. "( Reversal of methicillin resistance in Staphylococcus aureus by thioridazine.
Kallipolitis, BH; Klitgaard, JK; Kolmos, HJ; Skov, MN, 2008
)
2.03
"Thioridazine (TDZ) has been shown to have in vitro activity against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains of Mycobacterium tuberculosis, to promote the killing of intracellular MDR and XDR strains and to cure the mouse of antibiotic-susceptible and -resistant pulmonary tuberculosis (TB) infections. "( Thioridazine cures extensively drug-resistant tuberculosis (XDR-TB) and the need for global trials is now!
Amaral, L; Boeree, MJ; Gillespie, SH; Udwadia, ZF; van Soolingen, D, 2010
)
3.25
"Thioridazine has proven anti tuberculous effects in vitro and in vivo mouse models and we used this drug as salvage therapy in 4 Indian patients with XDR (near total drug resistance) with advanced disease."( Safety and efficacy of thioridazine as salvage therapy in Indian patients with XDR-TB.
Pinto, LM; Sen, T; Udwadia, ZF, 2011
)
1.4
"Thioridazine has little antiemetic action but perphenazine is prescribed for vomiting; hence it seems unlikely that the reported symptoms are due to a rebound action on the vomiting centre.These findings are relevant to the situation of withdrawal of ataractics prior to administration of anesthetics and to drug studies involving cross-over from an active compound to a placebo."( GASTROINTESTINAL DISTURBANCES ASSOCIATED WITH WITHDRAWAL OF ATARACTIC DRUGS.
HADEN, P, 1964
)
0.96
"Thioridazine (TZ) has previously been shown by us to have in vitro and ex vivo activity against antibiotic-susceptible and multidrug-resistant Mycobacterium tuberculosis (MDRTB). "( In vitro and ex vivo activity of thioridazine derivatives against Mycobacterium tuberculosis.
Aki-Sener, E; Amaral, L; Hajös, G; Martins, A; Martins, M; Molnar, J; Riedl, Z; Schelz, Z; Viveiros, M; Yalcin, I, 2007
)
2.06
"Thioridazine also has prominent anticholinergic effects, whereas mezilamine does not have anticholinergic effects."( Interactions of clozapine, thioridazine, and mezilamine with oxotremorine on schedule-controlled responding.
Leander, JD, 1983
)
1.28
"Thioridazine toxicity has been described as a 'progressive chorioretinopathy', but this designation can be misleading. "( Is thioridazine retinopathy progressive? Relationship of pigmentary changes to visual function.
Marmor, MF, 1990
)
2.34
"Thioridazine has two major active metabolites, which are formed from S-oxidation of its 2-methylthio group; the sulphoxide, mesoridazine, and the sulphone, sulforidazine. "( S-oxidation of thioridazine to psychoactive metabolites: an oral dose-proportionality study in healthy volunteers.
Chakraborty, BS; Choc, MG; Hawes, EM; Hubbard, JW; Korchinski, ED; McKay, G; Midha, KK; Robinson, WT, 1988
)
2.07

Actions

Thioridazine was found to inhibit growth in ovarian cancer cells (OVCAR-3 and 2774) The drug did not possess any inhibitory effects on normal cell types such as HOSE-E6E7.

ExcerptReferenceRelevance
"Thioridazine did suppress the size of abscesses produced when the bacteria were injected intradermally."( Effect of thioridazine on experimental cutaneous staphylococcal infections.
Hahn, BL; Sohnle, PG,
)
1.26
"Thioridazine was found to inhibit growth in ovarian cancer cells (OVCAR-3 and 2774), but did not possess any inhibitory effects on normal cell types such as HOSE-E6E7, MCF-10A, MRC-5, and BEAS-2B."( Anti-angiogenic effects of thioridazine involving the FAK-mTOR pathway.
Byun, HJ; Dong, SM; Kang, S; Kim, BR; Lee, JH; Lee, SH; Park, MS; Park, SH; Rho, SB, 2012
)
1.4
"Thioridazine did not inhibit the lengthening response."( Effects of thioridazine on mechanical responses of human vas deferens induced by noradrenaline or potassium.
Amobi, NI; Smith, IC, 1992
)
1.39
"Thioridazine was found to inhibit lysosomal enzyme activities of cathepsin B and acid phosphatase, but not beta-hexosaminidase when cell extracts were treated with the drug."( Thioridazine enhances lysosomal accumulation of epidermal growth factor and toxicity of conjugates of epidermal growth factor with Pseudomonas exotoxin.
Akiyama, S; Kuratomi, Y; Kuwano, M; Ohkuma, S; Ono, M; Shimada, T; Shiraishi, N, 1986
)
2.44
"Thioridazine was found to increase the serum prolactin level as well as the tumor size of a prolactin--secreting pituitary chromophobe adenoma in a schizophrenic man. "( The effect of thioridazine on prolactinoma growth in a schizophrenic man: case report.
Thompson, TL; Weingarten, JC, 1985
)
2.07

Treatment

Thioridazine treatment induced nuclear fragmentation, increased the proportion of sub-G1 phase cells, and elevated the percentage of Annexin V-positive cells. Treatment resulted in a significant reduction of colony-forming-units of the susceptible (-4.4 log CFU, p<0.05) and multidrug-resistant tuberculosis bacilli.

ExcerptReferenceRelevance
"Thioridazine treatment induced nuclear fragmentation, increased the proportion of sub-G1 phase cells, and elevated the percentage of Annexin V-positive cells, suggesting the occurrence of apoptosis."( Thioridazine, an antipsychotic drug, elicits potent antitumor effects in gastric cancer.
Ding, Q; Huang, W; Li, M; Liu, Y; Lu, J; Mu, J; Tan, Z; Wu, X; Xiao, J; Xu, H; Yang, Y; Zhang, L, 2014
)
2.57
"Thioridazine treatment of the cells resulted in up-regulated PDCD4 mRNA expression and down-regulated mRNA expressions of CCND1, CDK4, c-MYC, BCL2, CASPASE3, PARP1 and EIF4A, increased PDCD4 protein expression and reduced p-AKT protein expression."( [Mechanism of thioridazine-induced apoptosis of human colorectal cancer SW480 cells].
Cai, HB; Hao, YJ; Huang, JW; Li, X; Liu, JK; Peng, K, 2015
)
1.5
"Thioridazine treatment resulted in a significant reduction of colony-forming-units of the susceptible (-4.4 log CFU, p<0.05) and multidrug-resistant tuberculosis bacilli (-2.4 log CFU, p<0.009) in the lung both at one and two months after infection, compared to controls."( The antipsychotic thioridazine shows promising therapeutic activity in a mouse model of multidrug-resistant tuberculosis.
Aguilar, D; Amaral, L; Boeree, MJ; Hernandez-Pando, R; Magis-Escurra, C; Orozco, H; van Ingen, J; van Soolingen, D, 2010
)
1.42
"Thioridazine (12.5 microM)-treated glioma cells costained with PI and Hoechst 33342 revealed a red fluorescence of fragmented nuclei in treated cells and a blue fluorescence of intact control nuclei."( Characterization of phenothiazine-induced apoptosis in neuroblastoma and glioma cell lines: clinical relevance and possible application for brain-derived tumors.
Dayag, M; Gil-Ad, I; Levkovitz, Y; Shtaif, B; Weizman, A; Zeldich, E, 2004
)
1.04
"Thioridazine-treated rats had more dark neurons but the difference was not significant."( Correlation between cellular changes in supraoptic and paraventricular nuclei and water-drinking in neuroleptic-treated rats.
Connell, BJ; Ireland, WP, 1990
)
1
"Treatment with thioridazine or butaperazine also tended to decrease platelet MAO activity."( Effects of neuroleptics on platelet monoamine oxidase activity.
Allen, R; DeJohn, C; Ho, BT; Khan, M; Kralik, P; Schoolar, J; Smith, RC, 1982
)
0.6
"Treatment with thioridazine resulted in hyperpyrexia and ventricular tachycardia in a young woman who was later shown to have thyrotoxicosis. "( Does hyperthyroidism predispose to thioridazine-induced hyperpyrexia and cardiac arrhythmias?
FitzGerald, MX; Murphy, MB, 1984
)
0.9
"Treatment with thioridazine has been associated with electrocardiographic abnormalities, and there are individual case reports of fatal cardiac arrhythmias in patients taking thioridazine. "( Electrocardiographic changes following intravenous administration of thioridazine to macaque monkeys.
Moore, RH; Rainey, JM, 1982
)
0.85
"Treatment with thioridazine inhibited brain activation to all stimuli including phantosmia and phantageusia memory, as it did previously in patients with birhinal phantosmia."( Physiologically initiated and inhibited phantosmia: cyclic unirhinal, episodic, recurrent phantosmia revealed by brain fMRI.
Henkin, RI; Levy, LM,
)
0.47
"Cotreatment with thioridazine or scopolamine did alter the changes in DA biochemistry normally associated with haloperidol treatment, but failed to attenuate the DA receptor proliferation."( Dopaminergic alterations in cotreatments attenuating haloperidol-induced hypersensitivity.
Amdur, RL; Carvey, PM; Kao, LC; Klawans, HL; Lin, DH; Singh, R; Zhang, TJ, 1990
)
0.61

Toxicity

The effects of haloperidol, risperidone and thioridazine on the pharmacokinetics and side-effect profile of quetiapine were investigated in 36 patients with schizophrenia, schizoaffective disorder, or bipolar disorder.

ExcerptReferenceRelevance
" Because both of these drugs have an adverse effect on cardiac repolarization, this may be a particularly hazardous combination."( Cardiac toxicity with thioridazine-tricyclic antidepressant combination.
Heiman, EM, 1977
)
0.57
" The physicians should be aware of this disturbing side effect while treating their patients with antidepressant and neuroleptic medications."( SIADH: a serious side effect of psychotropic drugs.
Ananth, J; Lin, KM,
)
0.13
"Acute anticholinergic delirium has been reported to occur following ingestion of antidepressants, neuroleptics and antiparkinsonian drugs in toxic and therapeutic doses."( Chronic central anticholinergic toxicity in manic depressive illness mimicking dementia.
Banno, V; Jones, BD; Moreau, A, 1986
)
0.27
" Many of these adverse side effects can be greatly reduced or prevented with close monitoring of patients."( Ocular toxicity of systemic medications: a case series.
To, TQ; Townsend, JC, 2000
)
0.31
" Clinical cases illustrating possible adverse ocular side effects are presented, which include INH-induced optic neuropathy, phenothiazine-induced retinopathy, steroid-induced glaucoma, and vortex epitheliopathy secondary to amiodarone."( Ocular toxicity of systemic medications: a case series.
To, TQ; Townsend, JC, 2000
)
0.31
"The effects of haloperidol, risperidone, and thioridazine on the pharmacokinetics and side-effect profile of quetiapine were investigated in 36 patients with schizophrenia, schizoaffective disorder, or bipolar disorder in a single-center, two-period, multiple-dose, open-label, randomized trial."( The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.
Alva, G; Arvanitis, LA; Bera, R; Potkin, SG; Thyrum, PT; Yeh, C, 2002
)
0.79
"5 million adverse drug reaction (ADR) reports for 8620 drugs/biologics that are listed for 1191 Coding Symbols for Thesaurus of Adverse Reaction (COSTAR) terms of adverse effects."( Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL, 2004
)
0.32
" Azithromycin was not associated with excess serious adverse events (SAEs)."( Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment.
Butler-Laporte, G; Menzies, D; Winters, N, 2015
)
0.42
" Whereas free thioridazine was highly toxic in both cells and zebrafish embryos, after encapsulation in nanoparticles no toxicity was detected."( Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish.
Anes, E; Bogoeva, V; Fenaroli, F; Griffiths, G; Hildahl, J; Kalluru, R; Pires, D; Speth, M; Vibe, CB; Wilson, SR, 2016
)
2.24

Pharmacokinetics

Thioridazine's level in the brain tissue was diminished in the irradiated, cystamine-pretreated animals. The protective effect of metanabol was found to be due to shortening of the half-life time of thioridazines.

ExcerptReferenceRelevance
" Half-life period of thioridazine was found to be reduced and its level in the brain tissue was diminished in the irradiated, cystamine-pretreated animals in comparison with the irradiated, untreated ones."( Changes in pharmacodynamics and pharmacokinetics of psycholeptic drugs in the course of radiation disease. Effects of premedication with cystamine on dynamics and kinetics of thioridazine.
Cenajek, D; Chodera, A; Kozaryn, I; Szczawińska, K; Wójciak, Z,
)
0.64
" No significant differences in dose-corrected pharmacokinetic variables were found between the two groups."( Single dose pharmacodynamics of thioridazine and remoxipride in healthy younger and older volunteers.
Jackson, SH; Lee, DR; Maskrey, VL; Swift, CG; Tiplady, B; Yisak, W, 1999
)
0.59
" The varying concentration ratios of antidepressant/thioridazine in vivo appear to be more important to the final result of the pharmacokinetic interactions than are relative direct inhibitory effects of the antidepressants on thioridazine metabolism observed in vitro."( Pharmacokinetics and metabolism of thioridazine during co-administration of tricyclic antidepressants.
Daniel, WA; Haduch, A; Syrek, M; Wójcikowski, J, 2000
)
0.83
" Plasma concentrations of thioridazine were measured after each dose, and pharmacokinetic parameters were determined."( Repeated dosing with donepezil does not affect the safety, tolerability or pharmacokinetics of single-dose thioridazine in young volunteers.
Boyce, M; Dunn, K; Johnston, A; Ravic, M; Warrington, S, 2004
)
0.84

Compound-Compound Interactions

Thioridazine (TDZ) in combination with antibiotics to which extensively drug-resistant Mycobacterium tuberculosis (XDR-TB) is initially resistant yields a cure.

ExcerptReferenceRelevance
" The woman described in this article died after taking her usual dose of thioridazine, 100 mg/d, in combination with a single capsule of Contac."( Death attributed to ventricular arrhythmia induced by thioridazine in combination with a single Contac C capsule.
Chouinard, G; Ghadirian, AM; Jones, BD, 1978
)
0.74
"Groups of male Wistar rats were injected with either apomorphine alone twice daily for one week or with apomorphine in combination with chlorpromazine or thioridazine."( Behavioural effects of chronic treatment with apomorphine in combination with neuroleptic drugs.
Kenny, M; Leonard, BE, 1980
)
0.46
"The antipsychotic effect of alpha-methyltyrosine (alpha-MT) in combination with thioridazine was investigated by means of rating scales for "social behaviour" and "mental symptoms"."( Antipsychotic treatment with alpha-methyltyrosine in combination with thioridazine: prolactin response and interaction with dopaminergic precursor pools.
Carlsson, A; Larsson, M; Ohman, R; Wålinder, J; Wallin, L, 1984
)
0.73
"The purpose of this study was to propose a new method to predict in vivo drug-drug interactions (DDIs) for a high clearance drug from in vitro data."( Prediction of drug-drug interactions for AUCoral of high clearance drug from in vitro data: utilization of a microtiter plate assay and a dispersion model.
Kohno, Y; Nagata, K; Suzuki, A; Yamamoto, T; Yamazoe, Y, 2006
)
0.33
"Thioridazine (TDZ) in combination with antibiotics to which extensively drug-resistant Mycobacterium tuberculosis (XDR-TB) is initially resistant yields a cure."( Why thioridazine in combination with antibiotics cures extensively drug-resistant Mycobacterium tuberculosis infections.
Amaral, L; Viveiros, M, 2012
)
2.38
"The hepatic organic anion transporting polypeptides (OATPs) influence the pharmacokinetics of several drug classes and are involved in many clinical drug-drug interactions."( Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR, 2012
)
0.38
"Over a period of 14 years, the authors have studied thioridazine, an old neuroleptic, that has been shown to have in vitro activity against intracellular Mycobacterium tuberculosis, regardless of its antibiotic resistance status, thioridazine cures infected mice of antibiotic-susceptible and multidrug-resistant tuberculosis (TB) infections and, when used in combination with antibiotics used for therapy of TB, renders the organism significantly more susceptible."( Why and how thioridazine in combination with antibiotics to which the infective strain is resistant will cure totally drug-resistant tuberculosis.
Amaral, L; Molnar, J, 2012
)
1.01
" In this study, we sought to investigate the sterilizing activity of human-equivalent doses of thioridazine when given in combination with the "Denver regimen" against acute murine tuberculosis."( Sterilizing activity of thioridazine in combination with the first-line regimen against acute murine tuberculosis.
Dutta, NK; Karakousis, PC; Pinn, ML, 2014
)
0.93
"To investigate the efficacy of conservative systemic treatment with dicloxacillin (DCX) in combination with TDZ (DCX+TDZ), compared to DCX alone, against early APVGI caused by methicillin-sensitive Staphylococcus aureus (MSSA) in a porcine model."( Systemic thioridazine in combination with dicloxacillin against early aortic graft infections caused by Staphylococcus aureus in a porcine model: In vivo results do not reproduce the in vitro synergistic activity.
Andersen, TE; Behr-Rasmussen, C; Grønnemose, RB; Klein, K; Klitgaard, JK; Kolmos, HJ; Lindholt, JS; Stenger, M, 2017
)
0.87
"We completed a phase 1 dose-escalation trial to evaluate the safety of a dopamine receptor D2 (DRD2) antagonist thioridazine (TDZ), in combination with cytarabine."( A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia.
Almakadi, M; Aslostovar, L; Bhatia, M; Boyd, AL; Collins, TJ; Foley, R; Julian, JA; Kim, RB; Leber, B; Leong, DP; Levine, MN; Tirona, RG; Xenocostas, A, 2018
)
0.99
" The aim of this study was to evaluate the therapeutic efficiency of immunotherapy with thioridazine and loratadine in combination with resiqumiod (R848), a small-molecule TLR7 agonist, in suppressing CRC growth in a mouse model."( Pre-activation with TLR7 in combination with thioridazine and loratadine promotes tumoricidal T-cell activity in colorectal cancer.
Chen, T; Lin, G; Lin, X; Wang, X; Zhang, J, 2020
)
1.04

Bioavailability

ExcerptReferenceRelevance
"Polysorbate 80, which has been widely used in studies of the effects of surfactants on drug absorption, increases the rate of absorption of some drugs at concentrations near its critical micelle concentration (cmc)."( Non-ionic surfactants and membrane transport of thioridazine in goldfish.
Florence, AT; Gillan, JM, 1975
)
0.51
"The quantitative structure-bioavailability relationship of 232 structurally diverse drugs was studied to evaluate the feasibility of constructing a predictive model for the human oral bioavailability of prospective new medicinal agents."( QSAR model for drug human oral bioavailability.
Topliss, JG; Yoshida, F, 2000
)
0.31
" Exploiting the secondary activity of marketed drugs, on the other hand, may help in generating drug leads that can be optimized for the observed side-effect target, while maintaining acceptable bioavailability and toxicity profiles."( Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs.
Abagyan, R; Bisson, WH; Bruey-Sedano, N; Cheltsov, AV; Chen, J; Christopoulos, A; Dalton, JT; Goldberger, N; Lin, B; May, LT; Sexton, PM; Zhang, XK, 2007
)
0.34
" Furthermore, current water quality monitoring does not differentiate between soluble and colloidal phases in water samples, hindering our understanding of the bioavailability and bioaccumulation of pharmaceuticals in aquatic organisms."( Colloids as a sink for certain pharmaceuticals in the aquatic environment.
Maskaoui, K; Zhou, JL, 2010
)
0.36
" Such strong pharmaceutical/colloid interactions may provide a long-term storage of pharmaceuticals, hence, increasing their persistence while reducing their bioavailability in the environment."( Colloids as a sink for certain pharmaceuticals in the aquatic environment.
Maskaoui, K; Zhou, JL, 2010
)
0.36
" As aquatic colloids are abundant, ubiquitous, and highly powerful sorbents, they are expected to influence the bioavailability and bioaccumulation of such chemicals by aquatic organisms."( Colloids as a sink for certain pharmaceuticals in the aquatic environment.
Maskaoui, K; Zhou, JL, 2010
)
0.36
" A significant portion of the drugs are orally bioavailable and cross the blood-brain barrier, features key to the development of a widely applicable anticryptococcal agent."( A repurposing approach identifies off-patent drugs with fungicidal cryptococcal activity, a common structural chemotype, and pharmacological properties relevant to the treatment of cryptococcosis.
Baxter, BK; Butts, A; Chabrier-Rosello, Y; DiDone, L; Koselny, K; Krysan, DJ; Wellington, M, 2013
)
0.39
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

Thioridazine may influence the metabolism of concomitant drugs or produce clinically important adverse effects such as cardiotoxicity. The anxiolytic effect in low dosage appears to be promising in the treatment of unexplained infertility.

ExcerptRelevanceReference
" In determination of the optimal individual dosage must continue to be an empirical process based on clinical observations and experience."( [Correlation between plasma concentration and clinical effect of neuroleptics and antidepressants].
Modestin, J; Petrin, A, 1976
)
0.26
" Dose-response curves were established for the blockade of ICSS by the antipsychotic drugs chlorpromazine, thioridazine, clozapine, and pimozide and the alpha-antagonist phenoxybenzamine."( Blockade of intracranial self-stimulation by antipsychotic drugs: failure to correlate with central alpha-noradrenergic blockade.
Setler, P; Weidley, E; Zarevics, P, 1977
)
0.47
" Therefore, monitoring treatment by dosage adjustment alone is of little value."( Plasma level monitoring of antipsychotic drugs.
Cooper, TB,
)
0.13
" Their plasma levels are not correlated with their dosage in a man to another, but, for some of them, there is lineary relation for one person."( [Relations between the levels of neuroleptics and the doses, the therapeutic effects and the side effects].
Andersson, JC; Davy, JP; Halbecq, JJ; Morel, P; Moulin, M; Poilpre, E, 1978
)
0.26
" SHPGE2, PGE2, and C did not cause catalepsy and did not show statistically significant dose-response antagonism of rotational behavior at less than toxic doses."( Neuropharmacological and behavioral evaluation of prostaglandin E2 and 11-thiol-11-desoxy prostaglandin E2 in the mouse and rat.
Bloss, JL; Singer, GH, 1978
)
0.26
" Improvement was recorded in a double blind study of 18 patients treated with maximum tolerated dosage (mean 18."( Tardive dyskinesia treated with pimozide.
Calne, DB; Claveria, LE; Haskayne, L; Lodge-Patch, IC; Pallis, CA; Petrie, A; Teychenne, PF, 1975
)
0.25
"The effect of various antipsychotic drugs on the blockade of dopaminergic receptors in striatum and limbic forebrain was examined by establishing dose-response curves for the increase in HVA and for the antagonism of d-amphetamine-induced rotation in rats with unilateral lesions of the substantia nigra."( On the significance of the increase in homovanillic acid (HVA) caused by antipsychotic drugs in corpus striatum and limbic forebrain.
Dingell, JV; Hill, H; Robinson, SE; Setler, P; Stawarz, RJ; Sulser, F, 1975
)
0.25
" The minimum dosage given to produce the above change was 3 mg/kg/day for 7 days' administration."( Change in oscillatory potential by thioridazine.
Chotibutr, S; Hirosawa, H; Ishikawa, S; Miyata, M, 1979
)
0.54
"A randomized cross-over trial was conducted in 30 restless mentally subnormal patients by increasing the dosage of haloperidol from 10 to 60 mg and of thioridazine from 100 to 600 mg daily."( A controlled double-blind study of haloperidol versus thioridazine in the treatment of restless mentally subnormal patients. Serum levels and clinical effects.
Räisänen, P; Rimón, R; Väisänen, K; Viukari, M,
)
0.58
" The dose-response curves were carefully checked in each experiment to confirm that the second protectors did not interfere with the specific coverage provided by the first protector."( Purification of histamine receptor (VI). An improved double labeling method with "double protection".
Uchida, M, 1977
)
0.26
" In the present trial, the 779704 combination was maintained without any alterations in dosage for six months, and the therapeutic effect persisted unchanged."( Potentiation by metyrosine of thioridazine effects in chronic schizophrenics. A long-term trial using double-blind crossover technique.
Carlsson, A; Roos, BE; Skott, A; Wålinder, J, 1976
)
0.54
" Plasma levels of both drugs were clearly correlated to dosage after three weeks of treatment."( Plasma levels and clinical effects of thioridazine and thiothixene.
Bergling, R; Mjorndal, T; Oreland, L; Rapp, W; Wold, S,
)
0.4
" The data obtained from this study have tended to confirm the impression of previous investigators that penfluridol, administered in a dosage of 40 to 80 mg on a once-a-week basis in a single dose, compares favorably with the antipsychotic activity of those neuroleptics requiring administration on a daily basis."( Penfluridol: a long-acting oral neuroleptic. A controlled study.
Kurland, AA; Ota, KY; Slotnick, VB,
)
0.13
" The 32-day drug trial sought to determine the comparative effectiveness of thioridazine-placebo, thioridazine-chlordiazepoxide, and thioridazine-imipramine, with the daily dosage of openly administered thioridazine ranging from 100 to 900 mg and dosages for chlordiazepoxide and imipramine, administered in a double-blind fashion, fixed at daily dosages of 30 and 75 mg, respectively."( Effects of control techniques on therapeutic outcome in a controlled clinical trial.
Blatchley, RJ; Hanlon, TE; Kurland, AA, 1975
)
0.48
" A significant correlation was found both between dosage per kg body weight and plasma level, and between age and plasma level."( [Therapeutic effect and plasma level of thioridazine in schizophrenic patients (author's transl)].
Chandra, O; Klein, HE; Matussek, N, 1975
)
0.52
"There are many reasons why once a day oral dosage may be advantageous in administration of psychotropic drugs to mental patients, such as convenience for the patient, avoided side effects, ease of remembering, all of which contribute to reliable dosage as well as cost savings."( Clinical pharmacology and the prescription of psychotropic medication.
Davis, JM, 1975
)
0.25
" The risk of using chlorpromazine in moderate dosage is slight."( Deposits in the lens and cornea of the eye during long-term chlorpromazine medication.
Faurbye, A; Kirk, L; Rasmussen, K, 1976
)
0.26
" Thioridazine due to anxiolytic effect in low dosage appears to be promising in the treatment of unexplained infertility."( Role of thioridazine in unexplained infertility.
Sharma, JB; Sharma, S, 1992
)
1.63
" Discontinuation of the bromocriptine and increase in antipsychotic dosage resulted in complete remission."( Psychotic exacerbation attributed to low-dose bromocriptine treatment of galactorrhea and hyperprolactinemia.
Aronzon, R; Dorevitch, A; Stark, M, 1991
)
0.28
" Both drugs were given in a dosage range of 50-200 mg/day."( Remoxipride versus thioridazine in elderly psychotic patients.
Link, C; Phanjoo, AL, 1990
)
0.61
" Because of the interaction between dopamine (DA) and neurotensin (NT) in the target areas of these systems, and in order to study if the different action of typical and atypical neuroleptic drugs could be related to a modification of the DA/NT balance, we investigated DA2 and NT receptor modifications--by means of quantitative receptor autoradiography--after chronic treatment with low dosage of haloperidol, chlorpromazine, thioridazine and clozapine."( DA2/NT receptor balance in the mesostriatal and mesolimbocortical systems after chronic treatment with typical and atypical neuroleptic drugs.
Amato, G; Calzà, L; Giardino, L; Piazza, PV; Zanni, M, 1990
)
0.44
" The dose-response curve for methoxamine, but not for xylazine, was shifted to the left by the neuroleptic."( Increased peripheral alpha 1-adrenoceptor sensitivity following chronic thioridazine treatment in the pithed rat.
Badia, A; Cuffí, ML; Vila, E, 1989
)
0.51
"5 h) was administered to all the volunteers to investigate the effect of a slow rate of dosage input on the pharmacokinetic parameters of this drug."( Single dose kinetics of thioridazine and its two psychoactive metabolites in healthy humans: a dose proportionality study.
Chakraborty, BS; Choc, MG; Hawes, EM; Hubbard, JW; Korchinski, ED; McKay, G; Midha, KK; Robinson, WT, 1989
)
0.58
" It is suggested that additional studies, carefully designed, on dosage and plasma levels could help in achieving the lowest possible therapeutic dosage and thus in minimizing side effects."( Blood levels of neuroleptics: state of the art.
Simpson, GM; Yadalam, K, 1985
)
0.27
" Thioridazine-5-sulphoxide, N-desmethylthioridazine-5-sulphoxide and thioridazine-N-oxide diastereoisomers were found to be thioridazine metabolites following dosing in rats or after in-vitro incubation with rat liver homogenate."( Chromatographic separation of thioridazine sulphoxide and N-oxide diastereoisomers: identification as metabolites in the rat.
Buckley, DG; Curry, SH; Watkins, GM; Whelpton, R, 1986
)
1.47
" The findings were related to previous dosage research and the literature on stereotypic behavior."( Thioridazine dose effects with reference to stereotypic behavior in mentally retarded residents.
Aman, MG; White, AJ, 1988
)
1.72
"The relationship between chronic oral dosage with a long-acting formulation of propranolol and plasma propranolol levels 22 to 23 hours later is described in 12 adult male patients with organic brain disease."( Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations.
Greendyke, RM; Kanter, DR, 1987
)
0.52
" However, an inverted U-shaped dose-response curve was obtained with the combined administration of these agents."( Prophylactic effects of neuroleptics in symptom-free schizophrenics: roles of dopaminergic and noradrenergic blockers.
Koga, I; Nishikawa, T; Tanaka, M; Tsuda, A; Uchida, Y, 1985
)
0.27
"The phenothiazines have exhibited a history of problems associated with the bioequivalence of solid oral dosage forms."( Critical evaluation of thioridazine bioequivalence.
Barone, JA; Colaizzi, JL, 1985
)
0.58
"A case is reported of fatal aplastic anemia developing in a 50-year-old woman who received lithium carbonate in the generally accepted dosage for a manic-depressive disorder."( Aplastic anemia associated with lithium therapy.
Chaudhry, ZA; Hussain, MZ; Khan, AG, 1973
)
0.25
" The ED50s of the effective neuroleptics for this inhibition were similar to those reported for antagonism of amphetamine-induced stereotypic behavior in the rat and the slopes of the dose-response curves were parallel indicating a common site and mechanism of action, presumably blockade of postsynaptic dopaminergic receptors."( Effect of neuroleptics and tricyclic antidepressants upon d-amphetamine discrimination.
Schechter, MD, 1980
)
0.26
" The dose-response curves of the cellular accumulation of 45Ca2+ are of a bell shape, indicating a biphasic response."( Membrane effects of phenothiazines in yeasts. I. Stimulation of calcium and potassium fluxes.
Eilam, Y, 1983
)
0.27
"The authors studied high-potency versus low-potency neuroleptic dosing practices for 110 Boston-area psychiatric inpatients and compared the findings with the dosing practices reported in surveys of nearly 16,000 Veterans Administration patients."( Dissimilar dosing with high-potency and low-potency neuroleptics.
Baldessarini, RJ; Cotton, P; Katz, B, 1984
)
0.27
" There were also differences in the dose-response curves."( Neuroleptic-induced seizures. An in vitro technique for assessing relative risk.
Luchins, DJ; Oliver, AP; Wyatt, RJ, 1982
)
0.26
" Persons taking these drug combinations were identified and matched on the basis of age, sex, body weight, and antiepileptic drug (AED) dosage with persons from the same population who were taking only the AEDs."( Interaction between phenobarbital and thioridazine.
Gay, PE; Madsen, JA, 1983
)
0.54
" Dosage was significantly associated with the decrease in height and weight percentile."( Growth of hyperactive children on maintenance regimen of methylphenidate.
Gittelman, R; Mattes, JA, 1983
)
0.27
" clinically, it may be useful monitoring PRL levels, since the therapeutic dosage should usually be above the dosage required to produce maximal PRL levels."( The effect of thioridazine on prolactin levels in acutely schizophrenic patients: challenge-dose and steady-state levels.
Hunt, GE; Johnson, GF, 1980
)
0.62
"A randomized cross-over trial was conducted in 30 restless mentally subnormal patients by increasing the dosage of haloperidol from 10 to 60 mg and that of thioridazine from 100 to 600 mg daily."( Haloperidol, thioridazine and placebo in mentally subnormal patients-serum levels and clinical effects.
Räisänen, P; Rimón, R; Väisänen, K; Viukari, M, 1981
)
0.83
" Subjects were assessed on a relatively low standardized dose as well as on the individual dosage that had previously been determined clinically as most effective."( Effects of thioridazine dosage on the behavior of severely mentally retarded persons.
Aman, MG; Singh, NN, 1981
)
0.65
" The combination of a clinically useful medication in appropriate dosage schedules with relevant psychological treatments simultaneously directed to each of the child's many disabilities were associated with an unexpectedly good outcome at the end of one and two years."( Multimodality treatment. A two-year evaluation of 61 hyperactive boys.
Cantwell, DP; Satterfield, BT; Satterfield, JH, 1980
)
0.26
" This case merits its unique status because of the particular tint of the discoloration, the relative rapidity of onset of this symptoms, and the low dosage of thioridazine that was involved."( An unusual ocular complication of thioridazine.
Giannini, AJ; Mahar, PJ,
)
0.61
" Concentrations of THD, mesoridazine, and sulforidazine were measured in plasma samples obtained from 10 male inpatients, aged 36 to 78 years, at three different time points: A, during habitual monotherapy with THD at 88 +/-54 mg/day; B, after addition of a low dosage of fluvoxamine (25 mg twice a day) for 1 week; and C, 2 weeks after fluvoxamine discontinuation."( Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients.
Agundez, JA; Benítez, J; Berecz, R; Carrillo, JA; Duran, M; Herraiz, AG; Llerena, A; Ramos, SI, 1999
)
0.56
" Correlations between drug dosage and plasma drug levels were significant for haloperidol and thioridazine, but not for lorazepam."( Relationships between psychotropic drug dosage, plasma drug concentration, and prolactin levels in nursing home residents.
Billig, N; Cohen-Mansfield, J; Lipson, S; Taylor, L; Werner, P; Woosley, R, 2000
)
0.53
" One must consider the effects of thioridazine dosage on CYP2D6, because it may influence the metabolism of concomitant drugs or produce clinically important adverse effects such as cardiotoxicity."( Effect of thioridazine dosage on the debrisoquine hydroxylation phenotype in psychiatric patients with different CYP2D6 genotypes.
Berecz, R; de la Rubia, A; Dorado, P; Fernández-Salguero, P; LLerena, A, 2001
)
0.99
" Key assessments included the pharmacokinetics of quetiapine at steady state (area under the curve within a dosing interval [AUCtSS], maximum [CmaxSS], and minimum [CminSS] observed plasma concentrations, and oral clearance [Cl/f]), as well as the UKU Side Effect Rating Scale scores and safety evaluations."( The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone, or thioridazine.
Alva, G; Arvanitis, LA; Bera, R; Potkin, SG; Thyrum, PT; Yeh, C, 2002
)
0.53
"049) and a linear dose-response relation (P=0."( Cardiac arrest and ventricular arrhythmia in patients taking antipsychotic drugs: cohort study using administrative data.
Bilker, WB; Glasser, DB; Hennessy, S; Kimmel, SE; Knauss, JS; Margolis, DJ; Morrison, MF; Reynolds, RF; Strom, BL, 2002
)
0.31
" Each was used in four dosage levels (thioridazine and chlorpromazine: 200, 400, 800 and 1200 mg."( THE EFFECT OF PHENOTHIAZINES ON THE ELECTROCARDIOGRAM.
BAN, TA; STJEAN, A, 1964
)
0.51
" Cox regression was used to calculate rate ratios (RRs) and 95% confidence intervals (CIs), to examine potential confounding factors, and to examine dose-response relationships."( Comparative cardiac safety of low-dose thioridazine and low-dose haloperidol.
Bilker, WB; Glasser, DB; Hennessy, S; Kimmel, SE; Knauss, JS; Margolis, DJ; Morrison, MF; Reynolds, RF; Strom, BL, 2004
)
0.59
" Specifically, to examine dose-response relationships for thioridazine and chlorpromazine."( Electrocardiogram and cardiovascular changes in thioridazine and chlorpromazine poisoning.
Bateman, DN; Kelly, CA; Strachan, EM, 2004
)
0.82
" For thioridazine, there was a significant dose-response relationship for increasing heart rate and increasing QTc but not other cardiovascular changes."( Electrocardiogram and cardiovascular changes in thioridazine and chlorpromazine poisoning.
Bateman, DN; Kelly, CA; Strachan, EM, 2004
)
1.09
"Repeated dosing with donepezil, 5 mg daily for 2 weeks, had no significant effect on the safety, tolerability or pharmacokinetics of thioridazine."( Repeated dosing with donepezil does not affect the safety, tolerability or pharmacokinetics of single-dose thioridazine in young volunteers.
Boyce, M; Dunn, K; Johnston, A; Ravic, M; Warrington, S, 2004
)
0.74
"Encapsulating antibiotics such as rifampicin in biodegradable nanoparticles provides several advantages compared to free drug administration, including reduced dosing due to localized targeting and sustained release."( Thioridazine in PLGA nanoparticles reduces toxicity and improves rifampicin therapy against mycobacterial infection in zebrafish.
Anes, E; Bogoeva, V; Fenaroli, F; Griffiths, G; Hildahl, J; Kalluru, R; Pires, D; Speth, M; Vibe, CB; Wilson, SR, 2016
)
1.88
" In our current work, we used different dosage of thioridazine to test its effect on lung cancer stem cells sphere formation."( Targeting Lung Cancer Stem Cells with Antipsychological Drug Thioridazine.
Hua, L; Huang, D; Huang, H; Huang, J; Qin, L; Wang, G; Yue, H; Zheng, Z, 2016
)
0.93
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (7)

RoleDescription
serotonergic antagonistDrugs that bind to but do not activate serotonin receptors, thereby blocking the actions of serotonin or serotonergic agonists.
H1-receptor antagonistH1-receptor antagonists are the drugs that selectively bind to but do not activate histamine H1 receptors, thereby blocking the actions of endogenous histamine.
alpha-adrenergic antagonistAn agent that binds to but does not activate alpha-adrenergic receptors thereby blocking the actions of endogenous or exogenous alpha-adrenergic agonists. alpha-Adrenergic antagonists are used in the treatment of hypertension, vasospasm, peripheral vascular disease, shock, and pheochromocytoma.
dopaminergic antagonistA drug that binds to but does not activate dopamine receptors, thereby blocking the actions of dopamine or exogenous agonists.
first generation antipsychoticAntipsychotic drugs which can have different modes of action but which tend to be more likely than second generation antipsychotics to cause extrapyramidal motor control disabilities such as body rigidity or Parkinson's disease-type movements; such body movements can become permanent even after treatment has ceased.
EC 3.4.21.26 (prolyl oligopeptidase) inhibitorAny EC 3.4.21.* (serine endopeptidase) inhibitor that interferes with the action of prolyl oligopeptidase (EC 3.4.21.26).
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitorAn EC 1.8.1.* (oxidoreductase acting on sulfur group of donors, NAD+ or NADP+ as acceptor) inhibitor that interferes with the action of trypanothione-disulfide reductase (EC 1.8.1.12).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
phenothiazines
piperidines
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (157)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency25.11890.004023.8416100.0000AID485290
LuciferasePhotinus pyralis (common eastern firefly)Potency40.53340.007215.758889.3584AID624030
acetylcholinesteraseHomo sapiens (human)Potency28.72580.002541.796015,848.9004AID1347395; AID1347398
RAR-related orphan receptor gammaMus musculus (house mouse)Potency25.11510.006038.004119,952.5996AID1159523
Fumarate hydrataseHomo sapiens (human)Potency35.48130.00308.794948.0869AID1347053
USP1 protein, partialHomo sapiens (human)Potency50.11870.031637.5844354.8130AID504865
GALC proteinHomo sapiens (human)Potency39.810728.183828.183828.1838AID1159614
GLS proteinHomo sapiens (human)Potency11.22020.35487.935539.8107AID624146
TDP1 proteinHomo sapiens (human)Potency9.48180.000811.382244.6684AID686978; AID686979
GLI family zinc finger 3Homo sapiens (human)Potency8.49570.000714.592883.7951AID1259369; AID1259392
Microtubule-associated protein tauHomo sapiens (human)Potency17.78280.180013.557439.8107AID1460
AR proteinHomo sapiens (human)Potency28.64260.000221.22318,912.5098AID1259243; AID1259247; AID743035; AID743054; AID743063
caspase 7, apoptosis-related cysteine proteaseHomo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency9.43920.000657.913322,387.1992AID1259378
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency33.49150.001022.650876.6163AID1224893
progesterone receptorHomo sapiens (human)Potency31.67040.000417.946075.1148AID1346784; AID1346795
regulator of G-protein signaling 4Homo sapiens (human)Potency1.06210.531815.435837.6858AID504845
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency17.37680.01237.983543.2770AID1645841
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency26.83250.000214.376460.0339AID720691; AID720692; AID720719
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency28.03220.003041.611522,387.1992AID1159552; AID1159553; AID1159555
retinoid X nuclear receptor alphaHomo sapiens (human)Potency15.08900.000817.505159.3239AID1159531
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency33.17930.001530.607315,848.9004AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency33.48890.375827.485161.6524AID743217; AID743220
pregnane X nuclear receptorHomo sapiens (human)Potency5.95570.005428.02631,258.9301AID1346982
estrogen nuclear receptor alphaHomo sapiens (human)Potency25.89280.000229.305416,493.5996AID743069; AID743078; AID743079
cytochrome P450 2D6Homo sapiens (human)Potency0.10960.00108.379861.1304AID1645840
polyproteinZika virusPotency35.48130.00308.794948.0869AID1347053
ParkinHomo sapiens (human)Potency23.10930.819914.830644.6684AID720573
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency26.60110.001024.504861.6448AID743215
peroxisome proliferator activated receptor gammaHomo sapiens (human)Potency5.47800.001019.414170.9645AID743094; AID743191
vitamin D (1,25- dihydroxyvitamin D3) receptorHomo sapiens (human)Potency26.83250.023723.228263.5986AID743223
arylsulfatase AHomo sapiens (human)Potency37.93301.069113.955137.9330AID720538
caspase-3Homo sapiens (human)Potency33.49150.013326.981070.7614AID1346978
IDH1Homo sapiens (human)Potency31.62280.005210.865235.4813AID686970
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency16.81590.035520.977089.1251AID504332; AID588346
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_aHomo sapiens (human)Potency33.49150.001723.839378.1014AID743083
thyroid stimulating hormone receptorHomo sapiens (human)Potency31.67040.001628.015177.1139AID1259385; AID1259395
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_aHomo sapiens (human)Potency26.832519.739145.978464.9432AID1159509
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency5.06270.057821.109761.2679AID1159526; AID1159528
Histone H2A.xCricetulus griseus (Chinese hamster)Potency56.27620.039147.5451146.8240AID1224845; AID1224896
Caspase-7Cricetulus griseus (Chinese hamster)Potency33.49150.006723.496068.5896AID1346980
NPC intracellular cholesterol transporter 1 precursorHomo sapiens (human)Potency58.04790.01262.451825.0177AID485313
D(1A) dopamine receptorHomo sapiens (human)Potency2.81840.02245.944922.3872AID488983
atrial natriuretic peptide receptor 1 precursorHomo sapiens (human)Potency0.84920.134610.395030.1313AID1347049
chromobox protein homolog 1Homo sapiens (human)Potency28.18380.006026.168889.1251AID488953
potassium voltage-gated channel subfamily H member 2 isoform dHomo sapiens (human)Potency1.25890.01789.637444.6684AID588834
caspase-3Cricetulus griseus (Chinese hamster)Potency33.49150.006723.496068.5896AID1346980
thyroid hormone receptor beta isoform 2Rattus norvegicus (Norway rat)Potency7.35670.000323.4451159.6830AID743065; AID743067
heat shock protein beta-1Homo sapiens (human)Potency33.48890.042027.378961.6448AID743210
huntingtin isoform 2Homo sapiens (human)Potency19.95260.000618.41981,122.0200AID1688
atrial natriuretic peptide receptor 2 precursorHomo sapiens (human)Potency23.28090.00669.809418.4927AID1347050
ras-related protein Rab-9AHomo sapiens (human)Potency58.04790.00022.621531.4954AID485297
serine/threonine-protein kinase mTOR isoform 1Homo sapiens (human)Potency14.89210.00378.618923.2809AID2660; AID2666; AID2668
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency29.84700.000627.21521,122.0200AID743202
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency100.00000.050127.073689.1251AID588590
gemininHomo sapiens (human)Potency25.64050.004611.374133.4983AID624296; AID624297
peripheral myelin protein 22Rattus norvegicus (Norway rat)Potency28.69540.005612.367736.1254AID624032
M-phase phosphoprotein 8Homo sapiens (human)Potency26.67950.177824.735279.4328AID488949
Interferon betaHomo sapiens (human)Potency29.67330.00339.158239.8107AID1347407
Cellular tumor antigen p53Homo sapiens (human)Potency33.49150.002319.595674.0614AID651631; AID720552
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency11.22020.009610.525035.4813AID1479145
ATPase family AAA domain-containing protein 5Homo sapiens (human)Potency30.43320.011917.942071.5630AID651632; AID720516
Ataxin-2Homo sapiens (human)Potency23.81610.011912.222168.7989AID588378; AID651632
ATP-dependent phosphofructokinaseTrypanosoma brucei brucei TREU927Potency33.80780.060110.745337.9330AID485368
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.507510.0000AID71422
Voltage-dependent L-type calcium channel subunit alpha-1CCavia porcellus (domestic guinea pig)IC50 (µMol)1.32000.02201.64228.9000AID1207713
Voltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)IC50 (µMol)3.50000.00032.63119.0000AID1207778
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)IC50 (µMol)0.04400.00011.00768.7800AID625218
5-hydroxytryptamine receptor 4Cavia porcellus (domestic guinea pig)Ki0.02300.00000.887110.0000AID625218
Bile salt export pumpHomo sapiens (human)IC50 (µMol)24.33000.11007.190310.0000AID1449628
Epidermal growth factor receptorHomo sapiens (human)IC50 (µMol)2.94700.00000.536910.0000AID625184
AlbuminHomo sapiens (human)IC50 (µMol)3.50000.00131.62173.5000AID1207778
Cytochrome P450 1A2Homo sapiens (human)IC50 (µMol)9.33230.00011.774010.0000AID625245
Tyrosine-protein kinase FynHomo sapiens (human)IC50 (µMol)5.05000.00021.67898.6800AID625185
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)IC50 (µMol)1.55100.00041.877310.0000AID625207
Aldo-keto reductase family 1 member B1Rattus norvegicus (Norway rat)Ki1.53800.00322.28879.3160AID625207
Muscarinic acetylcholine receptor M2Homo sapiens (human)IC50 (µMol)0.10600.00001.23267.7930AID625152
Muscarinic acetylcholine receptor M2Homo sapiens (human)Ki0.03800.00000.690210.0000AID625152
Muscarinic acetylcholine receptor M4Homo sapiens (human)IC50 (µMol)0.08000.00001.15467.5858AID625154
Muscarinic acetylcholine receptor M4Homo sapiens (human)Ki0.01100.00000.79519.1201AID625154
Muscarinic acetylcholine receptor M1Rattus norvegicus (Norway rat)IC50 (µMol)0.10600.00052.773925.1700AID141425
Muscarinic acetylcholine receptor M3Rattus norvegicus (Norway rat)IC50 (µMol)0.10600.00052.891925.1700AID141425
Muscarinic acetylcholine receptor M4Rattus norvegicus (Norway rat)IC50 (µMol)0.10600.00052.747825.1700AID141425
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)0.03900.00040.629810.0000AID4783; AID4790
Muscarinic acetylcholine receptor M5Rattus norvegicus (Norway rat)IC50 (µMol)0.10600.00052.780225.1700AID141425
Muscarinic acetylcholine receptor M5Homo sapiens (human)IC50 (µMol)0.00920.00010.99178.0000AID625155
Muscarinic acetylcholine receptor M5Homo sapiens (human)Ki0.00660.00000.72926.9183AID625155
Alpha-2A adrenergic receptorHomo sapiens (human)IC50 (µMol)0.13300.00001.44217.3470AID625201
Alpha-2A adrenergic receptorHomo sapiens (human)Ki0.05000.00010.807410.0000AID625201
Tryptophan 5-hydroxylase 1Rattus norvegicus (Norway rat)IC50 (µMol)0.06000.03801.30806.4300AID64433
Replicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2IC50 (µMol)6.69000.00022.45859.9600AID1804171
Cytochrome P450 2D6Homo sapiens (human)IC50 (µMol)1.77260.00002.015110.0000AID625249
Muscarinic acetylcholine receptor M2Rattus norvegicus (Norway rat)IC50 (µMol)0.10600.00053.314249.5000AID141425
Muscarinic acetylcholine receptor M1Homo sapiens (human)IC50 (µMol)0.00700.00001.403910.0000AID625151
Muscarinic acetylcholine receptor M1Homo sapiens (human)Ki0.00170.00000.59729.1201AID625151
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)IC50 (µMol)1.58800.00001.612910.0000AID625171
Angiotensin-converting enzymeOryctolagus cuniculus (rabbit)Ki1.30100.00042.03378.6606AID625171
D(2) dopamine receptorHomo sapiens (human)IC50 (µMol)0.03500.00000.74728.0000AID625253
D(2) dopamine receptorHomo sapiens (human)Ki0.01570.00000.651810.0000AID1739776; AID625253; AID64143
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.03900.00040.908610.0000AID4783; AID4790
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.507510.0000AID71422
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.06500.00021.874210.0000AID36847; AID36863
Alpha-2B adrenergic receptorHomo sapiens (human)IC50 (µMol)0.38000.00001.23808.1590AID625202
Alpha-2B adrenergic receptorHomo sapiens (human)Ki0.17400.00020.725710.0000AID625202
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.507510.0000AID71422
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.505710.0000AID71422
Alpha-2C adrenergic receptorHomo sapiens (human)IC50 (µMol)0.17100.00001.47257.8980AID625203
Alpha-2C adrenergic receptorHomo sapiens (human)Ki0.02500.00030.483410.0000AID625203
DRattus norvegicus (Norway rat)IC50 (µMol)0.30460.00030.50267.7625AID243189; AID61021; AID61022; AID62868
D(3) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.08500.00030.39075.4000AID62868
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.06000.00031.38338.4000AID625190
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki0.03400.00010.739610.0000AID625190
Alpha-2B adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.03550.00031.09147.7625AID243189
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.497310.0000AID71422
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.507510.0000AID71422
Muscarinic acetylcholine receptor M3Homo sapiens (human)IC50 (µMol)0.09000.00011.01049.9280AID625153
Muscarinic acetylcholine receptor M3Homo sapiens (human)Ki0.01900.00000.54057.7600AID625153
D(1A) dopamine receptorHomo sapiens (human)IC50 (µMol)0.19400.00031.84739.2250AID625252
D(1A) dopamine receptorHomo sapiens (human)Ki0.09700.00010.836310.0000AID625252
D(4) dopamine receptorHomo sapiens (human)IC50 (µMol)1.46800.00011.14239.3280AID625255
D(4) dopamine receptorHomo sapiens (human)Ki0.51500.00000.436210.0000AID625255
Alpha-2C adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.03550.00031.09147.7625AID243189
Alpha-2A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.03550.00031.06917.7625AID243189
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.498810.0000AID71422
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.504610.0000AID71422
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.06500.00021.270410.0000AID36847; AID36863
Sodium-dependent noradrenaline transporter Homo sapiens (human)IC50 (µMol)1.55100.00081.541620.0000AID625207
Sodium-dependent noradrenaline transporter Homo sapiens (human)Ki1.53800.00031.465610.0000AID625207
Sodium-dependent dopamine transporterRattus norvegicus (Norway rat)IC50 (µMol)0.03550.00070.97749.7000AID243189
Histamine H2 receptorHomo sapiens (human)IC50 (µMol)0.95000.02202.298710.0000AID625270
Histamine H2 receptorHomo sapiens (human)Ki0.93400.00062.197310.0000AID625270
Alpha-1D adrenergic receptorHomo sapiens (human)IC50 (µMol)0.00590.00020.75688.8970AID625200
Alpha-1D adrenergic receptorHomo sapiens (human)Ki0.00290.00000.360910.0000AID625200
D(1B) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.08500.00030.35635.4000AID62868
5-hydroxytryptamine receptor 2AHomo sapiens (human)IC50 (µMol)0.00440.00010.88018.8500AID625192
5-hydroxytryptamine receptor 2AHomo sapiens (human)Ki0.04260.00000.385510.0000AID1739777; AID625192
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)0.04400.00011.03029.0000AID625218
5-hydroxytryptamine receptor 2CHomo sapiens (human)Ki0.02300.00010.954910.0000AID625218
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.507510.0000AID71422
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.507510.0000AID71422
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)0.06000.00051.48357.8000AID625190
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki0.03400.00031.29679.2440AID625190
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.507510.0000AID71422
D(4) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.08500.00030.38715.4000AID62868
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)0.03900.00040.615610.0000AID4783; AID4790
Histamine H1 receptorRattus norvegicus (Norway rat)IC50 (µMol)0.09900.00000.32271.2589AID87512
Sodium-dependent serotonin transporterHomo sapiens (human)IC50 (µMol)0.75100.00010.86458.7096AID625222
Sodium-dependent serotonin transporterHomo sapiens (human)Ki0.39900.00000.70488.1930AID625222
Cytochrome P450 2C19Homo sapiens (human)IC50 (µMol)6.37780.00002.398310.0000AID625247
Pleiotropic ABC efflux transporter of multiple drugsSaccharomyces cerevisiae S288CIC50 (µMol)1.30001.30003.37279.6000AID581672
5-hydroxytryptamine receptor 7Homo sapiens (human)Ki0.12550.00030.380610.0000AID1739779; AID6677
Histamine H1 receptorHomo sapiens (human)IC50 (µMol)0.07200.00000.44365.1768AID625269
Histamine H1 receptorHomo sapiens (human)Ki0.00840.00000.511010.0000AID625269
D(3) dopamine receptorHomo sapiens (human)IC50 (µMol)0.00990.00011.01788.7960AID625254
D(3) dopamine receptorHomo sapiens (human)Ki0.00340.00000.602010.0000AID625254
Kappa-type opioid receptorHomo sapiens (human)IC50 (µMol)2.49000.00001.201110.0000AID625162
Kappa-type opioid receptorHomo sapiens (human)Ki0.99600.00000.362410.0000AID625162
5-hydroxytryptamine receptor 2BHomo sapiens (human)IC50 (µMol)0.12900.00011.18738.9125AID625217
5-hydroxytryptamine receptor 2BHomo sapiens (human)Ki0.08200.00030.769310.0000AID625217
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)IC50 (µMol)0.06500.00001.819410.0000AID36847; AID36863
5-hydroxytryptamine receptor 6Homo sapiens (human)IC50 (µMol)0.07100.00170.83815.4200AID625221
5-hydroxytryptamine receptor 6Homo sapiens (human)Ki0.05200.00020.522910.0000AID1739778; AID625221
D(2) dopamine receptorRattus norvegicus (Norway rat)IC50 (µMol)0.05900.00010.54948.4000AID61326; AID62868; AID64294; AID64433
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.02700.00000.437510.0000AID64143
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.506510.0000AID71422
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.505710.0000AID71422
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.507510.0000AID71422
Cathepsin D Bos taurus (cattle)IC50 (µMol)0.06000.00700.91656.3000AID4783
Voltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)IC50 (µMol)3.50000.00032.59559.0000AID1207778
Sodium-dependent dopamine transporter Homo sapiens (human)IC50 (µMol)2.37600.00071.841946.0000AID625256
Sodium-dependent dopamine transporter Homo sapiens (human)Ki1.88800.00021.11158.0280AID625256
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)IC50 (µMol)0.24980.00091.901410.0000AID1207234; AID161281; AID161284; AID243151; AID243189; AID397743; AID408340; AID420668; AID576612; AID625171; AID82355
Potassium voltage-gated channel subfamily H member 2Homo sapiens (human)Ki1.08500.00211.840710.0000AID274128; AID625171
Voltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)IC50 (µMol)3.50000.00032.63119.0000AID1207778
Voltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)IC50 (µMol)2.41000.00032.25459.6000AID1207713; AID1207778
Sodium channel protein type 5 subunit alphaHomo sapiens (human)IC50 (µMol)1.83000.00033.64849.2000AID1207175
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)IC50 (µMol)1.58800.10482.83988.3173AID625171
Nuclear receptor subfamily 3 group C member 3 Bos taurus (cattle)Ki1.30100.08582.95428.6606AID625171
GABA theta subunitRattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.507510.0000AID71422
Sigma non-opioid intracellular receptor 1Homo sapiens (human)IC50 (µMol)0.36300.00030.70285.3660AID625223
Sigma non-opioid intracellular receptor 1Homo sapiens (human)Ki0.15300.00000.490110.0000AID625223
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)IC50 (µMol)1.00000.00010.507510.0000AID71422
Sigma non-opioid intracellular receptor 1Rattus norvegicus (Norway rat)IC50 (µMol)0.75000.00030.55704.2000AID179240
Mucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)IC50 (µMol)3.76500.42001.81574.1000AID1759221; AID1810959
Broad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)IC50 (µMol)6.60000.00401.966610.0000AID1873198
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
AlbuminRattus norvegicus (Norway rat)Kd6.69001.47006.53179.3100AID1215123
Proteasome subunit alpha type-6Homo sapiens (human)EC50 (µMol)12.00007.80008.85009.9000AID1794859
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Snq2pSaccharomyces cerevisiae EC1118INH19.40003.20006.26008.8000AID581808
Pleiotropic ABC efflux transporter of multiple drugsSaccharomyces cerevisiae S288CINH17.00004.20006.18338.3000AID581806
Aldehyde oxidaseHomo sapiens (human)Kii1.30000.00700.65351.3000AID1807421
Aldehyde oxidaseHomo sapiens (human)Kis1.30001.30001.30001.3000AID1807416
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (762)

Processvia Protein(s)Taxonomy
visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
detection of light stimulus involved in visual perceptionVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
MAPK cascadeEpidermal growth factor receptorHomo sapiens (human)
ossificationEpidermal growth factor receptorHomo sapiens (human)
embryonic placenta developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein phosphorylationEpidermal growth factor receptorHomo sapiens (human)
hair follicle developmentEpidermal growth factor receptorHomo sapiens (human)
translationEpidermal growth factor receptorHomo sapiens (human)
signal transductionEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
activation of phospholipase C activityEpidermal growth factor receptorHomo sapiens (human)
salivary gland morphogenesisEpidermal growth factor receptorHomo sapiens (human)
midgut developmentEpidermal growth factor receptorHomo sapiens (human)
learning or memoryEpidermal growth factor receptorHomo sapiens (human)
circadian rhythmEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell population proliferationEpidermal growth factor receptorHomo sapiens (human)
diterpenoid metabolic processEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
cerebral cortex cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell growthEpidermal growth factor receptorHomo sapiens (human)
lung developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cell migrationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of superoxide anion generationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
response to cobalaminEpidermal growth factor receptorHomo sapiens (human)
response to hydroxyisoflavoneEpidermal growth factor receptorHomo sapiens (human)
cellular response to reactive oxygen speciesEpidermal growth factor receptorHomo sapiens (human)
peptidyl-tyrosine autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
ERBB2-EGFR signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of epidermal growth factor receptor signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
negative regulation of protein catabolic processEpidermal growth factor receptorHomo sapiens (human)
vasodilationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphorylationEpidermal growth factor receptorHomo sapiens (human)
ovulation cycleEpidermal growth factor receptorHomo sapiens (human)
hydrogen peroxide metabolic processEpidermal growth factor receptorHomo sapiens (human)
negative regulation of apoptotic processEpidermal growth factor receptorHomo sapiens (human)
positive regulation of MAP kinase activityEpidermal growth factor receptorHomo sapiens (human)
tongue developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of cyclin-dependent protein serine/threonine kinase activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA repairEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA replicationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of bone resorptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of DNA-templated transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of vasoconstrictionEpidermal growth factor receptorHomo sapiens (human)
negative regulation of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIEpidermal growth factor receptorHomo sapiens (human)
regulation of JNK cascadeEpidermal growth factor receptorHomo sapiens (human)
symbiont entry into host cellEpidermal growth factor receptorHomo sapiens (human)
protein autophosphorylationEpidermal growth factor receptorHomo sapiens (human)
astrocyte activationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of fibroblast proliferationEpidermal growth factor receptorHomo sapiens (human)
digestive tract morphogenesisEpidermal growth factor receptorHomo sapiens (human)
positive regulation of smooth muscle cell proliferationEpidermal growth factor receptorHomo sapiens (human)
neuron projection morphogenesisEpidermal growth factor receptorHomo sapiens (human)
epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
positive regulation of epithelial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationEpidermal growth factor receptorHomo sapiens (human)
protein insertion into membraneEpidermal growth factor receptorHomo sapiens (human)
response to calcium ionEpidermal growth factor receptorHomo sapiens (human)
regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicEpidermal growth factor receptorHomo sapiens (human)
positive regulation of glial cell proliferationEpidermal growth factor receptorHomo sapiens (human)
morphogenesis of an epithelial foldEpidermal growth factor receptorHomo sapiens (human)
eyelid development in camera-type eyeEpidermal growth factor receptorHomo sapiens (human)
response to UV-AEpidermal growth factor receptorHomo sapiens (human)
positive regulation of mucus secretionEpidermal growth factor receptorHomo sapiens (human)
regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeEpidermal growth factor receptorHomo sapiens (human)
cellular response to amino acid stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to mechanical stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to cadmium ionEpidermal growth factor receptorHomo sapiens (human)
cellular response to epidermal growth factor stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to estradiol stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to xenobiotic stimulusEpidermal growth factor receptorHomo sapiens (human)
cellular response to dexamethasone stimulusEpidermal growth factor receptorHomo sapiens (human)
positive regulation of canonical Wnt signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
liver regenerationEpidermal growth factor receptorHomo sapiens (human)
cell-cell adhesionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein kinase C activityEpidermal growth factor receptorHomo sapiens (human)
positive regulation of G1/S transition of mitotic cell cycleEpidermal growth factor receptorHomo sapiens (human)
positive regulation of non-canonical NF-kappaB signal transductionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of prolactin secretionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of miRNA transcriptionEpidermal growth factor receptorHomo sapiens (human)
positive regulation of protein localization to plasma membraneEpidermal growth factor receptorHomo sapiens (human)
negative regulation of cardiocyte differentiationEpidermal growth factor receptorHomo sapiens (human)
neurogenesisEpidermal growth factor receptorHomo sapiens (human)
multicellular organism developmentEpidermal growth factor receptorHomo sapiens (human)
positive regulation of kinase activityEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayEpidermal growth factor receptorHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
cellular response to starvationAlbuminHomo sapiens (human)
negative regulation of mitochondrial depolarizationAlbuminHomo sapiens (human)
cellular response to calcium ion starvationAlbuminHomo sapiens (human)
cellular oxidant detoxificationAlbuminHomo sapiens (human)
transportAlbuminHomo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
steroid catabolic processCytochrome P450 1A2Homo sapiens (human)
porphyrin-containing compound metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 1A2Homo sapiens (human)
cholesterol metabolic processCytochrome P450 1A2Homo sapiens (human)
estrogen metabolic processCytochrome P450 1A2Homo sapiens (human)
toxin biosynthetic processCytochrome P450 1A2Homo sapiens (human)
post-embryonic developmentCytochrome P450 1A2Homo sapiens (human)
alkaloid metabolic processCytochrome P450 1A2Homo sapiens (human)
regulation of gene expressionCytochrome P450 1A2Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 1A2Homo sapiens (human)
dibenzo-p-dioxin metabolic processCytochrome P450 1A2Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
lung developmentCytochrome P450 1A2Homo sapiens (human)
methylationCytochrome P450 1A2Homo sapiens (human)
monocarboxylic acid metabolic processCytochrome P450 1A2Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 1A2Homo sapiens (human)
retinol metabolic processCytochrome P450 1A2Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 1A2Homo sapiens (human)
cellular respirationCytochrome P450 1A2Homo sapiens (human)
aflatoxin metabolic processCytochrome P450 1A2Homo sapiens (human)
hydrogen peroxide biosynthetic processCytochrome P450 1A2Homo sapiens (human)
oxidative demethylationCytochrome P450 1A2Homo sapiens (human)
cellular response to cadmium ionCytochrome P450 1A2Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 1A2Homo sapiens (human)
response to singlet oxygenTyrosine-protein kinase FynHomo sapiens (human)
neuron migrationTyrosine-protein kinase FynHomo sapiens (human)
stimulatory C-type lectin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
adaptive immune responseTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of inflammatory response to antigenic stimulusTyrosine-protein kinase FynHomo sapiens (human)
heart processTyrosine-protein kinase FynHomo sapiens (human)
protein phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
calcium ion transportTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
axon guidanceTyrosine-protein kinase FynHomo sapiens (human)
learningTyrosine-protein kinase FynHomo sapiens (human)
feeding behaviorTyrosine-protein kinase FynHomo sapiens (human)
regulation of cell shapeTyrosine-protein kinase FynHomo sapiens (human)
gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of gene expressionTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of hydrogen peroxide biosynthetic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of neuron projection developmentTyrosine-protein kinase FynHomo sapiens (human)
protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
forebrain developmentTyrosine-protein kinase FynHomo sapiens (human)
T cell costimulationTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein ubiquitinationTyrosine-protein kinase FynHomo sapiens (human)
intracellular signal transductionTyrosine-protein kinase FynHomo sapiens (human)
cellular response to platelet-derived growth factor stimulusTyrosine-protein kinase FynHomo sapiens (human)
Fc-gamma receptor signaling pathway involved in phagocytosisTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of protein catabolic processTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of tyrosine phosphorylation of STAT proteinTyrosine-protein kinase FynHomo sapiens (human)
response to ethanolTyrosine-protein kinase FynHomo sapiens (human)
vascular endothelial growth factor receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
dendrite morphogenesisTyrosine-protein kinase FynHomo sapiens (human)
regulation of peptidyl-tyrosine phosphorylationTyrosine-protein kinase FynHomo sapiens (human)
activated T cell proliferationTyrosine-protein kinase FynHomo sapiens (human)
modulation of chemical synaptic transmissionTyrosine-protein kinase FynHomo sapiens (human)
T cell receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
leukocyte migrationTyrosine-protein kinase FynHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of painTyrosine-protein kinase FynHomo sapiens (human)
cellular response to hydrogen peroxideTyrosine-protein kinase FynHomo sapiens (human)
cellular response to transforming growth factor beta stimulusTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein targeting to membraneTyrosine-protein kinase FynHomo sapiens (human)
dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to nucleusTyrosine-protein kinase FynHomo sapiens (human)
regulation of glutamate receptor signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
negative regulation of dendritic spine maintenanceTyrosine-protein kinase FynHomo sapiens (human)
response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to amyloid-betaTyrosine-protein kinase FynHomo sapiens (human)
cellular response to L-glutamateTyrosine-protein kinase FynHomo sapiens (human)
cellular response to glycineTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of protein localization to membraneTyrosine-protein kinase FynHomo sapiens (human)
regulation of calcium ion import across plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
positive regulation of cysteine-type endopeptidase activityTyrosine-protein kinase FynHomo sapiens (human)
innate immune responseTyrosine-protein kinase FynHomo sapiens (human)
cell differentiationTyrosine-protein kinase FynHomo sapiens (human)
cell surface receptor protein tyrosine kinase signaling pathwayTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of heart contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
response to virusMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M2Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M2Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M2Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M4Homo sapiens (human)
cell surface receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M4Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M4Homo sapiens (human)
gastric acid secretionMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
dopamine transportMuscarinic acetylcholine receptor M5Homo sapiens (human)
transmission of nerve impulseMuscarinic acetylcholine receptor M5Homo sapiens (human)
regulation of phosphatidylinositol dephosphorylationMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M5Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M5Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M5Homo sapiens (human)
positive regulation of cytokine productionAlpha-2A adrenergic receptorHomo sapiens (human)
DNA replicationAlpha-2A adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
Ras protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
Rho protein signal transductionAlpha-2A adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2A adrenergic receptorHomo sapiens (human)
actin cytoskeleton organizationAlpha-2A adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of cell migrationAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2A adrenergic receptorHomo sapiens (human)
cellular response to hormone stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2A adrenergic receptorHomo sapiens (human)
vasodilationAlpha-2A adrenergic receptorHomo sapiens (human)
glucose homeostasisAlpha-2A adrenergic receptorHomo sapiens (human)
fear responseAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of potassium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAP kinase activityAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of epidermal growth factor receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion-dependent exocytosisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2A adrenergic receptorHomo sapiens (human)
intestinal absorptionAlpha-2A adrenergic receptorHomo sapiens (human)
thermoceptionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of lipid catabolic processAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of membrane protein ectodomain proteolysisAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transportAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretion involved in cellular response to glucose stimulusAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of uterine smooth muscle contractionAlpha-2A adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
adenylate cyclase-inhibiting adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
phospholipase C-activating adrenergic receptor signaling pathwayAlpha-2A adrenergic receptorHomo sapiens (human)
positive regulation of wound healingAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionAlpha-2A adrenergic receptorHomo sapiens (human)
negative regulation of calcium ion transmembrane transporter activityAlpha-2A adrenergic receptorHomo sapiens (human)
xenobiotic metabolic processCytochrome P450 2D6Homo sapiens (human)
steroid metabolic processCytochrome P450 2D6Homo sapiens (human)
cholesterol metabolic processCytochrome P450 2D6Homo sapiens (human)
estrogen metabolic processCytochrome P450 2D6Homo sapiens (human)
coumarin metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
alkaloid catabolic processCytochrome P450 2D6Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2D6Homo sapiens (human)
isoquinoline alkaloid metabolic processCytochrome P450 2D6Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2D6Homo sapiens (human)
retinol metabolic processCytochrome P450 2D6Homo sapiens (human)
long-chain fatty acid biosynthetic processCytochrome P450 2D6Homo sapiens (human)
negative regulation of bindingCytochrome P450 2D6Homo sapiens (human)
oxidative demethylationCytochrome P450 2D6Homo sapiens (human)
negative regulation of cellular organofluorine metabolic processCytochrome P450 2D6Homo sapiens (human)
arachidonic acid metabolic processCytochrome P450 2D6Homo sapiens (human)
positive regulation of monoatomic ion transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
neuromuscular synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of locomotionMuscarinic acetylcholine receptor M1Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M1Homo sapiens (human)
cognitionMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of postsynaptic membrane potentialMuscarinic acetylcholine receptor M1Homo sapiens (human)
regulation of glial cell proliferationMuscarinic acetylcholine receptor M1Homo sapiens (human)
positive regulation of intracellular protein transportMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M1Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M1Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M1Homo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
temperature homeostasisD(2) dopamine receptorHomo sapiens (human)
response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein phosphorylationD(2) dopamine receptorHomo sapiens (human)
response to amphetamineD(2) dopamine receptorHomo sapiens (human)
nervous system process involved in regulation of systemic arterial blood pressureD(2) dopamine receptorHomo sapiens (human)
regulation of heart rateD(2) dopamine receptorHomo sapiens (human)
regulation of sodium ion transportD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(2) dopamine receptorHomo sapiens (human)
positive regulation of neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
positive regulation of receptor internalizationD(2) dopamine receptorHomo sapiens (human)
autophagyD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
neuron-neuron synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
neuroblast proliferationD(2) dopamine receptorHomo sapiens (human)
axonogenesisD(2) dopamine receptorHomo sapiens (human)
synapse assemblyD(2) dopamine receptorHomo sapiens (human)
sensory perception of smellD(2) dopamine receptorHomo sapiens (human)
long-term memoryD(2) dopamine receptorHomo sapiens (human)
grooming behaviorD(2) dopamine receptorHomo sapiens (human)
locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
adult walking behaviorD(2) dopamine receptorHomo sapiens (human)
protein localizationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell population proliferationD(2) dopamine receptorHomo sapiens (human)
associative learningD(2) dopamine receptorHomo sapiens (human)
visual learningD(2) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(2) dopamine receptorHomo sapiens (human)
response to light stimulusD(2) dopamine receptorHomo sapiens (human)
response to toxic substanceD(2) dopamine receptorHomo sapiens (human)
response to iron ionD(2) dopamine receptorHomo sapiens (human)
response to inactivityD(2) dopamine receptorHomo sapiens (human)
Wnt signaling pathwayD(2) dopamine receptorHomo sapiens (human)
striatum developmentD(2) dopamine receptorHomo sapiens (human)
orbitofrontal cortex developmentD(2) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(2) dopamine receptorHomo sapiens (human)
adenohypophysis developmentD(2) dopamine receptorHomo sapiens (human)
negative regulation of cell migrationD(2) dopamine receptorHomo sapiens (human)
peristalsisD(2) dopamine receptorHomo sapiens (human)
auditory behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of synaptic transmission, GABAergicD(2) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(2) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
response to histamineD(2) dopamine receptorHomo sapiens (human)
response to nicotineD(2) dopamine receptorHomo sapiens (human)
positive regulation of urine volumeD(2) dopamine receptorHomo sapiens (human)
positive regulation of renal sodium excretionD(2) dopamine receptorHomo sapiens (human)
positive regulation of multicellular organism growthD(2) dopamine receptorHomo sapiens (human)
response to cocaineD(2) dopamine receptorHomo sapiens (human)
negative regulation of circadian sleep/wake cycle, sleepD(2) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(2) dopamine receptorHomo sapiens (human)
drinking behaviorD(2) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(2) dopamine receptorHomo sapiens (human)
response to morphineD(2) dopamine receptorHomo sapiens (human)
pigmentationD(2) dopamine receptorHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
positive regulation of G protein-coupled receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(2) dopamine receptorHomo sapiens (human)
negative regulation of innate immune responseD(2) dopamine receptorHomo sapiens (human)
positive regulation of transcription by RNA polymerase IID(2) dopamine receptorHomo sapiens (human)
negative regulation of insulin secretionD(2) dopamine receptorHomo sapiens (human)
acid secretionD(2) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(2) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(2) dopamine receptorHomo sapiens (human)
regulation of long-term neuronal synaptic plasticityD(2) dopamine receptorHomo sapiens (human)
response to axon injuryD(2) dopamine receptorHomo sapiens (human)
branching morphogenesis of a nerveD(2) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(2) dopamine receptorHomo sapiens (human)
epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of epithelial cell proliferationD(2) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(2) dopamine receptorHomo sapiens (human)
release of sequestered calcium ion into cytosolD(2) dopamine receptorHomo sapiens (human)
dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
regulation of synapse structural plasticityD(2) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(2) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(2) dopamine receptorHomo sapiens (human)
excitatory postsynaptic potentialD(2) dopamine receptorHomo sapiens (human)
positive regulation of growth hormone secretionD(2) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(2) dopamine receptorHomo sapiens (human)
negative regulation of dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascadeD(2) dopamine receptorHomo sapiens (human)
regulation of locomotion involved in locomotory behaviorD(2) dopamine receptorHomo sapiens (human)
postsynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(2) dopamine receptorHomo sapiens (human)
negative regulation of cellular response to hypoxiaD(2) dopamine receptorHomo sapiens (human)
positive regulation of glial cell-derived neurotrophic factor productionD(2) dopamine receptorHomo sapiens (human)
positive regulation of long-term synaptic potentiationD(2) dopamine receptorHomo sapiens (human)
hyaloid vascular plexus regressionD(2) dopamine receptorHomo sapiens (human)
negative regulation of neuron migrationD(2) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(2) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(2) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(2) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(2) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(2) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(2) dopamine receptorHomo sapiens (human)
MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
angiogenesisAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of vascular associated smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2B adrenergic receptorHomo sapiens (human)
female pregnancyAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2B adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2B adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2B adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of blood pressureAlpha-2B adrenergic receptorHomo sapiens (human)
positive regulation of uterine smooth muscle contractionAlpha-2B adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2B adrenergic receptorHomo sapiens (human)
regulation of smooth muscle contractionAlpha-2C adrenergic receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of norepinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-2C adrenergic receptorHomo sapiens (human)
platelet activationAlpha-2C adrenergic receptorHomo sapiens (human)
activation of protein kinase B activityAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of epinephrine secretionAlpha-2C adrenergic receptorHomo sapiens (human)
receptor transactivationAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-2C adrenergic receptorHomo sapiens (human)
positive regulation of neuron differentiationAlpha-2C adrenergic receptorHomo sapiens (human)
adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-2C adrenergic receptorHomo sapiens (human)
negative regulation of insulin secretionAlpha-2C adrenergic receptorHomo sapiens (human)
calcium-mediated signalingMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of monoatomic ion transmembrane transporter activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
signal transductionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
phospholipase C-activating G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
synaptic transmission, cholinergicMuscarinic acetylcholine receptor M3Homo sapiens (human)
nervous system developmentMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of insulin secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein modification processMuscarinic acetylcholine receptor M3Homo sapiens (human)
positive regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
saliva secretionMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ion channel modulating, G protein-coupled receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
ligand-gated ion channel signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
regulation of smooth muscle contractionMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerMuscarinic acetylcholine receptor M3Homo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled acetylcholine receptor signaling pathwayMuscarinic acetylcholine receptor M3Homo sapiens (human)
chemical synaptic transmissionMuscarinic acetylcholine receptor M3Homo sapiens (human)
temperature homeostasisD(1A) dopamine receptorHomo sapiens (human)
conditioned taste aversionD(1A) dopamine receptorHomo sapiens (human)
behavioral fear responseD(1A) dopamine receptorHomo sapiens (human)
regulation of protein phosphorylationD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(1A) dopamine receptorHomo sapiens (human)
response to amphetamineD(1A) dopamine receptorHomo sapiens (human)
protein import into nucleusD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
activation of adenylate cyclase activityD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
synapse assemblyD(1A) dopamine receptorHomo sapiens (human)
memoryD(1A) dopamine receptorHomo sapiens (human)
mating behaviorD(1A) dopamine receptorHomo sapiens (human)
grooming behaviorD(1A) dopamine receptorHomo sapiens (human)
adult walking behaviorD(1A) dopamine receptorHomo sapiens (human)
visual learningD(1A) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(1A) dopamine receptorHomo sapiens (human)
astrocyte developmentD(1A) dopamine receptorHomo sapiens (human)
dopamine transportD(1A) dopamine receptorHomo sapiens (human)
transmission of nerve impulseD(1A) dopamine receptorHomo sapiens (human)
neuronal action potentialD(1A) dopamine receptorHomo sapiens (human)
dentate gyrus developmentD(1A) dopamine receptorHomo sapiens (human)
striatum developmentD(1A) dopamine receptorHomo sapiens (human)
cerebral cortex GABAergic interneuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of cell migrationD(1A) dopamine receptorHomo sapiens (human)
peristalsisD(1A) dopamine receptorHomo sapiens (human)
operant conditioningD(1A) dopamine receptorHomo sapiens (human)
synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
vasodilationD(1A) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(1A) dopamine receptorHomo sapiens (human)
maternal behaviorD(1A) dopamine receptorHomo sapiens (human)
positive regulation of potassium ion transportD(1A) dopamine receptorHomo sapiens (human)
glucose importD(1A) dopamine receptorHomo sapiens (human)
habituationD(1A) dopamine receptorHomo sapiens (human)
sensitizationD(1A) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(1A) dopamine receptorHomo sapiens (human)
positive regulation of release of sequestered calcium ion into cytosolD(1A) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of synaptic transmission, glutamatergicD(1A) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(1A) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic potentiationD(1A) dopamine receptorHomo sapiens (human)
long-term synaptic depressionD(1A) dopamine receptorHomo sapiens (human)
cellular response to catecholamine stimulusD(1A) dopamine receptorHomo sapiens (human)
modification of postsynaptic structureD(1A) dopamine receptorHomo sapiens (human)
presynaptic modulation of chemical synaptic transmissionD(1A) dopamine receptorHomo sapiens (human)
positive regulation of neuron migrationD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(1A) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(1A) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral fear responseD(4) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(4) dopamine receptorHomo sapiens (human)
response to amphetamineD(4) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
dopamine receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
adult locomotory behaviorD(4) dopamine receptorHomo sapiens (human)
positive regulation of sodium:proton antiporter activityD(4) dopamine receptorHomo sapiens (human)
positive regulation of kinase activityD(4) dopamine receptorHomo sapiens (human)
response to histamineD(4) dopamine receptorHomo sapiens (human)
social behaviorD(4) dopamine receptorHomo sapiens (human)
regulation of dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(4) dopamine receptorHomo sapiens (human)
fear responseD(4) dopamine receptorHomo sapiens (human)
regulation of circadian rhythmD(4) dopamine receptorHomo sapiens (human)
positive regulation of MAP kinase activityD(4) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(4) dopamine receptorHomo sapiens (human)
behavioral response to ethanolD(4) dopamine receptorHomo sapiens (human)
rhythmic processD(4) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(4) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(4) dopamine receptorHomo sapiens (human)
positive regulation of dopamine uptake involved in synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
inhibitory postsynaptic potentialD(4) dopamine receptorHomo sapiens (human)
regulation of postsynaptic neurotransmitter receptor internalizationD(4) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(4) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathwayD(4) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerD(4) dopamine receptorHomo sapiens (human)
chemical synaptic transmissionD(4) dopamine receptorHomo sapiens (human)
monoamine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent noradrenaline transporter Homo sapiens (human)
chemical synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent noradrenaline transporter Homo sapiens (human)
response to painSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent noradrenaline transporter Homo sapiens (human)
neuron cellular homeostasisSodium-dependent noradrenaline transporter Homo sapiens (human)
amino acid transportSodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine transportSodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent noradrenaline transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent noradrenaline transporter Homo sapiens (human)
gastric acid secretionHistamine H2 receptorHomo sapiens (human)
immune responseHistamine H2 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H2 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H2 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cell population proliferationAlpha-1D adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1D adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of vasoconstrictionAlpha-1D adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1D adrenergic receptorHomo sapiens (human)
temperature homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytokine production involved in immune response5-hydroxytryptamine receptor 2AHomo sapiens (human)
glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2AHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cytosolic calcium ion concentration5-hydroxytryptamine receptor 2AHomo sapiens (human)
memory5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2AHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
regulation of dopamine secretion5-hydroxytryptamine receptor 2AHomo sapiens (human)
artery smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
urinary bladder smooth muscle contraction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of heat generation5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of potassium ion transport5-hydroxytryptamine receptor 2AHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of neuron apoptotic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein localization to cytoskeleton5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of glycolytic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of vasoconstriction5-hydroxytryptamine receptor 2AHomo sapiens (human)
symbiont entry into host cell5-hydroxytryptamine receptor 2AHomo sapiens (human)
sensitization5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral response to cocaine5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of inflammatory response5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylation5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of temperature stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
detection of mechanical stimulus involved in sensory perception of pain5-hydroxytryptamine receptor 2AHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2AHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergic5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic modulation of chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of execution phase of apoptosis5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of platelet aggregation5-hydroxytryptamine receptor 2AHomo sapiens (human)
positive regulation of DNA biosynthetic process5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2AHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2AHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
monoamine transportSodium-dependent serotonin transporterHomo sapiens (human)
response to hypoxiaSodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transportSodium-dependent serotonin transporterHomo sapiens (human)
response to nutrientSodium-dependent serotonin transporterHomo sapiens (human)
memorySodium-dependent serotonin transporterHomo sapiens (human)
circadian rhythmSodium-dependent serotonin transporterHomo sapiens (human)
response to xenobiotic stimulusSodium-dependent serotonin transporterHomo sapiens (human)
response to toxic substanceSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of gene expressionSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of serotonin secretionSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of cerebellar granule cell precursor proliferationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of synaptic transmission, dopaminergicSodium-dependent serotonin transporterHomo sapiens (human)
response to estradiolSodium-dependent serotonin transporterHomo sapiens (human)
social behaviorSodium-dependent serotonin transporterHomo sapiens (human)
vasoconstrictionSodium-dependent serotonin transporterHomo sapiens (human)
sperm ejaculationSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of neuron differentiationSodium-dependent serotonin transporterHomo sapiens (human)
positive regulation of cell cycleSodium-dependent serotonin transporterHomo sapiens (human)
negative regulation of organ growthSodium-dependent serotonin transporterHomo sapiens (human)
behavioral response to cocaineSodium-dependent serotonin transporterHomo sapiens (human)
enteric nervous system developmentSodium-dependent serotonin transporterHomo sapiens (human)
brain morphogenesisSodium-dependent serotonin transporterHomo sapiens (human)
serotonin uptakeSodium-dependent serotonin transporterHomo sapiens (human)
membrane depolarizationSodium-dependent serotonin transporterHomo sapiens (human)
platelet aggregationSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to retinoic acidSodium-dependent serotonin transporterHomo sapiens (human)
cellular response to cGMPSodium-dependent serotonin transporterHomo sapiens (human)
regulation of thalamus sizeSodium-dependent serotonin transporterHomo sapiens (human)
conditioned place preferenceSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion transmembrane transportSodium-dependent serotonin transporterHomo sapiens (human)
amino acid transportSodium-dependent serotonin transporterHomo sapiens (human)
long-chain fatty acid metabolic processCytochrome P450 2C19Homo sapiens (human)
xenobiotic metabolic processCytochrome P450 2C19Homo sapiens (human)
steroid metabolic processCytochrome P450 2C19Homo sapiens (human)
monoterpenoid metabolic processCytochrome P450 2C19Homo sapiens (human)
epoxygenase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
xenobiotic catabolic processCytochrome P450 2C19Homo sapiens (human)
omega-hydroxylase P450 pathwayCytochrome P450 2C19Homo sapiens (human)
smooth muscle contraction5-hydroxytryptamine receptor 7Homo sapiens (human)
circadian rhythm5-hydroxytryptamine receptor 7Homo sapiens (human)
blood circulation5-hydroxytryptamine receptor 7Homo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 7Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 7Homo sapiens (human)
inflammatory responseHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
memoryHistamine H1 receptorHomo sapiens (human)
visual learningHistamine H1 receptorHomo sapiens (human)
regulation of vascular permeabilityHistamine H1 receptorHomo sapiens (human)
positive regulation of vasoconstrictionHistamine H1 receptorHomo sapiens (human)
regulation of synaptic plasticityHistamine H1 receptorHomo sapiens (human)
cellular response to histamineHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathwayHistamine H1 receptorHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messengerHistamine H1 receptorHomo sapiens (human)
chemical synaptic transmissionHistamine H1 receptorHomo sapiens (human)
response to ethanolD(3) dopamine receptorHomo sapiens (human)
synaptic transmission, dopaminergicD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor internalizationD(3) dopamine receptorHomo sapiens (human)
intracellular calcium ion homeostasisD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-inhibiting dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
learning or memoryD(3) dopamine receptorHomo sapiens (human)
learningD(3) dopamine receptorHomo sapiens (human)
locomotory behaviorD(3) dopamine receptorHomo sapiens (human)
visual learningD(3) dopamine receptorHomo sapiens (human)
response to xenobiotic stimulusD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine secretionD(3) dopamine receptorHomo sapiens (human)
positive regulation of cytokinesisD(3) dopamine receptorHomo sapiens (human)
circadian regulation of gene expressionD(3) dopamine receptorHomo sapiens (human)
response to histamineD(3) dopamine receptorHomo sapiens (human)
social behaviorD(3) dopamine receptorHomo sapiens (human)
response to cocaineD(3) dopamine receptorHomo sapiens (human)
dopamine metabolic processD(3) dopamine receptorHomo sapiens (human)
response to morphineD(3) dopamine receptorHomo sapiens (human)
negative regulation of blood pressureD(3) dopamine receptorHomo sapiens (human)
positive regulation of mitotic nuclear divisionD(3) dopamine receptorHomo sapiens (human)
acid secretionD(3) dopamine receptorHomo sapiens (human)
behavioral response to cocaineD(3) dopamine receptorHomo sapiens (human)
negative regulation of oligodendrocyte differentiationD(3) dopamine receptorHomo sapiens (human)
arachidonic acid secretionD(3) dopamine receptorHomo sapiens (human)
negative regulation of protein secretionD(3) dopamine receptorHomo sapiens (human)
musculoskeletal movement, spinal reflex actionD(3) dopamine receptorHomo sapiens (human)
regulation of dopamine uptake involved in synaptic transmissionD(3) dopamine receptorHomo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transductionD(3) dopamine receptorHomo sapiens (human)
prepulse inhibitionD(3) dopamine receptorHomo sapiens (human)
positive regulation of dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of adenylate cyclase activityD(3) dopamine receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
negative regulation of voltage-gated calcium channel activityD(3) dopamine receptorHomo sapiens (human)
regulation of potassium ion transportD(3) dopamine receptorHomo sapiens (human)
phospholipase C-activating dopamine receptor signaling pathwayD(3) dopamine receptorHomo sapiens (human)
positive regulation of MAPK cascadeD(3) dopamine receptorHomo sapiens (human)
negative regulation of cytosolic calcium ion concentrationD(3) dopamine receptorHomo sapiens (human)
negative regulation of synaptic transmission, glutamatergicD(3) dopamine receptorHomo sapiens (human)
immune responseKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
chemical synaptic transmissionKappa-type opioid receptorHomo sapiens (human)
sensory perceptionKappa-type opioid receptorHomo sapiens (human)
locomotory behaviorKappa-type opioid receptorHomo sapiens (human)
sensory perception of painKappa-type opioid receptorHomo sapiens (human)
adenylate cyclase-inhibiting opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
response to insulinKappa-type opioid receptorHomo sapiens (human)
positive regulation of dopamine secretionKappa-type opioid receptorHomo sapiens (human)
negative regulation of luteinizing hormone secretionKappa-type opioid receptorHomo sapiens (human)
response to nicotineKappa-type opioid receptorHomo sapiens (human)
G protein-coupled opioid receptor signaling pathwayKappa-type opioid receptorHomo sapiens (human)
maternal behaviorKappa-type opioid receptorHomo sapiens (human)
eating behaviorKappa-type opioid receptorHomo sapiens (human)
response to estrogenKappa-type opioid receptorHomo sapiens (human)
estrous cycleKappa-type opioid receptorHomo sapiens (human)
response to ethanolKappa-type opioid receptorHomo sapiens (human)
regulation of saliva secretionKappa-type opioid receptorHomo sapiens (human)
behavioral response to cocaineKappa-type opioid receptorHomo sapiens (human)
sensory perception of temperature stimulusKappa-type opioid receptorHomo sapiens (human)
defense response to virusKappa-type opioid receptorHomo sapiens (human)
cellular response to lipopolysaccharideKappa-type opioid receptorHomo sapiens (human)
cellular response to glucose stimulusKappa-type opioid receptorHomo sapiens (human)
positive regulation of p38MAPK cascadeKappa-type opioid receptorHomo sapiens (human)
positive regulation of potassium ion transmembrane transportKappa-type opioid receptorHomo sapiens (human)
response to acrylamideKappa-type opioid receptorHomo sapiens (human)
positive regulation of eating behaviorKappa-type opioid receptorHomo sapiens (human)
conditioned place preferenceKappa-type opioid receptorHomo sapiens (human)
neuropeptide signaling pathwayKappa-type opioid receptorHomo sapiens (human)
neural crest cell migration5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cytokine production5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of endothelial cell proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor internalization5-hydroxytryptamine receptor 2BHomo sapiens (human)
heart morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
cardiac muscle hypertrophy5-hydroxytryptamine receptor 2BHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
activation of phospholipase C activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell population proliferation5-hydroxytryptamine receptor 2BHomo sapiens (human)
response to xenobiotic stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
neural crest cell differentiation5-hydroxytryptamine receptor 2BHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphorylation5-hydroxytryptamine receptor 2BHomo sapiens (human)
calcium-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 2BHomo sapiens (human)
negative regulation of apoptotic process5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of MAP kinase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
phosphatidylinositol 3-kinase/protein kinase B signal transduction5-hydroxytryptamine receptor 2BHomo sapiens (human)
embryonic morphogenesis5-hydroxytryptamine receptor 2BHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of nitric-oxide synthase activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of cell division5-hydroxytryptamine receptor 2BHomo sapiens (human)
ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein kinase C signaling5-hydroxytryptamine receptor 2BHomo sapiens (human)
cellular response to temperature stimulus5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2BHomo sapiens (human)
cerebral cortex cell migration5-hydroxytryptamine receptor 6Homo sapiens (human)
positive regulation of TOR signaling5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 6Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 6Homo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processProteasome subunit alpha type-6Homo sapiens (human)
regulation of inflammatory responseProteasome subunit alpha type-6Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityProteasome subunit alpha type-6Homo sapiens (human)
proteolysis involved in protein catabolic processProteasome subunit alpha type-6Homo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
sensory perception of soundVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
positive regulation of calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion importVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
membrane depolarization during SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transporter activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
regulation of potassium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
monoamine transportSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transportSodium-dependent dopamine transporter Homo sapiens (human)
lactationSodium-dependent dopamine transporter Homo sapiens (human)
sensory perception of smellSodium-dependent dopamine transporter Homo sapiens (human)
locomotory behaviorSodium-dependent dopamine transporter Homo sapiens (human)
response to xenobiotic stimulusSodium-dependent dopamine transporter Homo sapiens (human)
response to iron ionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine transportSodium-dependent dopamine transporter Homo sapiens (human)
adenohypophysis developmentSodium-dependent dopamine transporter Homo sapiens (human)
response to nicotineSodium-dependent dopamine transporter Homo sapiens (human)
positive regulation of multicellular organism growthSodium-dependent dopamine transporter Homo sapiens (human)
regulation of dopamine metabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to cocaineSodium-dependent dopamine transporter Homo sapiens (human)
dopamine biosynthetic processSodium-dependent dopamine transporter Homo sapiens (human)
dopamine catabolic processSodium-dependent dopamine transporter Homo sapiens (human)
response to ethanolSodium-dependent dopamine transporter Homo sapiens (human)
cognitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptake involved in synaptic transmissionSodium-dependent dopamine transporter Homo sapiens (human)
response to cAMPSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
prepulse inhibitionSodium-dependent dopamine transporter Homo sapiens (human)
dopamine uptakeSodium-dependent dopamine transporter Homo sapiens (human)
hyaloid vascular plexus regressionSodium-dependent dopamine transporter Homo sapiens (human)
amino acid transportSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine transportSodium-dependent dopamine transporter Homo sapiens (human)
sodium ion transmembrane transportSodium-dependent dopamine transporter Homo sapiens (human)
lipid metabolic processAldehyde oxidaseHomo sapiens (human)
xenobiotic metabolic processAldehyde oxidaseHomo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by hormonePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of DNA-templated transcriptionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion homeostasisPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cardiac muscle contractionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cellular response to xenobiotic stimulusPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane depolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of heart rate by cardiac conductionPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
membrane repolarization during ventricular cardiac muscle cell action potentialPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
positive regulation of potassium ion transmembrane transportPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
negative regulation of potassium ion export across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
potassium ion import across plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
skeletal system developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
extraocular skeletal muscle developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
striated muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
endoplasmic reticulum organizationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
myoblast fusionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
neuromuscular junction developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle adaptationVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
skeletal muscle fiber developmentVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
release of sequestered calcium ion into cytosolVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cellular response to caffeineVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
immune system developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
heart developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
embryonic forelimb morphogenesisVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
camera-type eye developmentVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of adenylate cyclase activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
positive regulation of muscle contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transport into cytosolVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transport via high voltage-gated calcium channelVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion transmembrane transportVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cardiac muscle cell action potential involved in contractionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
cell communication by electrical coupling involved in cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rate by cardiac conductionVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of ventricular cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calcium ion import across plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
regulation of heart rateSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac conduction system developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac ventricle developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
brainstem developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of sodium ion transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
response to denervation involved in regulation of muscle adaptationSodium channel protein type 5 subunit alphaHomo sapiens (human)
telencephalon developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
cerebellum developmentSodium channel protein type 5 subunit alphaHomo sapiens (human)
sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
odontogenesis of dentin-containing toothSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
positive regulation of epithelial cell proliferationSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of atrial cardiac muscle cell membrane repolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of ventricular cardiac muscle cell membrane depolarizationSodium channel protein type 5 subunit alphaHomo sapiens (human)
cellular response to calcium ionSodium channel protein type 5 subunit alphaHomo sapiens (human)
cardiac muscle cell action potential involved in contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of cardiac muscle cell contractionSodium channel protein type 5 subunit alphaHomo sapiens (human)
ventricular cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during Purkinje myocyte cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
AV node cell to bundle of His cell communicationSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of heart rate by cardiac conductionSodium channel protein type 5 subunit alphaHomo sapiens (human)
membrane depolarization during atrial cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
regulation of sodium ion transmembrane transportSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell population proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of B cell proliferationATPase family AAA domain-containing protein 5Homo sapiens (human)
nuclear DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
signal transduction in response to DNA damageATPase family AAA domain-containing protein 5Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
isotype switchingATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of DNA replicationATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of isotype switching to IgG isotypesATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloadingATPase family AAA domain-containing protein 5Homo sapiens (human)
regulation of mitotic cell cycle phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorATPase family AAA domain-containing protein 5Homo sapiens (human)
positive regulation of cell cycle G2/M phase transitionATPase family AAA domain-containing protein 5Homo sapiens (human)
negative regulation of receptor internalizationAtaxin-2Homo sapiens (human)
regulation of translationAtaxin-2Homo sapiens (human)
RNA metabolic processAtaxin-2Homo sapiens (human)
P-body assemblyAtaxin-2Homo sapiens (human)
stress granule assemblyAtaxin-2Homo sapiens (human)
RNA transportAtaxin-2Homo sapiens (human)
lipid transportSigma non-opioid intracellular receptor 1Homo sapiens (human)
nervous system developmentSigma non-opioid intracellular receptor 1Homo sapiens (human)
G protein-coupled opioid receptor signaling pathwaySigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of neuron apoptotic processSigma non-opioid intracellular receptor 1Homo sapiens (human)
protein homotrimerizationSigma non-opioid intracellular receptor 1Homo sapiens (human)
regulation of apoptotic processMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
B-1 B cell differentiationMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
positive regulation of T cell cytokine productionMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
proteolysisMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
defense responseMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
response to fungusMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
positive regulation of protein ubiquitinationMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
lipopolysaccharide-mediated signaling pathwayMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
positive regulation of interleukin-1 beta productionMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
positive regulation of interleukin-2 productionMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
T cell proliferationMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
negative regulation of apoptotic processMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transductionMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
positive regulation of cysteine-type endopeptidase activity involved in apoptotic processMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
T cell receptor signaling pathwayMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
regulation of T cell receptor signaling pathwayMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
positive regulation of NF-kappaB transcription factor activityMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
nuclear exportMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
proteolysis involved in protein catabolic processMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
positive regulation of T-helper 17 cell differentiationMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
innate immune responseMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
B cell activationMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
lipid transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid biosynthetic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate metabolic processBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transmembrane transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transepithelial transportBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
renal urate salt excretionBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
export across plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
cellular detoxificationBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transport across blood-brain barrierBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (214)

Processvia Protein(s)Taxonomy
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
virus receptor activityEpidermal growth factor receptorHomo sapiens (human)
chromatin bindingEpidermal growth factor receptorHomo sapiens (human)
double-stranded DNA bindingEpidermal growth factor receptorHomo sapiens (human)
MAP kinase kinase kinase activityEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane signaling receptor activityEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor receptor activityEpidermal growth factor receptorHomo sapiens (human)
integrin bindingEpidermal growth factor receptorHomo sapiens (human)
protein bindingEpidermal growth factor receptorHomo sapiens (human)
calmodulin bindingEpidermal growth factor receptorHomo sapiens (human)
ATP bindingEpidermal growth factor receptorHomo sapiens (human)
enzyme bindingEpidermal growth factor receptorHomo sapiens (human)
kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein kinase bindingEpidermal growth factor receptorHomo sapiens (human)
protein phosphatase bindingEpidermal growth factor receptorHomo sapiens (human)
protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
transmembrane receptor protein tyrosine kinase activator activityEpidermal growth factor receptorHomo sapiens (human)
ubiquitin protein ligase bindingEpidermal growth factor receptorHomo sapiens (human)
identical protein bindingEpidermal growth factor receptorHomo sapiens (human)
cadherin bindingEpidermal growth factor receptorHomo sapiens (human)
actin filament bindingEpidermal growth factor receptorHomo sapiens (human)
ATPase bindingEpidermal growth factor receptorHomo sapiens (human)
epidermal growth factor bindingEpidermal growth factor receptorHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
oxygen bindingAlbuminHomo sapiens (human)
DNA bindingAlbuminHomo sapiens (human)
fatty acid bindingAlbuminHomo sapiens (human)
copper ion bindingAlbuminHomo sapiens (human)
protein bindingAlbuminHomo sapiens (human)
toxic substance bindingAlbuminHomo sapiens (human)
antioxidant activityAlbuminHomo sapiens (human)
pyridoxal phosphate bindingAlbuminHomo sapiens (human)
identical protein bindingAlbuminHomo sapiens (human)
protein-folding chaperone bindingAlbuminHomo sapiens (human)
exogenous protein bindingAlbuminHomo sapiens (human)
enterobactin bindingAlbuminHomo sapiens (human)
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
monooxygenase activityCytochrome P450 1A2Homo sapiens (human)
iron ion bindingCytochrome P450 1A2Homo sapiens (human)
protein bindingCytochrome P450 1A2Homo sapiens (human)
electron transfer activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activityCytochrome P450 1A2Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 1A2Homo sapiens (human)
enzyme bindingCytochrome P450 1A2Homo sapiens (human)
heme bindingCytochrome P450 1A2Homo sapiens (human)
demethylase activityCytochrome P450 1A2Homo sapiens (human)
caffeine oxidase activityCytochrome P450 1A2Homo sapiens (human)
aromatase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 16-alpha-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
estrogen 2-hydroxylase activityCytochrome P450 1A2Homo sapiens (human)
hydroperoxy icosatetraenoate dehydratase activityCytochrome P450 1A2Homo sapiens (human)
protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
non-membrane spanning protein tyrosine kinase activityTyrosine-protein kinase FynHomo sapiens (human)
protein bindingTyrosine-protein kinase FynHomo sapiens (human)
ATP bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase activator activityTyrosine-protein kinase FynHomo sapiens (human)
enzyme bindingTyrosine-protein kinase FynHomo sapiens (human)
type 5 metabotropic glutamate receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
identical protein bindingTyrosine-protein kinase FynHomo sapiens (human)
alpha-tubulin bindingTyrosine-protein kinase FynHomo sapiens (human)
phospholipase bindingTyrosine-protein kinase FynHomo sapiens (human)
transmembrane transporter bindingTyrosine-protein kinase FynHomo sapiens (human)
metal ion bindingTyrosine-protein kinase FynHomo sapiens (human)
ephrin receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
tau protein bindingTyrosine-protein kinase FynHomo sapiens (human)
tau-protein kinase activityTyrosine-protein kinase FynHomo sapiens (human)
growth factor receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
scaffold protein bindingTyrosine-protein kinase FynHomo sapiens (human)
disordered domain specific bindingTyrosine-protein kinase FynHomo sapiens (human)
signaling receptor bindingTyrosine-protein kinase FynHomo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
arrestin family protein bindingMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M2Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M4Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M5Homo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein kinase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-1B adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
alpha-2C adrenergic receptor bindingAlpha-2A adrenergic receptorHomo sapiens (human)
thioesterase bindingAlpha-2A adrenergic receptorHomo sapiens (human)
heterotrimeric G-protein bindingAlpha-2A adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2A adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
norepinephrine bindingAlpha-2A adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2A adrenergic receptorHomo sapiens (human)
3'-5'-RNA exonuclease activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA-dependent RNA polymerase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
cysteine-type endopeptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA 5'-cap (guanine-N7-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA (nucleoside-2'-O-)-methyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mRNA guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
RNA endonuclease activity, producing 3'-phosphomonoestersReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
ISG15-specific peptidase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
5'-3' RNA helicase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
protein guanylyltransferase activityReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
monooxygenase activityCytochrome P450 2D6Homo sapiens (human)
iron ion bindingCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activityCytochrome P450 2D6Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2D6Homo sapiens (human)
heme bindingCytochrome P450 2D6Homo sapiens (human)
anandamide 8,9 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 11,12 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
anandamide 14,15 epoxidase activityCytochrome P450 2D6Homo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M1Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(2) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(2) dopamine receptorHomo sapiens (human)
protein bindingD(2) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(2) dopamine receptorHomo sapiens (human)
dopamine bindingD(2) dopamine receptorHomo sapiens (human)
ionotropic glutamate receptor bindingD(2) dopamine receptorHomo sapiens (human)
identical protein bindingD(2) dopamine receptorHomo sapiens (human)
heterocyclic compound bindingD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(2) dopamine receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2B adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2B adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2B adrenergic receptorHomo sapiens (human)
alpha2-adrenergic receptor activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein bindingAlpha-2C adrenergic receptorHomo sapiens (human)
alpha-2A adrenergic receptor bindingAlpha-2C adrenergic receptorHomo sapiens (human)
protein homodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-2C adrenergic receptorHomo sapiens (human)
epinephrine bindingAlpha-2C adrenergic receptorHomo sapiens (human)
guanyl-nucleotide exchange factor activityAlpha-2C adrenergic receptorHomo sapiens (human)
phosphatidylinositol phospholipase C activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
protein bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled acetylcholine receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
signaling receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
acetylcholine bindingMuscarinic acetylcholine receptor M3Homo sapiens (human)
G protein-coupled serotonin receptor activityMuscarinic acetylcholine receptor M3Homo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via GsD(1A) dopamine receptorHomo sapiens (human)
G-protein alpha-subunit bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(1A) dopamine receptorHomo sapiens (human)
protein bindingD(1A) dopamine receptorHomo sapiens (human)
heterotrimeric G-protein bindingD(1A) dopamine receptorHomo sapiens (human)
dopamine bindingD(1A) dopamine receptorHomo sapiens (human)
arrestin family protein bindingD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(1A) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(4) dopamine receptorHomo sapiens (human)
dopamine neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
protein bindingD(4) dopamine receptorHomo sapiens (human)
potassium channel regulator activityD(4) dopamine receptorHomo sapiens (human)
SH3 domain bindingD(4) dopamine receptorHomo sapiens (human)
dopamine bindingD(4) dopamine receptorHomo sapiens (human)
identical protein bindingD(4) dopamine receptorHomo sapiens (human)
metal ion bindingD(4) dopamine receptorHomo sapiens (human)
epinephrine bindingD(4) dopamine receptorHomo sapiens (human)
norepinephrine bindingD(4) dopamine receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityD(4) dopamine receptorHomo sapiens (human)
neurotransmitter receptor activityD(4) dopamine receptorHomo sapiens (human)
serotonin bindingD(4) dopamine receptorHomo sapiens (human)
actin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
neurotransmitter:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
protein bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent noradrenaline transporter Homo sapiens (human)
alpha-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
metal ion bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
beta-tubulin bindingSodium-dependent noradrenaline transporter Homo sapiens (human)
histamine receptor activityHistamine H2 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H2 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H2 receptorHomo sapiens (human)
protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
identical protein bindingAlpha-1D adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1D adrenergic receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
virus receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein tyrosine kinase activator activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
protein-containing complex binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2AHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2AHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
integrin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoatomic cation channel activitySodium-dependent serotonin transporterHomo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
serotonin:sodium:chloride symporter activitySodium-dependent serotonin transporterHomo sapiens (human)
protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent serotonin transporterHomo sapiens (human)
antiporter activitySodium-dependent serotonin transporterHomo sapiens (human)
syntaxin-1 bindingSodium-dependent serotonin transporterHomo sapiens (human)
cocaine bindingSodium-dependent serotonin transporterHomo sapiens (human)
sodium ion bindingSodium-dependent serotonin transporterHomo sapiens (human)
identical protein bindingSodium-dependent serotonin transporterHomo sapiens (human)
nitric-oxide synthase bindingSodium-dependent serotonin transporterHomo sapiens (human)
actin filament bindingSodium-dependent serotonin transporterHomo sapiens (human)
serotonin bindingSodium-dependent serotonin transporterHomo sapiens (human)
monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
iron ion bindingCytochrome P450 2C19Homo sapiens (human)
steroid hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
(S)-limonene 7-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxygen bindingCytochrome P450 2C19Homo sapiens (human)
enzyme bindingCytochrome P450 2C19Homo sapiens (human)
heme bindingCytochrome P450 2C19Homo sapiens (human)
(R)-limonene 6-monooxygenase activityCytochrome P450 2C19Homo sapiens (human)
aromatase activityCytochrome P450 2C19Homo sapiens (human)
long-chain fatty acid omega-1 hydroxylase activityCytochrome P450 2C19Homo sapiens (human)
arachidonic acid epoxygenase activityCytochrome P450 2C19Homo sapiens (human)
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygenCytochrome P450 2C19Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 7Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 7Homo sapiens (human)
histamine receptor activityHistamine H1 receptorHomo sapiens (human)
G protein-coupled serotonin receptor activityHistamine H1 receptorHomo sapiens (human)
neurotransmitter receptor activityHistamine H1 receptorHomo sapiens (human)
dopamine neurotransmitter receptor activity, coupled via Gi/GoD(3) dopamine receptorHomo sapiens (human)
protein bindingD(3) dopamine receptorHomo sapiens (human)
G protein-coupled receptor activityD(3) dopamine receptorHomo sapiens (human)
G protein-coupled opioid receptor activityKappa-type opioid receptorHomo sapiens (human)
protein bindingKappa-type opioid receptorHomo sapiens (human)
receptor serine/threonine kinase bindingKappa-type opioid receptorHomo sapiens (human)
dynorphin receptor activityKappa-type opioid receptorHomo sapiens (human)
neuropeptide bindingKappa-type opioid receptorHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
G-protein alpha-subunit binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
GTPase activator activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2BHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2BHomo sapiens (human)
histamine receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
protein binding5-hydroxytryptamine receptor 6Homo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 6Homo sapiens (human)
RNA bindingProteasome subunit alpha type-6Homo sapiens (human)
endopeptidase activityProteasome subunit alpha type-6Homo sapiens (human)
protein bindingProteasome subunit alpha type-6Homo sapiens (human)
purine ribonucleoside triphosphate bindingProteasome subunit alpha type-6Homo sapiens (human)
NF-kappaB bindingProteasome subunit alpha type-6Homo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
ankyrin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel activity involved SA node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
protease bindingSodium-dependent dopamine transporter Homo sapiens (human)
signaling receptor bindingSodium-dependent dopamine transporter Homo sapiens (human)
neurotransmitter transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
protein bindingSodium-dependent dopamine transporter Homo sapiens (human)
monoamine transmembrane transporter activitySodium-dependent dopamine transporter Homo sapiens (human)
dopamine bindingSodium-dependent dopamine transporter Homo sapiens (human)
amine bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein-containing complex bindingSodium-dependent dopamine transporter Homo sapiens (human)
metal ion bindingSodium-dependent dopamine transporter Homo sapiens (human)
protein phosphatase 2A bindingSodium-dependent dopamine transporter Homo sapiens (human)
heterocyclic compound bindingSodium-dependent dopamine transporter Homo sapiens (human)
norepinephrine:sodium symporter activitySodium-dependent dopamine transporter Homo sapiens (human)
aldehyde oxidase activityAldehyde oxidaseHomo sapiens (human)
iron ion bindingAldehyde oxidaseHomo sapiens (human)
identical protein bindingAldehyde oxidaseHomo sapiens (human)
protein homodimerization activityAldehyde oxidaseHomo sapiens (human)
molybdopterin cofactor bindingAldehyde oxidaseHomo sapiens (human)
flavin adenine dinucleotide bindingAldehyde oxidaseHomo sapiens (human)
NAD bindingAldehyde oxidaseHomo sapiens (human)
2 iron, 2 sulfur cluster bindingAldehyde oxidaseHomo sapiens (human)
FAD bindingAldehyde oxidaseHomo sapiens (human)
transcription cis-regulatory region bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
delayed rectifier potassium channel activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
ubiquitin protein ligase bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
identical protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
protein homodimerization activityPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
C3HC4-type RING finger domain bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
scaffold protein bindingPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarizationPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
small molecule bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
molecular function activator activityVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
protein bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
calmodulin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
high voltage-gated calcium channel activityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
metal ion bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
alpha-actinin bindingVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in cardiac muscle cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel activity involved in AV node cell action potentialVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated sodium channel activitySodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
calmodulin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
fibroblast growth factor bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
enzyme bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein kinase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein domain specific bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ankyrin bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
ubiquitin protein ligase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
transmembrane transporter bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
nitric-oxide synthase bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in cardiac muscle cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in AV node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in bundle of His cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in Purkinje myocyte action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel activity involved in SA node cell action potentialSodium channel protein type 5 subunit alphaHomo sapiens (human)
scaffold protein bindingSodium channel protein type 5 subunit alphaHomo sapiens (human)
protein bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
ATP hydrolysis activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA clamp unloader activityATPase family AAA domain-containing protein 5Homo sapiens (human)
DNA bindingATPase family AAA domain-containing protein 5Homo sapiens (human)
RNA bindingAtaxin-2Homo sapiens (human)
epidermal growth factor receptor bindingAtaxin-2Homo sapiens (human)
protein bindingAtaxin-2Homo sapiens (human)
mRNA bindingAtaxin-2Homo sapiens (human)
G protein-coupled opioid receptor activitySigma non-opioid intracellular receptor 1Homo sapiens (human)
protein bindingSigma non-opioid intracellular receptor 1Homo sapiens (human)
kinase activator activityMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
protease bindingMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
endopeptidase activityMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
cysteine-type endopeptidase activityMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
ubiquitin-protein transferase activityMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
protein bindingMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
peptidase activityMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
small molecule bindingMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
identical protein bindingMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
organic anion transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ABC-type xenobiotic transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
urate transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
biotin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
efflux transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATP hydrolysis activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
riboflavin transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
ATPase-coupled transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
identical protein bindingBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
protein homodimerization activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
xenobiotic transmembrane transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
sphingolipid transporter activityBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (137)

Processvia Protein(s)Taxonomy
photoreceptor outer segmentVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1FHomo sapiens (human)
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
ruffle membraneEpidermal growth factor receptorHomo sapiens (human)
Golgi membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceEpidermal growth factor receptorHomo sapiens (human)
nucleusEpidermal growth factor receptorHomo sapiens (human)
cytoplasmEpidermal growth factor receptorHomo sapiens (human)
endosomeEpidermal growth factor receptorHomo sapiens (human)
endoplasmic reticulum membraneEpidermal growth factor receptorHomo sapiens (human)
plasma membraneEpidermal growth factor receptorHomo sapiens (human)
focal adhesionEpidermal growth factor receptorHomo sapiens (human)
cell surfaceEpidermal growth factor receptorHomo sapiens (human)
endosome membraneEpidermal growth factor receptorHomo sapiens (human)
membraneEpidermal growth factor receptorHomo sapiens (human)
basolateral plasma membraneEpidermal growth factor receptorHomo sapiens (human)
apical plasma membraneEpidermal growth factor receptorHomo sapiens (human)
cell junctionEpidermal growth factor receptorHomo sapiens (human)
clathrin-coated endocytic vesicle membraneEpidermal growth factor receptorHomo sapiens (human)
early endosome membraneEpidermal growth factor receptorHomo sapiens (human)
nuclear membraneEpidermal growth factor receptorHomo sapiens (human)
membrane raftEpidermal growth factor receptorHomo sapiens (human)
perinuclear region of cytoplasmEpidermal growth factor receptorHomo sapiens (human)
multivesicular body, internal vesicle lumenEpidermal growth factor receptorHomo sapiens (human)
intracellular vesicleEpidermal growth factor receptorHomo sapiens (human)
protein-containing complexEpidermal growth factor receptorHomo sapiens (human)
receptor complexEpidermal growth factor receptorHomo sapiens (human)
Shc-EGFR complexEpidermal growth factor receptorHomo sapiens (human)
basal plasma membraneEpidermal growth factor receptorHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
extracellular regionAlbuminHomo sapiens (human)
extracellular spaceAlbuminHomo sapiens (human)
nucleusAlbuminHomo sapiens (human)
endoplasmic reticulumAlbuminHomo sapiens (human)
endoplasmic reticulum lumenAlbuminHomo sapiens (human)
Golgi apparatusAlbuminHomo sapiens (human)
platelet alpha granule lumenAlbuminHomo sapiens (human)
extracellular exosomeAlbuminHomo sapiens (human)
blood microparticleAlbuminHomo sapiens (human)
protein-containing complexAlbuminHomo sapiens (human)
cytoplasmAlbuminHomo sapiens (human)
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 1A2Homo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
nucleusTyrosine-protein kinase FynHomo sapiens (human)
mitochondrionTyrosine-protein kinase FynHomo sapiens (human)
endosomeTyrosine-protein kinase FynHomo sapiens (human)
cytosolTyrosine-protein kinase FynHomo sapiens (human)
actin filamentTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
postsynaptic densityTyrosine-protein kinase FynHomo sapiens (human)
dendriteTyrosine-protein kinase FynHomo sapiens (human)
perikaryonTyrosine-protein kinase FynHomo sapiens (human)
cell bodyTyrosine-protein kinase FynHomo sapiens (human)
membrane raftTyrosine-protein kinase FynHomo sapiens (human)
perinuclear region of cytoplasmTyrosine-protein kinase FynHomo sapiens (human)
perinuclear endoplasmic reticulumTyrosine-protein kinase FynHomo sapiens (human)
glial cell projectionTyrosine-protein kinase FynHomo sapiens (human)
Schaffer collateral - CA1 synapseTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneTyrosine-protein kinase FynHomo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
clathrin-coated endocytic vesicle membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
asymmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
symmetric synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
neuronal cell bodyMuscarinic acetylcholine receptor M2Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M2Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M2Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M2Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M2Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M4Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M4Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M5Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M5Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M5Homo sapiens (human)
cytoplasmAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
basolateral plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
neuronal cell bodyAlpha-2A adrenergic receptorHomo sapiens (human)
axon terminusAlpha-2A adrenergic receptorHomo sapiens (human)
presynaptic active zone membraneAlpha-2A adrenergic receptorHomo sapiens (human)
dopaminergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
postsynaptic density membraneAlpha-2A adrenergic receptorHomo sapiens (human)
glutamatergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
GABA-ergic synapseAlpha-2A adrenergic receptorHomo sapiens (human)
receptor complexAlpha-2A adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2A adrenergic receptorHomo sapiens (human)
double membrane vesicle viral factory outer membraneReplicase polyprotein 1abSevere acute respiratory syndrome coronavirus 2
mitochondrionCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulumCytochrome P450 2D6Homo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2D6Homo sapiens (human)
cytoplasmCytochrome P450 2D6Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2D6Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
presynaptic membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
axon terminusMuscarinic acetylcholine receptor M1Homo sapiens (human)
Schaffer collateral - CA1 synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
postsynaptic density membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
glutamatergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
cholinergic synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M1Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M1Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M1Homo sapiens (human)
Golgi membraneD(2) dopamine receptorHomo sapiens (human)
acrosomal vesicleD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
ciliumD(2) dopamine receptorHomo sapiens (human)
lateral plasma membraneD(2) dopamine receptorHomo sapiens (human)
endocytic vesicleD(2) dopamine receptorHomo sapiens (human)
axonD(2) dopamine receptorHomo sapiens (human)
dendriteD(2) dopamine receptorHomo sapiens (human)
synaptic vesicle membraneD(2) dopamine receptorHomo sapiens (human)
sperm flagellumD(2) dopamine receptorHomo sapiens (human)
dendritic spineD(2) dopamine receptorHomo sapiens (human)
perikaryonD(2) dopamine receptorHomo sapiens (human)
axon terminusD(2) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(2) dopamine receptorHomo sapiens (human)
ciliary membraneD(2) dopamine receptorHomo sapiens (human)
non-motile ciliumD(2) dopamine receptorHomo sapiens (human)
dopaminergic synapseD(2) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(2) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(2) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(2) dopamine receptorHomo sapiens (human)
presynaptic membraneD(2) dopamine receptorHomo sapiens (human)
plasma membraneD(2) dopamine receptorHomo sapiens (human)
cytosolAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
cell surfaceAlpha-2B adrenergic receptorHomo sapiens (human)
intracellular membrane-bounded organelleAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2B adrenergic receptorHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
cytoplasmAlpha-2C adrenergic receptorHomo sapiens (human)
endosomeAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-2C adrenergic receptorHomo sapiens (human)
endoplasmic reticulum membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basal plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
basolateral plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
postsynaptic membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
synapseMuscarinic acetylcholine receptor M3Homo sapiens (human)
plasma membraneMuscarinic acetylcholine receptor M3Homo sapiens (human)
dendriteMuscarinic acetylcholine receptor M3Homo sapiens (human)
nucleusD(1A) dopamine receptorHomo sapiens (human)
endoplasmic reticulum membraneD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
ciliumD(1A) dopamine receptorHomo sapiens (human)
presynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
dendritic spineD(1A) dopamine receptorHomo sapiens (human)
postsynaptic membraneD(1A) dopamine receptorHomo sapiens (human)
ciliary membraneD(1A) dopamine receptorHomo sapiens (human)
non-motile ciliumD(1A) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(1A) dopamine receptorHomo sapiens (human)
GABA-ergic synapseD(1A) dopamine receptorHomo sapiens (human)
G protein-coupled receptor complexD(1A) dopamine receptorHomo sapiens (human)
plasma membraneD(1A) dopamine receptorHomo sapiens (human)
centrosomeD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
membraneD(4) dopamine receptorHomo sapiens (human)
postsynapseD(4) dopamine receptorHomo sapiens (human)
glutamatergic synapseD(4) dopamine receptorHomo sapiens (human)
plasma membraneD(4) dopamine receptorHomo sapiens (human)
dendriteD(4) dopamine receptorHomo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
cell surfaceSodium-dependent noradrenaline transporter Homo sapiens (human)
membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
presynaptic membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneSodium-dependent noradrenaline transporter Homo sapiens (human)
axonSodium-dependent noradrenaline transporter Homo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
synapseHistamine H2 receptorHomo sapiens (human)
plasma membraneHistamine H2 receptorHomo sapiens (human)
dendriteHistamine H2 receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1D adrenergic receptorHomo sapiens (human)
neurofilament5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
caveola5-hydroxytryptamine receptor 2AHomo sapiens (human)
axon5-hydroxytryptamine receptor 2AHomo sapiens (human)
cytoplasmic vesicle5-hydroxytryptamine receptor 2AHomo sapiens (human)
presynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
neuronal cell body5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendritic shaft5-hydroxytryptamine receptor 2AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
cell body fiber5-hydroxytryptamine receptor 2AHomo sapiens (human)
glutamatergic synapse5-hydroxytryptamine receptor 2AHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2AHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
focal adhesionSodium-dependent serotonin transporterHomo sapiens (human)
endosome membraneSodium-dependent serotonin transporterHomo sapiens (human)
endomembrane systemSodium-dependent serotonin transporterHomo sapiens (human)
presynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
membrane raftSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
postsynaptic membraneSodium-dependent serotonin transporterHomo sapiens (human)
serotonergic synapseSodium-dependent serotonin transporterHomo sapiens (human)
synapseSodium-dependent serotonin transporterHomo sapiens (human)
plasma membraneSodium-dependent serotonin transporterHomo sapiens (human)
neuron projectionSodium-dependent serotonin transporterHomo sapiens (human)
endoplasmic reticulum membraneCytochrome P450 2C19Homo sapiens (human)
plasma membraneCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
intracellular membrane-bounded organelleCytochrome P450 2C19Homo sapiens (human)
cytoplasmCytochrome P450 2C19Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
trans-Golgi network membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
synapse5-hydroxytryptamine receptor 7Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 7Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 7Homo sapiens (human)
cytosolHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
synapseHistamine H1 receptorHomo sapiens (human)
dendriteHistamine H1 receptorHomo sapiens (human)
plasma membraneHistamine H1 receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
synapseD(3) dopamine receptorHomo sapiens (human)
plasma membraneD(3) dopamine receptorHomo sapiens (human)
nucleoplasmKappa-type opioid receptorHomo sapiens (human)
mitochondrionKappa-type opioid receptorHomo sapiens (human)
cytosolKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
membraneKappa-type opioid receptorHomo sapiens (human)
sarcoplasmic reticulumKappa-type opioid receptorHomo sapiens (human)
T-tubuleKappa-type opioid receptorHomo sapiens (human)
dendriteKappa-type opioid receptorHomo sapiens (human)
synaptic vesicle membraneKappa-type opioid receptorHomo sapiens (human)
presynaptic membraneKappa-type opioid receptorHomo sapiens (human)
perikaryonKappa-type opioid receptorHomo sapiens (human)
axon terminusKappa-type opioid receptorHomo sapiens (human)
postsynaptic membraneKappa-type opioid receptorHomo sapiens (human)
plasma membraneKappa-type opioid receptorHomo sapiens (human)
neuron projectionKappa-type opioid receptorHomo sapiens (human)
nucleoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
cytoplasm5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2BHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2BHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
cilium5-hydroxytryptamine receptor 6Homo sapiens (human)
synapse5-hydroxytryptamine receptor 6Homo sapiens (human)
dendrite5-hydroxytryptamine receptor 6Homo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 6Homo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
nucleusProteasome subunit alpha type-6Homo sapiens (human)
cytoplasmProteasome subunit alpha type-6Homo sapiens (human)
proteasome complexProteasome subunit alpha type-6Homo sapiens (human)
P-bodyProteasome subunit alpha type-6Homo sapiens (human)
nucleusProteasome subunit alpha type-6Homo sapiens (human)
nucleoplasmProteasome subunit alpha type-6Homo sapiens (human)
cytosolProteasome subunit alpha type-6Homo sapiens (human)
ribosomeProteasome subunit alpha type-6Homo sapiens (human)
nuclear matrixProteasome subunit alpha type-6Homo sapiens (human)
myofibrilProteasome subunit alpha type-6Homo sapiens (human)
sarcomereProteasome subunit alpha type-6Homo sapiens (human)
extracellular exosomeProteasome subunit alpha type-6Homo sapiens (human)
proteasome core complexProteasome subunit alpha type-6Homo sapiens (human)
proteasome core complex, alpha-subunit complexProteasome subunit alpha type-6Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
extracellular regionCathepsin D Bos taurus (cattle)
lysosomeCathepsin D Bos taurus (cattle)
melanosomeCathepsin D Bos taurus (cattle)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1D Homo sapiens (human)
cytoplasmSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
cell surfaceSodium-dependent dopamine transporter Homo sapiens (human)
membraneSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
neuron projectionSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell bodySodium-dependent dopamine transporter Homo sapiens (human)
axon terminusSodium-dependent dopamine transporter Homo sapiens (human)
membrane raftSodium-dependent dopamine transporter Homo sapiens (human)
postsynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
dopaminergic synapseSodium-dependent dopamine transporter Homo sapiens (human)
flotillin complexSodium-dependent dopamine transporter Homo sapiens (human)
axonSodium-dependent dopamine transporter Homo sapiens (human)
presynaptic membraneSodium-dependent dopamine transporter Homo sapiens (human)
plasma membraneSodium-dependent dopamine transporter Homo sapiens (human)
neuronal cell body membraneSodium-dependent dopamine transporter Homo sapiens (human)
cytosolAldehyde oxidaseHomo sapiens (human)
extracellular exosomeAldehyde oxidaseHomo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cell surfacePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
perinuclear region of cytoplasmPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
voltage-gated potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
inward rectifier potassium channel complexPotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
plasma membranePotassium voltage-gated channel subfamily H member 2Homo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
sarcoplasmic reticulumVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
T-tubuleVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
I bandVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1SHomo sapiens (human)
cytoplasmVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
plasma membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic densityVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
Z discVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
dendriteVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
perikaryonVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
postsynaptic density membraneVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
L-type voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
voltage-gated calcium channel complexVoltage-dependent L-type calcium channel subunit alpha-1CHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
nucleolusSodium channel protein type 5 subunit alphaHomo sapiens (human)
endoplasmic reticulumSodium channel protein type 5 subunit alphaHomo sapiens (human)
plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
caveolaSodium channel protein type 5 subunit alphaHomo sapiens (human)
cell surfaceSodium channel protein type 5 subunit alphaHomo sapiens (human)
intercalated discSodium channel protein type 5 subunit alphaHomo sapiens (human)
membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
lateral plasma membraneSodium channel protein type 5 subunit alphaHomo sapiens (human)
Z discSodium channel protein type 5 subunit alphaHomo sapiens (human)
T-tubuleSodium channel protein type 5 subunit alphaHomo sapiens (human)
sarcolemmaSodium channel protein type 5 subunit alphaHomo sapiens (human)
perinuclear region of cytoplasmSodium channel protein type 5 subunit alphaHomo sapiens (human)
voltage-gated sodium channel complexSodium channel protein type 5 subunit alphaHomo sapiens (human)
Elg1 RFC-like complexATPase family AAA domain-containing protein 5Homo sapiens (human)
nucleusATPase family AAA domain-containing protein 5Homo sapiens (human)
cytoplasmAtaxin-2Homo sapiens (human)
Golgi apparatusAtaxin-2Homo sapiens (human)
trans-Golgi networkAtaxin-2Homo sapiens (human)
cytosolAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
membraneAtaxin-2Homo sapiens (human)
perinuclear region of cytoplasmAtaxin-2Homo sapiens (human)
ribonucleoprotein complexAtaxin-2Homo sapiens (human)
cytoplasmic stress granuleAtaxin-2Homo sapiens (human)
nuclear envelopeSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear inner membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
nuclear outer membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulum membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
lipid dropletSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytosolSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic densitySigma non-opioid intracellular receptor 1Homo sapiens (human)
membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
growth coneSigma non-opioid intracellular receptor 1Homo sapiens (human)
cytoplasmic vesicleSigma non-opioid intracellular receptor 1Homo sapiens (human)
anchoring junctionSigma non-opioid intracellular receptor 1Homo sapiens (human)
postsynaptic density membraneSigma non-opioid intracellular receptor 1Homo sapiens (human)
endoplasmic reticulumSigma non-opioid intracellular receptor 1Homo sapiens (human)
fibrillar centerMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
nucleusMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
cytoplasmMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
cytosolMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
perinuclear region of cytoplasmMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
polkadotsMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
CBM complexMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
protein-containing complexMucosa-associated lymphoid tissue lymphoma translocation protein 1Homo sapiens (human)
nucleoplasmBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
brush border membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
mitochondrial membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
membrane raftBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
external side of apical plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
plasma membraneBroad substrate specificity ATP-binding cassette transporter ABCG2Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (674)

Assay IDTitleYearJournalArticle
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588349qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay
AID1347410qHTS for inhibitors of adenylyl cyclases using a fission yeast platform: a pilot screen against the NCATS LOPAC library2019Cellular signalling, 08, Volume: 60A fission yeast platform for heterologous expression of mammalian adenylyl cyclases and high throughput screening.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1347045Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot counterscreen GloSensor control cell line2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID1347151Optimization of GU AMC qHTS for Zika virus inhibitors: Unlinked NS2B-NS3 protease assay2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347405qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS LOPAC collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347050Natriuretic polypeptide receptor (hNpr2) antagonism - Pilot subtype selectivity assay2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID588378qHTS for Inhibitors of ATXN expression: Validation
AID1347049Natriuretic polypeptide receptor (hNpr1) antagonism - Pilot screen2019Science translational medicine, 07-10, Volume: 11, Issue:500
Inhibition of natriuretic peptide receptor 1 reduces itch in mice.
AID504836Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation2002The Journal of biological chemistry, Apr-19, Volume: 277, Issue:16
Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.
AID1347057CD47-SIRPalpha protein protein interaction - LANCE assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347058CD47-SIRPalpha protein protein interaction - HTRF assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID1347059CD47-SIRPalpha protein protein interaction - Alpha assay qHTS validation2019PloS one, , Volume: 14, Issue:7
Quantitative high-throughput screening assays for the discovery and development of SIRPα-CD47 interaction inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID1273428Modulation factor, ratio of refampin MIC to compound MIC for Mycobacterium tuberculosis H37Rv ATCC 27294T at 8 ug/ml in presence of refampin2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502826Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring ciprofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273486Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as amikacin MIC at 4 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502712Antimycobacterial activity against Mycobacterium avium isolate MAV3 assessed as reduction in bacterial viability incubated for 3 days by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273485Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as amikacin MIC at 2 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502895Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring ethidium bromide MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 25 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID126471Effect on EPS liability in squirrel monkeys sensitized to haloperidol at 2.5 mg/kg; A=Active1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Dopamine autoreceptor agonists as potential antipsychotics. 1. (Aminoalkoxy)anilines.
AID1502893Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring ethidium bromide MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 25 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502872Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring ofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 64 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502908Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring reduction in ethidium bromide MIC at 1/4 MIC incubated for 3 days by MTT assay relati2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502775Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID141425Binding affinity against Muscarinic acetylcholine receptor was measured using radioligand ([3H]QNB) binding assay1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID127305Inhibition of Sidman avoidance in squirrel monkeys after the compound administered perorally1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID1215126Ratio of fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method to fraction unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID1502901Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring ethidium bromide MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 50 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273442Modulation factor, ratio of amikacin MIC to compound MIC for Mycobacterium tuberculosis H37Rv ATCC 27294T at 4 ug/ml in presence of amikacin2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID36847In vitro affinity for cortical alpha-1 adrenergic receptor labelled with [3H]WB-41011986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID1426434Antimycobacterial activity against Mycobacterium smegmatis MC2 155 ATCC 700084 by microplate alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis.
AID1502709Antimycobacterial activity against Mycobacterium avium ATCC 25291 assessed as reduction in bacterial viability incubated for 3 days by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502891Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring ethidium bromide MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 25 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID588218FDA HLAED, lactate dehydrogenase (LDH) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1502916Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring reduction in ethidium bromide MIC at 1/2 MIC incubated for 3 days by MTT assay rela2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502798Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of azithromycin-induced antibacterial activity by measuring azithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502772Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID576612Inhibition of human ERG2011European journal of medicinal chemistry, Feb, Volume: 46, Issue:2
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
AID1136138Ratio of MED for inhibition of amphetamine-induced stereotyped-behavior in ip dosed Sprague-Dawley rat to ED50 for suppression of conditioned avoidance response in ip dosed Sprague-Dawley rat1978Journal of medicinal chemistry, Jul, Volume: 21, Issue:7
Neuroleptics related to butaclamol. Synthesis and some psychopharmacological effects of a series of 3-aryl analogues.
AID117007Compound was evaluated for the inhibition of Locomotion-Screen falloff test, at dose (mg/Kg) = 10; 60-100%1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
(1,3-Dialkyl-5-amino-1H-pyrazol-4-yl)arylmethanones. A series of novel central nervous system depressants.
AID1502756Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring reduction in clarithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relativ2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502855Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring reduction in ciprofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502821Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of azithromycin-induced antibacterial activity by measuring reduction in azithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID604020Unbound drug concentration in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID588215FDA HLAED, alkaline phosphatase increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1079947Comments (NB not yet translated). [column 'COMMENTAIRES' in source]
AID1502739Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring clarithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = >1024 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502881Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring reduction in ofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to ofloxa2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID395326Fraction unbound in rat brain2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1502810Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of azithromycin-induced antibacterial activity by measuring reduction in azithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to azithromy2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273464Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as ethidium bromide MIC at 8 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID180520The compound was tested for inhibition of conditional avoid in rats after peroral administration1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
(5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.
AID274128Displacement of [3H]Astemizole from hERG expressed in HEK293 cells at 10 uM2006Bioorganic & medicinal chemistry letters, Oct-15, Volume: 16, Issue:20
Ureas with histamine H3-antagonist receptor activity--a new scaffold discovered by lead-hopping from cinnamic acid amides.
AID1502793Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of azithromycin-induced antibacterial activity by measuring azithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273396Cytotoxicity against human MDM assessed as cell viability after 3 days by Alamar blue dye-based fluorocytometric analysis relative to control2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1235755Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as ofloxacin MIC at 7.5 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1235756Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as ofloxacin MIC at 3.75 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID496826Antimicrobial activity against Entamoeba histolytica2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1502707Antimycobacterial activity against Mycobacterium avium 104 mc'2 3 assessed as reduction in bacterial viability incubated for 3 days by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID61020Affinity for displacement of [3H]SCH-23390 labeled Dopamine receptor D1; ND means no data1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
1,3-Dialkyl-4-(iminoarylmethyl)-1H-pyrazol-5-ols. A series of novel potential antipsychotic agents.
AID178060Inhibition of locomotion in rats after the compound administered perorally1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID404304Effect on human MRP2-mediated estradiol-17-beta-glucuronide transport in Sf9 cells inverted membrane vesicles relative to control2008Journal of medicinal chemistry, Jun-12, Volume: 51, Issue:11
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
AID1079943Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source]
AID1502840Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring ciprofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 32 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID51564Extrapyramidal syndrome(EPS) signs in cebus monkeys, activity expressed as MED mg/kg per orally.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
1,3-Dialkyl-4-(iminoarylmethyl)-1H-pyrazol-5-ols. A series of novel potential antipsychotic agents.
AID395327Dissociation constant, pKa by capillary electrophoresis2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID41351Displacement of [3H]DHA (Dihydroalprenolol) from beta-2 adrenergic receptor in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID1502871Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring ofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 64 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502758Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring reduction in clarithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relativ2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1298979Cytotoxicity against mouse L5178Y cells assessed as growth inhibition after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Jun-15, Volume: 26, Issue:12
Identification of selenocompounds with promising properties to reverse cancer multidrug resistance.
AID1079948Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source]
AID131399Oral effective dose against spontaneous motor activity in mouse1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID131723Effective dose for inhibition of physostigmine induced lethality in mouse1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID177487Effect on Motor activity(MA) in rat was measured as ED50 by perorally administration of compound.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID1235804Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as reduction in ethidium bromide MIC at 3.75 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1235772Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as ethidium bromide MIC at 3.75 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID205170Compound was tested for its inhibition of Sidman avoidance after peroral administration in Squirrel monkeys.1991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Dopamine autoreceptor agonists as potential antipsychotics. 2. (Aminoalkoxy)-4H-1-benzopyran-4-ones.
AID581806Inhibition of Saccharomyces cerevisiae MKPDR5h multidrug transporter Pdr5p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.
AID1426438Antimycobacterial activity against drug-succeptible Mycobacterium tuberculosis CF73 incubated for 7 days measured 24 hrs post incubation by resazurin microtiter assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis.
AID1502844Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring reduction in ciprofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502847Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring reduction in ciprofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay relative t2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502833Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring ciprofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 8 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1426436Antimycobacterial activity against Mycobacterium tuberculosis MC2 7000 by microplate alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis.
AID113689Inhibition of locomotor activity (LMA) and motor coordination in mice by intraperitoneal administration.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
1,3-Dialkyl-4-(iminoarylmethyl)-1H-pyrazol-5-ols. A series of novel potential antipsychotic agents.
AID532578Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing marA::aph mutant by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID61022Affinity for displacement of [3H]clonidine labeled Dopamine receptor D11987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
1,3-Dialkyl-4-(iminoarylmethyl)-1H-pyrazol-5-ols. A series of novel potential antipsychotic agents.
AID1502831Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring ciprofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 2 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID173466Effect on serum prolactin level, activity expressed as percent control at 27.0 mg/kg per orally.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
1,3-Dialkyl-4-(iminoarylmethyl)-1H-pyrazol-5-ols. A series of novel potential antipsychotic agents.
AID1235696Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv using ethidium bromide as substrate assessed as relative final fluorescence at 1/2 MIC by real-time fluorometry2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502799Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of azithromycin-induced antibacterial activity by measuring azithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 256 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID87512Binding affinity against Histamine H1 receptor was measured using radioligand ([3H]pyrilamine) binding assay1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID36590Displacement of [3H]WB-4101 from alpha-1 adrenergic receptor in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID28681Partition coefficient (logD6.5)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID588217FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1502782Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of erythromycin-induced antibacterial activity by measuring reduction in erythromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to er2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273416Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as rifampin MIC at 1 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID176431Oral effective dose against ethanol potentiation in rat1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID1502801Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of azithromycin-induced antibacterial activity by measuring azithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID496831Antimicrobial activity against Cryptosporidium parvum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID169824Compound was assessed for its ability to block a conditioned avoidance response; Dose administered perorally is 50 mg/kg; 51-75%block1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
4-Piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as potential neuroleptics.
AID1502842Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring reduction in ciprofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to ciprofl2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502917Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring reduction in ethidium bromide MIC at 1/4 MIC incubated for 3 days by MTT assay rela2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1136351Neuroleptic activity in ip dosed Long-Evans rat assessed as increase in escape failure1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 4. Central nervous system depressants.
AID1502902Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring ethidium bromide MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 50 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273482Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as amikacin MIC at 0.25 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502733Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring clarithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502854Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring reduction in ciprofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay relative t2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1207713Inhibition of L-type calcium channel measured using 2-electrode voltage-clamp in human embryonic kidney cells heterologically expressing alpha-1C subunit2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID205016Compound was tested for inhibition of Sidman conditioned avoidance in squirrel monkeys upon peroral administration1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dopamine autoreceptor agonists as potential antipsychotics. 3.6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.
AID311934Dissociation constant, pKa of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID51562Compound was tested for inhibition of extrapyramidal side effect test in cebus monkey1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
(5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.
AID1502852Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring reduction in ciprofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay relative t2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1810959Inhibition of N-terminal his-tagged GCN4 leucine zipper fused human MALT1 (340-281 residues) expressed in Escherichia coli using Ac-LVSR-AMC as substrate by HTS assay2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.
AID1502726Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as increase in EtBr accumulation by measuring relative final fluorescence incubated for 60 mins by real-time fluorometry relative to control2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID131722Effective dose for inhibition of norepinephrine induced lethality in mouse1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID243151Inhibitory concentration against potassium channel HERG2005Bioorganic & medicinal chemistry letters, Jun-02, Volume: 15, Issue:11
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
AID581807Inhibition of Saccharomyces cerevisiae MKCDR1h multidrug transporter Cdr1p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.
AID178238Inhibition of self-stimulation in rats, activity expressed as ED50 mg/kg per orally.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
1,3-Dialkyl-4-(iminoarylmethyl)-1H-pyrazol-5-ols. A series of novel potential antipsychotic agents.
AID1273475Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as ofloxacin MIC at 8 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502767Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID178397Effective dose for inhibition of spontaneous motor activity in rats1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID1502770Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273448Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as isoniazid MIC at 0.25 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502761Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring reduction in clarithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay relative 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID588214FDA HLAED, liver enzyme composite activity2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1502830Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring ciprofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID532573Antimicrobial activity against Salmonella serovar Typhimurium SL1344 by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID1273414Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as rifampin MIC at 0.25 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502889Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring ethidium bromide MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 25 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1810960Antiproliferative activity against human HBL1 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.
AID564969Upregulation of p55 gene expression Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1079938Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source]
AID1273441Modulation factor, ratio of amikacin MIC to compound MIC for Mycobacterium tuberculosis H37Rv ATCC 27294T at 8 ug/ml in presence of amikacin2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1273404Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as isoniazid MIC at 2 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID61326Compound was tested in vitro for its affinity towards rat striatal Dopamine receptor D2 labeled with [3H]- spiperone1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID1502904Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring ethidium bromide MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 50 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID116898Lethal dose in mice after perorla administration1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
10-Piperazinyl-4H-theino[3,2-b][1,5]- and -[3,4-b][1,5]benzodiazepines as potential neuroleptics.
AID1235710Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as isoniazid MIC at 0.94 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1079944Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source]
AID1273459Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as ethidium bromide MIC at 0.25 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID588219FDA HLAED, gamma-glutamyl transferase (GGT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1273399Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as accumulation of EtBr at 0.5 ug/ml after 3 days by real time fluorometric analysis relative to control2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502736Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring clarithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 4 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1364923Cytotoxicity against BHK cells assessed as reduction in cell viability after 48 hrs in presence of ATP by Celltiter-Glo luminescent assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID699540Inhibition of human liver OATP1B3 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E17-betaG uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1273470Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as ofloxacin MIC at 0.25 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1136369Non-specific toxicity in ip dosed Wistar rat assessed as inhibition of d-amphetamine sulfate-induced stereotypy administered 1 hr prior to d-amphetamine sulfate challenge measured after 55 to 65 mins1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 4. Central nervous system depressants.
AID1502706Antimycobacterial activity against Mycobacterium avium 104 assessed as reduction in bacterial viability incubated for 3 days by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID178395Effective dose for ethanol potentiation in rats1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID699539Inhibition of human liver OATP1B1 expressed in HEK293 Flp-In cells assessed as reduction in E17-betaG uptake at 20 uM by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1502920Cytotoxicity in human monocyte-derived macrophages assessed as reduction in cell viability incubated for 3 days by alamar blue dye based assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID625292Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1502836Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring ciprofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 32 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1235692Inhibition of multidrug resistance efflux pump in Mycobacterium smegmatis MC2 155 using ethidium bromide as substrate assessed as relative final fluorescence at 1/2 MIC by real-time fluorometry2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1209582Unbound volume of distribution in Sprague-Dawley rat brain slices at 100 nM after 5 hrs2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1136368Non-specific toxicity in sc dosed Wistar rat assessed as inhibition of apomorphine hydrochloride-induced stereotypy administered 1 hr prior to apomorphine hydrochloride challenge measured after 5 to 20 mins1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 4. Central nervous system depressants.
AID1079946Presence of at least one case with successful reintroduction. [column 'REINT' in source]
AID1235745Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as amikacin MIC at 0.12 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID496818Antimicrobial activity against Trypanosoma brucei brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1502765Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502796Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of azithromycin-induced antibacterial activity by measuring azithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502874Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring reduction in ofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to ofloxacin alone2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID64433In vitro inhibitory against radioligand [3H]spiperone binding to rat striatal Dopamine receptor D21992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID1164949Cytotoxicity against african green monkey Vero cells assessed as reduction in cell viability by MTT assay2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olympicin A and derivatives.
AID625283Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1502813Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of azithromycin-induced antibacterial activity by measuring reduction in azithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to az2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273474Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as ofloxacin MIC at 4 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID177488Effect on Sidman conditioned avoidance in rat.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID1502898Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring ethidium bromide MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 12.5 ug/ml2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID40398Displacement of [3H]DHA (Dihydroalprenolol) from beta-1 adrenergic receptor in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID250135Inhibition of compound against MES-SA/DX5 cell line was determined using P-glycoprotein assay2005Journal of medicinal chemistry, Apr-21, Volume: 48, Issue:8
A pharmacophore hypothesis for P-glycoprotein substrate recognition using GRIND-based 3D-QSAR.
AID625284Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID205152Minimal effective oral dose that induced EPS signs in at least one squirrel monkey upon peroral administration.1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dopamine autoreceptor agonists as potential antipsychotics. 3.6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.
AID1426439Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis CF104 clinical isolate incubated for 7 days measured 24 hrs post incubation by resazurin microtiter assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1502763Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 256 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502839Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring ciprofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 32 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502708Antimycobacterial activity against Mycobacterium avium 104 mc'2 4 assessed as reduction in bacterial viability incubated for 3 days by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID141419Displacement of [3H]quinuclidinyl benzilate (QNB) from Muscarinic acetylcholine receptor in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID1502802Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of azithromycin-induced antibacterial activity by measuring azithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273481Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as amikacin MIC at 0.12 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID71422Inhibition of [3H]muscimol binding to Gamma-aminobutyric acid (GABA-A) receptor1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID1235727Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as rifampin MIC at 0.47 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502778Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of erythromycin-induced antibacterial activity by measuring reduction in erythromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to erythromy2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502787Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of erythromycin-induced antibacterial activity by measuring reduction in erythromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID176231Effective peroral dose for inhibition of conditioned avoidance response in rats1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID178242Inhibition of shelf-jump avoidance in rats after peroral administration.1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID1502903Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring ethidium bromide MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 50 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502900Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring ethidium bromide MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 12.5 ug/ml2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID19262Aqueous solubility2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Prediction of drug solubility from Monte Carlo simulations.
AID1235758Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as ofloxacin MIC at 0.94 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID130391Hypothermia in mice after peroral administration1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
4-Piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as potential neuroleptics.
AID1502861Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring ofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1207778Inhibition of Cav1.2 current measured using QPatch automatic path clamp system in CHO cells expressing Cav1.2, beta-2 and alpha-2/delta-1 subunits2013Scientific reports, , Volume: 3MICE models: superior to the HERG model in predicting Torsade de Pointes.
AID564968Upregulation of p27 gene expression in Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID64294In vitro binding affinity against Dopamine receptor D2 by displacement of [3H]haloperidol from rat striatal membranes.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
1,3-Dialkyl-4-(iminoarylmethyl)-1H-pyrazol-5-ols. A series of novel potential antipsychotic agents.
AID496821Antimicrobial activity against Leishmania2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1759226Inhibition of NF-kappaB (unknown origin) assessed as reduction in IL-2 production at 5 uM by cell based assay relative to control2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Structure-activity relationship studies of 3-substituted pyrazoles as novel allosteric inhibitors of MALT1 protease.
AID625280Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1207203Inhibition of calcium current (ICaL) measured using whole-cell patch clamp experiments in isolated guinea pig ventricular myocytes2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1235743Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as amikacin MIC at 0.47 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1235773Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as ethidium bromide MIC at 1.88 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502911Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring reduction in ethidium bromide MIC at 1/2 MIC incubated for 3 days by MTT assay rela2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID205267Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID327647Inhibition of wild type androgen receptor expressed in CV1 cells assessed as dihydrotestosterone-stimulated transactivation at 500 nM by CAT reporter gene assay2007Proceedings of the National Academy of Sciences of the United States of America, Jul-17, Volume: 104, Issue:29
Discovery of antiandrogen activity of nonsteroidal scaffolds of marketed drugs.
AID64143Binding affinity towards Dopamine receptor D22003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
AID126337Effect on Inhibition of Sidman avoidance in squirrel monkeys was determined1988Journal of medicinal chemistry, Aug, Volume: 31, Issue:8
Dopamine autoreceptor agonists as potential antipsychotics. 1. (Aminoalkoxy)anilines.
AID1739764Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability incubated for 72 hrs by resazurin assay2020European journal of medicinal chemistry, Sep-01, Volume: 201Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.
AID1298980Cytotoxicity against multi-drug resistant mouse L5178Y cells assessed as growth inhibition after 72 hrs by MTT assay2016Bioorganic & medicinal chemistry letters, Jun-15, Volume: 26, Issue:12
Identification of selenocompounds with promising properties to reverse cancer multidrug resistance.
AID1545792Antiproliferative activity against human MDA-MB-231 cells assessed as reduction in cell viability incubated for 2 days by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Design, synthesis and evaluation of novel phenothiazine derivatives as inhibitors of breast cancer stem cells.
AID1502887Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring reduction in ofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to ofloxaci2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273423Modulation factor, ratio of isoniazid MIC to compound MIC for Mycobacterium tuberculosis H37Rv ATCC 27294T at 4 ug/ml in presence of isoniazid2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID134417Lethal dose in mice after perorla administration1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
4-Piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as potential neuroleptics.
AID1235712Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as isoniazid MIC at 0.23 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1810961Antiproliferative activity against human TMD8 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.
AID1502837Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring ciprofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 32 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273494Modulation factor, ratio of ethidium bromide MIC to compound MIC for Mycobacterium tuberculosis H37Rv ATCC 27294T at 4 ug/ml in presence of ethidium bromide2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502885Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring reduction in ofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to ofloxa2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1215122Percentage unbound in solid supported porcine brain membrane vesicles at 5 uM by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID1502815Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of azithromycin-induced antibacterial activity by measuring reduction in azithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1235709Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as isoniazid MIC at 1.88 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID205030Displacement of [3H]-5-HT from serotonin-1 neurotransmitter receptor in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID175169Compound was tested for effect on brain DOPA synthesis in the striatum of NSD 1015 rat; NA=Not available1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dopamine autoreceptor agonists as potential antipsychotics. 3.6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.
AID1210013Inhibition of recombinant CYP2J2 (unknown origin)-mediated terfenadine hydroxylation assessed as remaining activity at 30 uM after 5 mins by LC-MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID625290Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID205145Inhibition of sidman avoidance in squirrel monkeys, activity expressed as ED50 mg/kg per orally.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
1,3-Dialkyl-4-(iminoarylmethyl)-1H-pyrazol-5-ols. A series of novel potential antipsychotic agents.
AID1502764Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID177879Inhibition of Sidman avoidance in rats after peroral administration1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID1502766Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID395324Lipophilicity, log D at pH 7.4 by liquid chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1502843Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring reduction in ciprofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID625286Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID61021Affinity for displacement of [3H]WB-4101 labeled Dopamine receptor D11987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
1,3-Dialkyl-4-(iminoarylmethyl)-1H-pyrazol-5-ols. A series of novel potential antipsychotic agents.
AID1502808Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of azithromycin-induced antibacterial activity by measuring azithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 64 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502760Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring reduction in clarithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1863562Antiviral activity against pseudotyped Ebola virus assessed as inhibition of viral entry2022European journal of medicinal chemistry, Oct-05, Volume: 240Discovery of potent ebola entry inhibitors with (3S,4aS,8aS)-2-(3-amino-2-hydroxypropyl) decahydroisoquinoline-3-carboxamide scaffold.
AID1502744Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring clarithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 8 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273493Modulation factor, ratio of ethidium bromide MIC to compound MIC for Mycobacterium tuberculosis H37Rv ATCC 27294T at 8 ug/ml in presence of ethidium bromide2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502913Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring reduction in ethidium bromide MIC at 1/2 MIC incubated for 3 days by MTT assay rela2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502907Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring reduction in ethidium bromide MIC at 1/2 MIC incubated for 3 days by MTT assay relati2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502875Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring reduction in ofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to ofloxaci2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502838Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring ciprofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 32 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502918Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring reduction in ethidium bromide MIC at 1/2 MIC incubated for 3 days by MTT assay relati2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273422Modulation factor, ratio of isoniazid MIC to compound MIC for Mycobacterium tuberculosis H37Rv ATCC 27294T at 8 ug/ml in presence of isoniazid2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502791Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of erythromycin-induced antibacterial activity by measuring reduction in erythromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to er2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1209583Unbound drug partitioning coefficient, Kp of the compound assessed as ratio of unbound concentration in Sprague-Dawley rat brain to unbound concentration in plasma2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1502713Antimycobacterial activity against Mycobacterium avium isolate MAV4 assessed as reduction in bacterial viability incubated for 3 days by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID114809Compound was evaluated for the inhibition of Locomotion-Screen falloff test by ip route1984Journal of medicinal chemistry, Nov, Volume: 27, Issue:11
(1,3-Dialkyl-5-amino-1H-pyrazol-4-yl)arylmethanones. A series of novel central nervous system depressants.
AID1739774Synergistic antimycobacterial activity against Mycobacterium tuberculosis assessed as fractional inhibitory concentration in presence of Pretomanid by Checkerboard assay2020European journal of medicinal chemistry, Sep-01, Volume: 201Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.
AID1502722Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as increase in EtBr accumulation by measuring relative final fluorescence at 1/2 times MIC incubated for 60 mins by real-time fluorometry relative to control2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID19006Calculated membrane partition coefficient (Kmemb)2004Journal of medicinal chemistry, Mar-25, Volume: 47, Issue:7
Surface activity profiling of drugs applied to the prediction of blood-brain barrier permeability.
AID1502822Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of azithromycin-induced antibacterial activity by measuring reduction in azithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID29812Oral bioavailability in human2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1502873Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring reduction in ofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to ofloxacin alone2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID604021Unbound volume of distribution in Sprague-Dawley rat brain measured per gram of brain tissue administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr b2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1502728Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as increase in EtBr accumulation by measuring relative final fluorescence incubated for 60 mins by real-time fluorometry relative to control2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273394Anti-tubercular activity against Mycobacterium smegmatis MC2 155 ATCC 700084 after 3 days by microdilution method2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502734Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring clarithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502851Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring reduction in ciprofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay relative t2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID588212Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1502834Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring ciprofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 8 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1364913Antiviral activity against Chikungunya virus LR2006 OPY1 infected in BHK cells measured at 14 hrs post infection by luciferase reporter gene assay2017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID588211Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1545799Antiproliferative activity against human KG1a cells assessed as reduction in cell viability incubated for 2 days by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Design, synthesis and evaluation of novel phenothiazine derivatives as inhibitors of breast cancer stem cells.
AID1235771Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as ethidium bromide MIC at 7.5 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID532576Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing acrF::aph mutant by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID1545794Antiproliferative activity against human SKBR3 cells assessed as reduction in cell viability incubated for 2 days by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Design, synthesis and evaluation of novel phenothiazine derivatives as inhibitors of breast cancer stem cells.
AID1502805Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of azithromycin-induced antibacterial activity by measuring azithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 256 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID232327Ratio of APO Sterotype ED50 vs catalepsy ED501986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID588216FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase2004Current drug discovery technologies, Dec, Volume: 1, Issue:4
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
AID1739777Displacement of [3H]-Ketanserin from human 5HT2A receptor expressed in CHO-K1 cells2020European journal of medicinal chemistry, Sep-01, Volume: 201Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.
AID177895Inhibition of conditioned avoidance response (CAR) in fasted male Sprague-Dawley rats.1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Buspirone analogues. 1. Structure-activity relationships in a series of N-aryl- and heteroarylpiperazine derivatives.
AID1235774Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as ethidium bromide MIC at 0.94 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID178517Inhibition of conditioned avoidance response (CAR)1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID1739779Displacement of [3H]-5-CT from human 5HT7 receptor expressed in HEK293 cells2020European journal of medicinal chemistry, Sep-01, Volume: 201Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.
AID1426441Cytotoxicity against human MRC5 cells assessed as decrease in cell viability after 24 hrs by resazurin reduction assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis.
AID397743Inhibition of human ERG channel2009Journal of medicinal chemistry, Jul-23, Volume: 52, Issue:14
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
AID176432Oral effective dose against hexobarbatial potentiation in rat1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID604025Unbound CSF to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID178541Compound was tested for its ability to induce catalepsy in rats.1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID1502752Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring reduction in clarithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relativ2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502746Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring reduction in clarithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to clar2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502769Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 256 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1593043Antibacterial activity against Mycobacterium tuberculosis H37Rv infected in Swiss albino mouse assessed as log reduction in bacterial burden in spleen at 26 mg/kg, po administered via gavage starting from 6 weeks post infection measured after 3 to 4 weeks2019European journal of medicinal chemistry, Apr-15, Volume: 168Molecular hybridization approach for phenothiazine incorporated 1,2,3-triazole hybrids as promising antimicrobial agents: Design, synthesis, molecular docking and in silico ADME studies.
AID177479Effect on Ataxia(ATX) in rat was measured as ED50 by perorally administration of compound.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID1502748Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring reduction in clarithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502859Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring ofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502716Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as increase in EtBr accumulation by measuring relative final fluorescence at 1/2 times MIC incubated for 60 mins by real-time fluorometry relative to control2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502757Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring reduction in clarithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay relativ2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1739763Antitubercular activity against Mycobacterium tuberculosis H37Rv assessed as growth inhibition incubated for 3 weeks by Microplate Alamar Blue Assay2020European journal of medicinal chemistry, Sep-01, Volume: 201Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.
AID1273499Modulation factor, ratio of ethidium bromide MIC to compound MIC for Mycobacterium tuberculosis H37Rv ATCC 27294T at 2 ug/ml in presence of ethidium bromide2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502735Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring clarithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1235798Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as reduction in ofloxacin MIC at 7.5 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID408340Inhibition of human ERG expressed in CHO cells by whole cell patch clamp technique2008Bioorganic & medicinal chemistry, Jun-01, Volume: 16, Issue:11
Support vector machines classification of hERG liabilities based on atom types.
AID1235725Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as rifampin MIC at 1.88 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1235757Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as ofloxacin MIC at 1.88 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502878Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring reduction in ofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to ofloxaci2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1148006Binding affinity to bovine serum albumin by circular dichroic probe technique1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Quantitative correlations between albumin binding constants and chromatographic Rm values of phenothiazine derivatives.
AID1502866Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring ofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 4 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1129361Unbound fraction in HEK293 cell homogenate at 0.1 uM by equilibrium dialysis based UPLC-MS/MS analysis2014Journal of medicinal chemistry, Apr-10, Volume: 57, Issue:7
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
AID1426437Antimycobacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294 incubated for 7 days measured 24 hrs post incubation by resazurin microtiter assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis.
AID1871982Antimycobacterial activity against Mycobacterium tuberculosis2022European journal of medicinal chemistry, Feb-05, Volume: 229Tuberculosis drug discovery: Progression and future interventions in the wake of emerging resistance.
AID1502731Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring clarithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 8 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1759223Inhibition of NF-kappaB (unknown origin)2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Structure-activity relationship studies of 3-substituted pyrazoles as novel allosteric inhibitors of MALT1 protease.
AID1759224Inhibition of NF-kappaB (unknown origin) at 5 uM relative to control2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Structure-activity relationship studies of 3-substituted pyrazoles as novel allosteric inhibitors of MALT1 protease.
AID1502800Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of azithromycin-induced antibacterial activity by measuring azithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 256 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID113685Inhibition of ataxia in mice by intraperitoneal administration.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
1,3-Dialkyl-4-(iminoarylmethyl)-1H-pyrazol-5-ols. A series of novel potential antipsychotic agents.
AID1810962Antiproliferative activity against human OCI-Ly1 cells assessed as inhibition of cell growth incubated for 72 hrs by Celltiter-Glo luminescent assay2021Journal of medicinal chemistry, 07-08, Volume: 64, Issue:13
Identification of Novel Fused Heteroaromatics-Based MALT1 Inhibitors by High-Throughput Screening to Treat B Cell Lymphoma.
AID29359Ionization constant (pKa)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1273447Modulation factor, ratio of ofloxacin MIC to compound MIC for Mycobacterium tuberculosis H37Rv ATCC 27294T at 8 ug/ml in presence of ofloxacin2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1079931Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source]
AID178244Inhibition of sidman avoidance in rats, activity expressed as ED50 mg/kg per orally.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
1,3-Dialkyl-4-(iminoarylmethyl)-1H-pyrazol-5-ols. A series of novel potential antipsychotic agents.
AID1235759Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as ofloxacin MIC at 0.47 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1235742Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as amikacin MIC at 0.94 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502858Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring ofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1079941Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source]
AID1235711Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as isoniazid MIC at 0.47 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1235741Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as amikacin MIC at 1.88 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502809Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of azithromycin-induced antibacterial activity by measuring reduction in azithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to azithromy2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502828Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring ciprofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502750Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring reduction in clarithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502905Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring reduction in ethidium bromide MIC at 1/2 MIC incubated for 3 days by MTT assay relative to e2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1235713Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as isoniazid MIC at 0.12 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502784Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of erythromycin-induced antibacterial activity by measuring reduction in erythromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID603953In-vivo plasma to lung partition coefficients of the compound, logP(lung) in rat2008European journal of medicinal chemistry, Mar, Volume: 43, Issue:3
Air to lung partition coefficients for volatile organic compounds and blood to lung partition coefficients for volatile organic compounds and drugs.
AID1235723Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as rifampin MIC at 7.5 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502865Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring ofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 4 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1739776Displacement of [3H]-Raclopride from human D2 receptor (unknown origin) expressed in HEK293 cell membranes2020European journal of medicinal chemistry, Sep-01, Volume: 201Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.
AID1273395Inhibition of multidrug resistance efflux pump in Mycobacterium smegmatis MC2 155 ATCC 700084 assessed as accumulation of EtBr at 0.25 ug/ml after 3 days by real time fluorometric analysis relative to control2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1079939Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source]
AID1273417Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as rifampin MIC at 2 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1164948Solubility of the compound in DMEM/FBS medium2014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olympicin A and derivatives.
AID1235729Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as rifampin MIC at 0.12 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID496817Antimicrobial activity against Trypanosoma cruzi2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1502841Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring reduction in ciprofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to ciprofl2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID161284Inhibitory activity against Potassium channel HERG2003Journal of medicinal chemistry, May-22, Volume: 46, Issue:11
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
AID496824Antimicrobial activity against Toxoplasma gondii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1273419Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as rifampin MIC at 8 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502804Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of azithromycin-induced antibacterial activity by measuring azithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 256 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1887947Inhibition of full length FLAG/HA/Strep-tagged TLK2 (unknown origin) transfected in HEK293T cells assessed as reduction in TLK mediated ASF1a phosphorylation at 50 uM by Western blot analysis2022European journal of medicinal chemistry, Jan-05, Volume: 227Design, synthesis and biological evaluation of bisindole derivatives as anticancer agents against Tousled-like kinases.
AID1209593Dissociation constant, pKa of the acidic compound by capillary electrophoresis-mass spectrometry analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1273463Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as ethidium bromide MIC at 4 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1215121Fraction unbound in Wistar rat brain homogenate at 5 uM after 5 hrs by equilibrium dialysis method2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID36863Inhibition of [3H]WB-4101 binding to rat cortical Alpha-1 adrenergic receptor in vitro1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID532577Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing tolC::aph mutant by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID1502863Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring ofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 4 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1504671Inhibition of NDH2 in Mycobacterium bovis BCG ATCC 35734 assessed as reduction in oxygen consumption at 80 uM after 1 hr by methylene blue-based assay2017ACS medicinal chemistry letters, Nov-09, Volume: 8, Issue:11
Indolylalkyltriphenylphosphonium Analogues Are Membrane-Depolarizing Mycobactericidal Agents.
AID1235775Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as ethidium bromide MIC at 0.47 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1273460Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as ethidium bromide MIC at 0.5 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502857Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring ofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID232353Ratio of CAR ED50 vs catalepsy ED501986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID194153The percent loss of escape responding was determined for the estimated effective dose 50 values for CAR block1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
AID554098Inhibition of NorA in Staphylococcus aureus 1199B assessed as reduction in ethidium bromide efflux at 50 uM by fluorimetry after 5 mins2011Journal of medicinal chemistry, Jan-13, Volume: 54, Issue:1
Discovery of novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus.
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID27370Lethal dose after peroral administration in mouse1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID1235744Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as amikacin MIC at 0.23 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502762Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 256 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502729Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as increase in EtBr accumulation by measuring relative final fluorescence incubated for 60 mins by real-time fluorometry relative to control2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502827Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring ciprofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID112949Compound was tested for inhibition of apomorphine-induced climbing in mice after intraperitoneal administration1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
(5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.
AID243189Inhibition of partially open human voltage-gated potassium channel subunit Kv11.1 (ERG K+ channel)2005Bioorganic & medicinal chemistry letters, Mar-15, Volume: 15, Issue:6
A two-state homology model of the hERG K+ channel: application to ligand binding.
AID1545793Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability incubated for 2 days by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Design, synthesis and evaluation of novel phenothiazine derivatives as inhibitors of breast cancer stem cells.
AID1273413Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as rifampin MIC at 0.12 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1235740Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as amikacin MIC at 3.75 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502803Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of azithromycin-induced antibacterial activity by measuring azithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 256 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502727Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as increase in EtBr accumulation by measuring relative final fluorescence incubated for 60 mins by real-time fluorometry relative to control2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1215124Binding affinity to Wistar rat brain lipid assessed as percentage unbound by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID1502719Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as increase in EtBr accumulation by measuring relative final fluorescence at 1/2 times MIC incubated for 60 mins by real-time fluorometry relative to control2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID496819Antimicrobial activity against Plasmodium falciparum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID59385Compound was tested for inhibition of emesis test in dogs administered per orally; Antiemetic1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
(5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.
AID1079935Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source]
AID1458340Inhibition of efflux pump in wild type Mycobacterium tuberculosis H37Rv assessed as increase in accumulation of ethidium bromide by measuring relative final fluorescence index at 18.5 uM measured every second for 60 mins in absence of glucose by real time2017Journal of medicinal chemistry, 08-24, Volume: 60, Issue:16
Substituted N-Phenyl-5-(2-(phenylamino)thiazol-4-yl)isoxazole-3-carboxamides Are Valuable Antitubercular Candidates that Evade Innate Efflux Machinery.
AID625288Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1739778Displacement of [3H]-LSD from human 5HT6 receptor expressed in HEK293 cells2020European journal of medicinal chemistry, Sep-01, Volume: 201Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.
AID1545791Antiproliferative activity against human SUM159 cells assessed as reduction in cell viability incubated for 2 days by MTT assay2019European journal of medicinal chemistry, Dec-01, Volume: 183Design, synthesis and evaluation of novel phenothiazine derivatives as inhibitors of breast cancer stem cells.
AID420668Inhibition of human ERG in MCF7 cells2009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID179240Displacement of (+)-[3H]-3-PPP from rat cortical sigma site1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID1502890Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring ethidium bromide MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 25 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID532575Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing acrD::aph mutant by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID1235708Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as isoniazid MIC at 3.75 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502773Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502823Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of azithromycin-induced antibacterial activity by measuring reduction in azithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to az2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1207712Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID588208Literature-mined public compounds from Lowe et al phospholipidosis modelling dataset2010Molecular pharmaceutics, Oct-04, Volume: 7, Issue:5
Predicting phospholipidosis using machine learning.
AID1502824Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of azithromycin-induced antibacterial activity by measuring reduction in azithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to az2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502909Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring reduction in ethidium bromide MIC at 1/2 MIC incubated for 3 days by MTT assay relati2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1739762Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as inhibition of luminescence incubated for 10 days under anaerobic condition followed by incubated for 28 hrs under aerobic condition by low oxygen recovery assay relative to co2020European journal of medicinal chemistry, Sep-01, Volume: 201Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.
AID227718Binding energy by using the equation deltaG obsd = -RT ln KD1984Journal of medicinal chemistry, Dec, Volume: 27, Issue:12
Functional group contributions to drug-receptor interactions.
AID1207175Inhibition of sodium current measured using whole-cell patch clamp experiments in HEK-293 cells stably transfected with hNaV1.5 cDNA2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1273473Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as ofloxacin MIC at 2 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID496827Antimicrobial activity against Leishmania amazonensis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1235776Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as ethidium bromide MIC at 0.23 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502817Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of azithromycin-induced antibacterial activity by measuring reduction in azithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273469Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as ofloxacin MIC at 0.12 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502771Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502797Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of azithromycin-induced antibacterial activity by measuring azithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID625282Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1235789Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as reduction in rifampin MIC at 7.5 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1364924Selectivity index, ratio of CC50 for BHK cells to IC50 for Chikungunya virus LR2006 OPY12017Bioorganic & medicinal chemistry, 08-15, Volume: 25, Issue:16
The medicinal chemistry of Chikungunya virus.
AID1235781Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as reduction in isoniazid MIC at 7.5 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502792Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of erythromycin-induced antibacterial activity by measuring reduction in erythromycin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to er2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID604022Fraction unbound in Sprague-Dawley rat plasma administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID112962Compound was tested for its ability to inhibit locomotor activity using ataxia test1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
(5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.
AID1235726Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as rifampin MIC at 0.94 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502882Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring reduction in ofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to ofloxa2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1593045Antibacterial activity against Mycobacterium tuberculosis H37Rv infected in Swiss albino mouse assessed as log reduction in bacterial burden in lungs at 26 mg/kg, po administered via gavage starting from 6 weeks post infection measured after 3 to 4 weeks 2019European journal of medicinal chemistry, Apr-15, Volume: 168Molecular hybridization approach for phenothiazine incorporated 1,2,3-triazole hybrids as promising antimicrobial agents: Design, synthesis, molecular docking and in silico ADME studies.
AID31388Displacement of [3H]-CHA (N6-Cyclohexyl adenosine) from adenosine A1 receptor in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID170130Compound was evaluated for its ability to block conditioned avoidance response (CAR) in rats; Dose administered perorally is 50 mg/kg; 51-75% block1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
10-Piperazinyl-4H-theino[3,2-b][1,5]- and -[3,4-b][1,5]benzodiazepines as potential neuroleptics.
AID1235728Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as rifampin MIC at 0.23 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID395325Lipophilicity, log P by microemulsion electrokinetic chromatography2009Journal of medicinal chemistry, Mar-26, Volume: 52, Issue:6
Relationship between brain tissue partitioning and microemulsion retention factors of CNS drugs.
AID1502867Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring ofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1235691Antimycobacterial activity against Mycobacterium smegmatis MC2 155 after 3 days by broth microdilution method2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1079940Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source]
AID1235707Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as isoniazid MIC at 7.5 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502714Inhibition of multidrug resistance efflux pump in Mycobacterium smegmatis str. MC2 155 assessed as increase in EtBr accumulation by measuring relative final fluorescence at 1/2 times MIC incubated for 60 mins by real-time fluorometry relative to control2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502730Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring clarithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 8 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502877Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring reduction in ofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to ofloxaci2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1079936Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source]
AID496828Antimicrobial activity against Leishmania donovani2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1759225Inhibition of NF-kappaB (unknown origin) assessed as reduction in IL-2 production by cell based assay2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Structure-activity relationship studies of 3-substituted pyrazoles as novel allosteric inhibitors of MALT1 protease.
AID1502846Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring reduction in ciprofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID141418The compound was tested for inhibition of sidman avoid in rats after peroral administration1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
(5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.
AID1164950Selectivity index, ratio of CC50 for african green monkey Vero cells to IC50 for methicillin-resistant Staphylococcus aureus NRS 702014Journal of medicinal chemistry, Oct-23, Volume: 57, Issue:20
Synthesis, structure-activity relationship studies, and antibacterial evaluation of 4-chromanones and chalcones, as well as olympicin A and derivatives.
AID1079933Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is
AID1502705Antimycobacterial activity against Mycobacterium smegmatis str. MC2 155 assessed as reduction in bacterial viability incubated for 3 days by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502754Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring reduction in clarithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relativ2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1739771Synergistic antimycobacterial activity against Mycobacterium tuberculosis assessed as fractional inhibitory concentration in presence of Isoniazid by Checkerboard assay2020European journal of medicinal chemistry, Sep-01, Volume: 201Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.
AID1136364Non-specific toxicity in ip dosed Wistar rat assessed as inhibition of amphetamine-induced circling administered 60 mins prior to amphetamine challenge1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 4. Central nervous system depressants.
AID1502868Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring ofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502785Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of erythromycin-induced antibacterial activity by measuring reduction in erythromycin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID496832Antimicrobial activity against Trypanosoma brucei rhodesiense2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID171957compound was evaluated for its ability to produce catalepsy activity in rats; Dose administered perorally is 25 mg/kg1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
10-Piperazinyl-4H-theino[3,2-b][1,5]- and -[3,4-b][1,5]benzodiazepines as potential neuroleptics.
AID1593042Antibacterial activity against Mycobacterium tuberculosis H37Rv infected in Swiss albino mouse assessed as log reduction in bacterial burden in lungs at 26 mg/kg, po administered via gavage starting from 6 weeks post infection measured after 3 to 4 weeks 2019European journal of medicinal chemistry, Apr-15, Volume: 168Molecular hybridization approach for phenothiazine incorporated 1,2,3-triazole hybrids as promising antimicrobial agents: Design, synthesis, molecular docking and in silico ADME studies.
AID4790Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID205171Inhibition of sidman avoid in squirrel monkeys after peroral administration1986Journal of medicinal chemistry, Sep, Volume: 29, Issue:9
(5-Amino-1,3-dimethyl-1H-pyrazol-4-yl)(2-fluorophenyl)methanones . A series of novel potential antipsychotic agents.
AID1209581Fraction unbound in Sprague-Dawley rat brain homogenates at 5 uM by equilibrium dialysis analysis2011Drug metabolism and disposition: the biological fate of chemicals, Mar, Volume: 39, Issue:3
Measurement of unbound drug exposure in brain: modeling of pH partitioning explains diverging results between the brain slice and brain homogenate methods.
AID1235695Antimycobacterial activity against Mycobacterium tuberculosis H37Rv after 3 days by broth microdilution method2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502776Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 128 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502795Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of azithromycin-induced antibacterial activity by measuring azithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID625285Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID61382Displacement of [3H]haloperidol from Dopamine receptor D2 in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID1502741Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring clarithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID61017Displacement of [3H]cis-flupenthixol from Dopamine receptor D1 in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID1502816Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of azithromycin-induced antibacterial activity by measuring reduction in azithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502753Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring reduction in clarithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay relativ2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502910Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring reduction in ethidium bromide MIC at 1/4 MIC incubated for 3 days by MTT assay relati2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1215120Binding affinity to Wistar rat brain lipid by TRANSIL assay2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID6677Binding affinity towards human 5-hydroxytryptamine 7 receptor2003Journal of medicinal chemistry, Jul-03, Volume: 46, Issue:14
Higher-end serotonin receptors: 5-HT(5), 5-HT(6), and 5-HT(7).
AID604023Ratio of total drug level in brain to plasma in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr by LC-MS/MS method2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1210014Inhibition of recombinant CYP2J2 (unknown origin)-mediated astemizole O-demethylation assessed as remaining activity at 30 uM after 5 mins by LC-MS/MS analysis relative to control2012Drug metabolism and disposition: the biological fate of chemicals, May, Volume: 40, Issue:5
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
AID1502880Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring reduction in ofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to ofloxa2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1739772Synergistic antimycobacterial activity against Mycobacterium tuberculosis assessed as fractional inhibitory concentration in presence of Linezolid by Checkerboard assay2020European journal of medicinal chemistry, Sep-01, Volume: 201Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.
AID1502906Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring reduction in ethidium bromide MIC at 1/4 MIC incubated for 3 days by MTT assay relative to e2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502737Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring clarithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 4 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID205175Compound tested for its liability for extrapyramidal side effects (EPS) in terms of no. of animals showing signs of EPS/no. of animals tested upon peroral administration at a dose of 2.5 mg/Kg; 3/31991Journal of medicinal chemistry, Jan, Volume: 34, Issue:1
Dopamine autoreceptor agonists as potential antipsychotics. 2. (Aminoalkoxy)-4H-1-benzopyran-4-ones.
AID169962Compound was assessed for its ability to produce catalepsy in rats; Dose administered perorally is 25 mg/kg; Group score is 4-71980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
4-Piperazinyl-10H-thieno[2,3-b][1,5]benzodiazepines as potential neuroleptics.
AID1502738Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring clarithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = >1024 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502892Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring ethidium bromide MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 25 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502794Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of azithromycin-induced antibacterial activity by measuring azithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1873198Inhibition of ABCG2 (unknown origin) expressed in human HEK293 cells membrane vesicles assessed inhibition of BCRP- mediated transport of 3[H]-E1S for 1 mins using [3H]-estrone sulfate as substrate by rapid filtration technique2022European journal of medicinal chemistry, Jul-05, Volume: 237Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
AID1273471Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as ofloxacin MIC at 0.5 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502807Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of azithromycin-induced antibacterial activity by measuring azithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 64 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID496820Antimicrobial activity against Trypanosoma brucei2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID588213Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents2010Chemical research in toxicology, Jan, Volume: 23, Issue:1
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
AID1502896Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring ethidium bromide MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 25 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID496829Antimicrobial activity against Leishmania infantum2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1502711Antimycobacterial activity against Mycobacterium avium isolate MAV2 assessed as reduction in bacterial viability incubated for 3 days by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID161281Inhibition of human Potassium channel HERG expressed in mammalian cells2003Bioorganic & medicinal chemistry letters, Aug-18, Volume: 13, Issue:16
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
AID112708Hypothermia in mice after perorla administration1980Journal of medicinal chemistry, Aug, Volume: 23, Issue:8
10-Piperazinyl-4H-theino[3,2-b][1,5]- and -[3,4-b][1,5]benzodiazepines as potential neuroleptics.
AID40805Displacement of [3H]CHA (N6-Cyclohexyl adenosine) from rat brain adenosine A1 receptor1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID131363Effect on Motor activity in mouse following i.p. administration.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID1502745Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring clarithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 8 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1136418Antipsychotic activity in mouse assessed as increase in brain dopamine turnover at 25 to 30 mg/kg, ip pretreated with 200 mg/kg, ip alpha-methyl-p-tyrosine tyrosine hydroxylase inhibitor1978Journal of medicinal chemistry, Sep, Volume: 21, Issue:9
Synthesis and biological evaluation of some 2-amino-4-aryl-3H-1,5-benzodiazepine analogues of clozapine.
AID1502864Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring ofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 4 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID532574Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing acrB::aph mutant by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID1273484Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as amikacin MIC at 1 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1136350Neuroleptic activity in ip dosed Long-Evans rat assessed as inhibition of pole-climb avoidance1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 4. Central nervous system depressants.
AID497005Antimicrobial activity against Pneumocystis carinii2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1502850Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring reduction in ciprofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay relative t2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID311935Partition coefficient, log P of the compound2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1148004Oleyl alcohol-water partition coefficient, Rm of the compound measured at 0% methanol by reverse-phase thin layer chromatography1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Quantitative correlations between albumin binding constants and chromatographic Rm values of phenothiazine derivatives.
AID1739770Synergistic antimycobacterial activity against Mycobacterium tuberculosis assessed as fractional inhibitory concentration in presence of Rifampin by Checkerboard assay2020European journal of medicinal chemistry, Sep-01, Volume: 201Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.
AID1148003Dissociation constant, pKa of the compound by UV-visible spectrophotometer analysis1977Journal of medicinal chemistry, Mar, Volume: 20, Issue:3
Quantitative correlations between albumin binding constants and chromatographic Rm values of phenothiazine derivatives.
AID1273458Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as ethidium bromide MIC at 0.12 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID27167Delta logD (logD6.5 - logD7.4)2000Journal of medicinal chemistry, Jun-29, Volume: 43, Issue:13
QSAR model for drug human oral bioavailability.
AID1502780Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of erythromycin-induced antibacterial activity by measuring reduction in erythromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to er2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID176225Inhibition of apomorphine-induced stereotypy in rats via peroral route1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID4783Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID1215123Binding affinity to Wistar rat serum albumin2011Drug metabolism and disposition: the biological fate of chemicals, Feb, Volume: 39, Issue:2
Brain tissue binding of drugs: evaluation and validation of solid supported porcine brain membrane vesicles (TRANSIL) as a novel high-throughput method.
AID1759221Inhibition of MALT1 (unknown origin)2021Bioorganic & medicinal chemistry letters, 06-01, Volume: 41Structure-activity relationship studies of 3-substituted pyrazoles as novel allosteric inhibitors of MALT1 protease.
AID1502740Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring clarithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1136349Neuroleptic activity in Sprague-Dawley rat assessed as inhibition of Sidman avoidance at 20 mg/kg, ip relative to control1978Journal of medicinal chemistry, Nov, Volume: 21, Issue:11
Synthesis of spiro[isobenzofuran-1(3H),4'-piperidines] as potential central nervous system agents. 4. Central nervous system depressants.
AID1502912Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring reduction in ethidium bromide MIC at 1/4 MIC incubated for 3 days by MTT assay rela2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273483Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as amikacin MIC at 0.5 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1235794Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as reduction in amikacin MIC at 7.5 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID176222Effective in vivo peroral dose against induction of catalepsy in rats1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID532579Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing soxS::aph mutant by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID178197Effective dose in blocking conditioned avoidance responding (CAR) in the rat when administered intraperitoneally1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
AID1235693Cytotoxicity against human PBMC assessed as cell viability after 3 days by AlamarBlue assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1502820Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of azithromycin-induced antibacterial activity by measuring reduction in azithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID625291Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1273407Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as amikacin MIC at 8 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502888Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring reduction in ofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to ofloxaci2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID604026Unbound CSF to plasma concentration ratio in human2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1847246Antiviral activity against Ebola virus infected in African green monkey assessed as reduction in viral infection incubated for 48 hrs by CellTiter-Glo Luminescent Cell Viability Assay2021European journal of medicinal chemistry, Nov-05, Volume: 223Potential pharmacological strategies targeting the Niemann-Pick C1 receptor and Ebola virus glycoprotein interaction.
AID581672Inhibition of Pdr5p-mediated rhodamine 6G transport in Saccharomyces cerevisiae MKPDR5h plasma membrane by spectrofluorometric assay2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.
AID420669Lipophilicity, log D at pH 7.02009European journal of medicinal chemistry, May, Volume: 44, Issue:5
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
AID311932Inhibition of ASM in human H4 cells assessed as residual activity at 10 uM2008Journal of medicinal chemistry, Jan-24, Volume: 51, Issue:2
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
AID1079934Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source]
AID1079949Proposed mechanism(s) of liver damage. [column 'MEC' in source]
AID1235724Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as rifampin MIC at 3.75 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502825Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring ciprofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1079932Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source]
AID1426442Cytotoxicity against mouse J774 cells assessed as decrease in cell viability after 24 hrs by resazurin reduction assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis.
AID1593044Antibacterial activity against Mycobacterium tuberculosis H37Rv infected in Swiss albino mouse assessed as log reduction in bacterial burden in spleen at 26 mg/kg, po administered via gavage starting from 6 weeks post infection measured after 3 to 4 weeks2019European journal of medicinal chemistry, Apr-15, Volume: 168Molecular hybridization approach for phenothiazine incorporated 1,2,3-triazole hybrids as promising antimicrobial agents: Design, synthesis, molecular docking and in silico ADME studies.
AID1207265Effective free therapeutic plasma concentration (EFTPC): the concentration of unbound compund in the blood plasma at therapeutic dose (mean of range)2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID1273449Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as isoniazid MIC at 0.12 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID131397Oral effective dose against norepinephrine-induced lethality in mouse1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID1502835Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring ciprofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 32 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1739773Synergistic antimycobacterial activity against Mycobacterium tuberculosis assessed as fractional inhibitory concentration in presence of Moxifloxacin by Checkerboard assay2020European journal of medicinal chemistry, Sep-01, Volume: 201Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.
AID1273461Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as ethidium bromide MIC at 1 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1426435Antimycobacterial activity against Mycobacterium bovis BCG Pasteur ATCC 35734 by microplate alamar blue assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis.
AID1502870Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring ofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502845Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring reduction in ciprofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID82355K+ channel blocking activity in human embryonic kidney cells expressing HERG Kv11.12002Journal of medicinal chemistry, Aug-29, Volume: 45, Issue:18
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
AID1502806Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of azithromycin-induced antibacterial activity by measuring azithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 256 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1807421Noncompetitive type inhibition of human AOX assessed as inhibitor dissociation constant by measuring changes in intercept of the double reciprocal plot using phthalazine as substrate by Michaelis-Menten analysis2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Interrogating the Inhibition Mechanisms of Human Aldehyde Oxidase by X-ray Crystallography and NMR Spectroscopy: The Raloxifene Case.
AID1273398Anti-tubercular activity against Mycobacterium tuberculosis H37Rv ATCC 27294T after 7 days by mircodilution method2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502849Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring reduction in ciprofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay relative t2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1426440Antimycobacterial activity against multidrug-resistant Mycobacterium tuberculosis CF81 clinical isolate incubated for 7 days measured 24 hrs post incubation by resazurin microtiter assay2017European journal of medicinal chemistry, Feb-15, Volume: 127Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis.
AID1235761Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as ofloxacin MIC at 0.12 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID178399Effective dose for motor incoordination in rats was determined by rotarod method1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID1502919Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring reduction in ethidium bromide MIC at 1/4 MIC incubated for 3 days by MTT assay relati2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1207234Inhibition of hERG K channel2011Cardiovascular research, Jul-01, Volume: 91, Issue:1
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
AID178868Compound was tested for the inhibition of apomorphine-induced stereotype1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID1502819Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of azithromycin-induced antibacterial activity by measuring reduction in azithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1739775Synergistic Antimycobacterial activity against Mycobacterium tuberculosis H37Rv assessed as fractional inhibitory concentration in presence of Bedaquiline by Checkerboard assay2020European journal of medicinal chemistry, Sep-01, Volume: 201Antitubercular polyhalogenated phenothiazines and phenoselenazine with reduced binding to CNS receptors.
AID604024Unbound brain to plasma concentration ratio in Sprague-Dawley rat administered in casettes of 2/3 drugs at 4 hr constant rate intravenous infusions using flow rate of 1 (ml/kg)/hr corresponding to dosage rate of 2 (umol/kg)/hr2009Journal of medicinal chemistry, Oct-22, Volume: 52, Issue:20
Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids.
AID1079945Animal toxicity known. [column 'TOXIC' in source]
AID1375644Antiviral activity against Ebolavirus expressing eGFP infected in African green monkey Vero E6 cells assessed as inhibition of viral replication after 48 hrs by spectrofluorometric method2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID1502897Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV2 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring ethidium bromide MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 12.5 ug/ml2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273402Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as isoniazid MIC at 8 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID131362Effect on Ataxia in mouse following i.p. administration.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
N6-(2,2-diphenylethyl)adenosine, a novel adenosine receptor agonist with antipsychotic-like activity.
AID532580Antimicrobial activity against Salmonella serovar Typhimurium SL1344 expressing ramA::aph mutant by broth dilution method2008Antimicrobial agents and chemotherapy, Oct, Volume: 52, Issue:10
RamA confers multidrug resistance in Salmonella enterica via increased expression of acrB, which is inhibited by chlorpromazine.
AID167992Effective dose for reversal of trifluoperazine-induced catalepsy in rats; I=Inactive (ED50 mg/Kg)1992Journal of medicinal chemistry, Nov-27, Volume: 35, Issue:24
Synthesis and biological characterization of alpha-(4-fluorophenyl)-4-(5-fluoro-2-pyrimidinyl)-1-piperazinebutanol and analogues as potential atypical antipsychotic agents.
AID1502862Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring ofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID177717Induction of catalepsy in nonfasted, male Sprague-Dawley rats (dose that produced catalepsy in 50% of the animals); value may range from 27.5 to 74.31983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Buspirone analogues. 1. Structure-activity relationships in a series of N-aryl- and heteroarylpiperazine derivatives.
AID1502725Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as increase in EtBr accumulation by measuring relative final fluorescence incubated for 60 mins by real-time fluorometry relative to control2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID61042Compound was tested in vitro for binding affinity against dopamine receptor D1 in rat striatal membrane by using DA antagonist [3H]NPA; NA=Not available1991Journal of medicinal chemistry, Sep, Volume: 34, Issue:9
Dopamine autoreceptor agonists as potential antipsychotics. 3.6-Propyl-4,5,5a,6,7,8-hexahydrothiazolo[4,5-f]quinolin-2-amine.
AID625279Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID130893Inhibition of induction of ataxia in mouse after intraperitoneal administration1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID130897Inhibition of locomotor activity in mouse after intraperitoneal administration1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID1235777Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as ethidium bromide MIC at 0.12 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID62868Inhibition of [3H]spiperone binding to dopamine receptor from rat corpus striatal membranes1983Journal of medicinal chemistry, Feb, Volume: 26, Issue:2
Buspirone analogues. 1. Structure-activity relationships in a series of N-aryl- and heteroarylpiperazine derivatives.
AID1502860Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring ofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID564971Downregulation of p55 gene expression Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID131398Oral effective dose against physostigmine-induced lethality in mouse1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID36663Displacement of [3H]clonidine from alpha-2 adrenergic receptor in rat brain1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID1502848Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring reduction in ciprofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay relative t2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1696660Cytotoxicity against multidrug resistance mouse L5178Y cells expressing human MDR1 assessed as reduction in cell viability by MTT assay2020Bioorganic & medicinal chemistry letters, 11-15, Volume: 30, Issue:22
N-Substituted piperazine derivatives as potential multitarget agents acting on histamine H
AID1502789Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of erythromycin-induced antibacterial activity by measuring reduction in erythromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1235803Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as reduction in ethidium bromide MIC at 7.5 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502790Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of erythromycin-induced antibacterial activity by measuring reduction in erythromycin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502876Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring reduction in ofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to ofloxaci2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1079937Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source]
AID178236Inhibition of self-stimulation in rats after the compound administered perorally1988Journal of medicinal chemistry, Feb, Volume: 31, Issue:2
Synthesis and potential antipsychotic activity of 1H-imidazo[1,2-c]pyrazolo[3,4-e]pyrimidines.
AID1502788Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of erythromycin-induced antibacterial activity by measuring reduction in erythromycin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to 2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1887981Inhibition of full length GFP-tagged TLK1 (unknown origin) transfected in HEK293T cells at 50 uM using GST-ASF1a as substrate incubated for 30 mins by Western blot analysis2022European journal of medicinal chemistry, Jan-05, Volume: 227Design, synthesis and biological evaluation of bisindole derivatives as anticancer agents against Tousled-like kinases.
AID625287Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1696659Cytotoxicity against mouse L5178Y cells assessed as reduction in cell viability by MTT assay2020Bioorganic & medicinal chemistry letters, 11-15, Volume: 30, Issue:22
N-Substituted piperazine derivatives as potential multitarget agents acting on histamine H
AID625289Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1375643Antiviral activity against Ebolavirus like particle harboring full length EBOV Zaire wt/GIN/2014/ Kissidougou-C15 envelope glycoprotein and Influenzae virus envelope assessed as inhibition of viral infection in MDCK-SIAT1 cells after 48 hrs by e-GFP-based2018Journal of medicinal chemistry, 06-14, Volume: 61, Issue:11
Structures of Ebola Virus Glycoprotein Complexes with Tricyclic Antidepressant and Antipsychotic Drugs.
AID1502710Antimycobacterial activity against Mycobacterium avium isolate MAV1 assessed as reduction in bacterial viability incubated for 3 days by MTT assay2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273403Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as isoniazid MIC at 4 ug/ml after 7 days by microdilution checkerboard2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID420787Antagonist activity at human 5HT3A receptor expressed in HEK293 cells assessed as inhibition of serotonin-induced inward Na+ current at >= 10 uM2009European journal of medicinal chemistry, Jun, Volume: 44, Issue:6
Molecular properties of psychopharmacological drugs determining non-competitive inhibition of 5-HT3A receptors.
AID1502774Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273418Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as rifampin MIC at 4 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID564970Downregulation of p27 gene expression Mycobacterium tuberculosis by microarray2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Role of the Mycobacterium tuberculosis P55 efflux pump in intrinsic drug resistance, oxidative stress responses, and growth.
AID1502743Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring clarithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 8 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID581808Inhibition of Saccharomyces cerevisiae MKSNQ2h multidrug transporter Snq2p assessed as concentration required to threefold increase in rate of fluorescence signal relative to absence of inhibitor by fluorescein diacetate based high-throughput screening sp2009Antimicrobial agents and chemotherapy, Apr, Volume: 53, Issue:4
New high-throughput screening assay to reveal similarities and differences in inhibitory sensitivities of multidrug ATP-binding cassette transporters.
AID1502879Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring reduction in ofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to ofloxa2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1235760Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as ofloxacin MIC at 0.23 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1502832Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring ciprofloxacin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 2 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502768Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV1 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 256 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502747Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring reduction in clarithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay relative to clar2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502883Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring reduction in ofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to ofloxa2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID19424Partition coefficient (logD7.4)2001Journal of medicinal chemistry, Jul-19, Volume: 44, Issue:15
ElogD(oct): a tool for lipophilicity determination in drug discovery. 2. Basic and neutral compounds.
AID1502869Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of ofloxacin-induced antibacterial activity by measuring ofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID496825Antimicrobial activity against Leishmania mexicana2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1502777Inhibition of multidrug resistance efflux pump in Mycobacterium avium ATCC 25291 assessed as potentiation of erythromycin-induced antibacterial activity by measuring erythromycin MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 128 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1079942Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source]
AID496823Antimicrobial activity against Trichomonas vaginalis2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1502829Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring ciprofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 16 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1807416Noncompetitive type inhibition of human AOX assessed as inhibitor dissociation constant by measuring slope of the double reciprocal plot using phthalazine as substrate by Michaelis-Menten analysis2021Journal of medicinal chemistry, 09-09, Volume: 64, Issue:17
Interrogating the Inhibition Mechanisms of Human Aldehyde Oxidase by X-ray Crystallography and NMR Spectroscopy: The Raloxifene Case.
AID1502732Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring clarithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = >512 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID496830Antimicrobial activity against Leishmania major2010Bioorganic & medicinal chemistry, Mar-15, Volume: 18, Issue:6
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
AID1273406Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as isoniazid MIC at 0.5 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1502853Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of ciprofloxacin-induced antibacterial activity by measuring reduction in ciprofloxacin MIC at 1/2 MIC incubated for 3 days by MTT assay relative t2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273462Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as ethidium bromide MIC at 2 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1235739Inhibition of multidrug resistance efflux pump in Mycobacterium tuberculosis H37Rv assessed as amikacin MIC at 7.5 ug/ml after 7 days by two-dimensional broth microdilution checkerboard assay2015Journal of medicinal chemistry, Aug-13, Volume: 58, Issue:15
Rational Design and Synthesis of Thioridazine Analogues as Enhancers of the Antituberculosis Therapy.
AID1426443Selectivity index, ratio of IC50 for human MRC5 cells to MIC90 for drug-succeptible Mycobacterium tuberculosis CF732017European journal of medicinal chemistry, Feb-15, Volume: 127Synthesis and SAR evaluation of novel thioridazine derivatives active against drug-resistant tuberculosis.
AID135326BBB penetration classification2000Journal of medicinal chemistry, Jun-01, Volume: 43, Issue:11
Predicting blood-brain barrier permeation from three-dimensional molecular structure.
AID205268Inhibition of binding of Batrachotoxinin [3H]BTX-B to high affinity sites on voltage dependent sodium channels in a vesicular preparation from guinea pig cerebral cortex at 10 uM1985Journal of medicinal chemistry, Mar, Volume: 28, Issue:3
[3H]Batrachotoxinin A 20 alpha-benzoate binding to voltage-sensitive sodium channels: a rapid and quantitative assay for local anesthetic activity in a variety of drugs.
AID176433Oral effective dose against spontaneous motor activity in rat1986Journal of medicinal chemistry, Mar, Volume: 29, Issue:3
Synthesis and biological evaluation of 1-(1,2-benzisothiazol-3-yl)- and (1,2-benzisoxazol-3-yl)piperazine derivatives as potential antipsychotic agents.
AID1502811Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 3 assessed as potentiation of azithromycin-induced antibacterial activity by measuring reduction in azithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay relative to az2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502759Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring reduction in clarithromycin MIC at 1/4 MIC incubated for 3 days by MTT assay relativ2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID173465Effect on serum prolactin level, activity expressed as percent control at 23.7 mg/kg per orally.1987Journal of medicinal chemistry, Oct, Volume: 30, Issue:10
1,3-Dialkyl-4-(iminoarylmethyl)-1H-pyrazol-5-ols. A series of novel potential antipsychotic agents.
AID1502899Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV3 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring ethidium bromide MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 12.5 ug/ml2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1273405Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as isoniazid MIC at 1 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1273415Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as rifampin MIC at 0.5 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID1273472Antibacterial activity against Mycobacterium tuberculosis H37Rv ATCC 27294T assessed as ofloxacin MIC at 1 ug/ml after 7 days by microdilution checkerboard assay2016European journal of medicinal chemistry, Jan-01, Volume: 107Hybrid triazoles: Design and synthesis as potential dual inhibitor of growth and efflux inhibition in tuberculosis.
AID625281Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis2011PLoS computational biology, Dec, Volume: 7, Issue:12
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
AID1502742Inhibition of multidrug resistance efflux pump in Mycobacterium avium isolate MAV4 assessed as potentiation of clarithromycin -induced antibacterial activity by measuring clarithromycin MIC at 1/2 MIC incubated for 3 days by MTT assay (Rvb = 8 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID1502894Inhibition of multidrug resistance efflux pump in Mycobacterium avium 104 mc'2 4 assessed as potentiation of ethidium bromide-induced antibacterial activity by measuring ethidium bromide MIC at 1/4 MIC incubated for 3 days by MTT assay (Rvb = 25 ug/ml)2017European journal of medicinal chemistry, Nov-10, Volume: 140Natural isoflavone biochanin A as a template for the design of new and potent 3-phenylquinolone efflux inhibitors against Mycobacterium avium.
AID699541Inhibition of human liver OATP2B1 expressed in HEK293 Flp-In cells assessed as reduction in [3H]E3S uptake at 20 uM incubated for 5 mins by scintillation counting2012Journal of medicinal chemistry, May-24, Volume: 55, Issue:10
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1259419Human 5-HT2A receptor (5-Hydroxytryptamine receptors)2003Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Mar, Volume: 28, Issue:3
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
AID1345615Human 5-HT1A receptor (5-Hydroxytryptamine receptors)1998European journal of pharmacology, Aug-21, Volume: 355, Issue:2-3
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
AID1259419Human 5-HT2A receptor (5-Hydroxytryptamine receptors)2002European journal of pharmacology, Aug-16, Volume: 450, Issue:1
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.
AID1345879Human D5 receptor (Dopamine receptors)1991Nature, Apr-18, Volume: 350, Issue:6319
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
AID624215Antagonists at Human 5-Hydroxytryptamine receptor 5-HT1A1998European journal of pharmacology, Aug-21, Volume: 355, Issue:2-3
Agonist and antagonist actions of antipsychotic agents at 5-HT1A receptors: a [35S]GTPgammaS binding study.
AID1346501Mouse Kir3.2 (Inwardly rectifying potassium channels)2000British journal of pharmacology, Apr, Volume: 129, Issue:8
Inhibition by various antipsychotic drugs of the G-protein-activated inwardly rectifying K(+) (GIRK) channels expressed in xenopus oocytes.
AID1345235Rat 5-HT7 receptor (5-Hydroxytryptamine receptors)1994The Journal of pharmacology and experimental therapeutics, Mar, Volume: 268, Issue:3
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.
AID1345170Human 5-HT6 receptor (5-Hydroxytryptamine receptors)2005Psychopharmacology, May, Volume: 179, Issue:2
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.
AID1345718Human D1 receptor (Dopamine receptors)1991Nature, Apr-18, Volume: 350, Issue:6319
Cloning of the gene for a human dopamine D5 receptor with higher affinity for dopamine than D1.
AID1345154Rat 5-HT6 receptor (5-Hydroxytryptamine receptors)1994The Journal of pharmacology and experimental therapeutics, Mar, Volume: 268, Issue:3
Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors.
AID624223Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A2003Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Mar, Volume: 28, Issue:3
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)2003Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Mar, Volume: 28, Issue:3
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
AID624223Antagonists at Human 5-Hydroxytryptamine receptor 5-HT2A2002European journal of pharmacology, Aug-16, Volume: 450, Issue:1
A comparison of the receptor binding and HERG channel affinities for a series of antipsychotic drugs.
AID1346037Human H1 receptor (Histamine receptors)2003Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, Mar, Volume: 28, Issue:3
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
AID1345291Human 5-HT7 receptor (5-Hydroxytryptamine receptors)2005Psychopharmacology, May, Volume: 179, Issue:2
Stable expression of constitutively activated mutant h5HT6 and h5HT7 serotonin receptors: inverse agonist activity of antipsychotic drugs.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)2000The Journal of pharmacology and experimental therapeutics, Oct, Volume: 295, Issue:1
Inverse agonist activity of atypical antipsychotic drugs at human 5-hydroxytryptamine2C receptors.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1794859Proteasome Activity Assay from Article 10.1021/acschembio.7b00489: \\Small Molecule Enhancement of 20S Proteasome Activity Targets Intrinsically Disordered Proteins.\\2017ACS chemical biology, 09-15, Volume: 12, Issue:9
Small Molecule Enhancement of 20S Proteasome Activity Targets Intrinsically Disordered Proteins.
AID1804171DRC analysis by immunofluorescence from Article 10.1128/AAC.00819-20: \\Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.\\2020Antimicrobial agents and chemotherapy, 06-23, Volume: 64, Issue:7
Identification of Antiviral Drug Candidates against SARS-CoV-2 from FDA-Approved Drugs.
AID1508629Cell Viability qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508628Confirmatory qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1508627Counterscreen qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: GLuc-NoTag assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (2,297)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901655 (72.05)18.7374
1990's216 (9.40)18.2507
2000's200 (8.71)29.6817
2010's185 (8.05)24.3611
2020's41 (1.78)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 67.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index67.50 (24.57)
Research Supply Index7.92 (2.92)
Research Growth Index4.35 (4.65)
Search Engine Demand Index120.72 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (67.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials255 (10.20%)5.53%
Reviews117 (4.68%)6.00%
Case Studies301 (12.04%)4.05%
Observational0 (0.00%)0.25%
Other1,828 (73.09%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (6)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Phase I Trial Evaluating Oral Thioridazine in Combination With Intermediate Dose Cytarabine in Patients 55 Years and Older With Acute Myeloid Leukemia Who Have Relapsed or Have Refractory Disease [NCT02096289]Phase 113 participants (Actual)Interventional2014-07-31Completed
Evaluation of the Necessity of Long-term Pharmacological Treatment With Antipsychotics for the Prevention of Relapse in Long-term Stabilized Schizophrenic Patients: a Randomized, Single-blind, Longitudinal Trial [NCT02307396]Phase 421 participants (Actual)Interventional2015-02-01Completed
Atypical Antipsychotics and Hyperglycemic Emergencies: Multicentre, Retrospective Cohort Study of Administrative Data [NCT02582736]725,489 participants (Actual)Observational2012-04-30Completed
A 12-Month Randomized, Open-Label Study of Caregiver Psycho-education and Skills Training in Patients Recently Diagnosed With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder and Receiving Paliperidone Palmitate or Oral Antipsychotic [NCT02600741]296 participants (Actual)Observational2015-07-24Completed
A Single Institution Feasibility Study to Assess Thioridazine as a Mobilizing Agent for CD34+ Hematopoietic Progenitor Cells [NCT01765803]Early Phase 16 participants (Actual)Interventional2013-06-30Terminated(stopped due to Primary objective not met after planned interim analysis)
Pharmacovigilance in Gerontopsychiatric Patients [NCT02374567]Phase 3407 participants (Actual)Interventional2015-01-31Terminated
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT01765803 (2) [back to overview]CD34+ Progenitor Cell Mobilization
NCT01765803 (2) [back to overview]Toxicity

CD34+ Progenitor Cell Mobilization

To measure CD34+ cells, a peripheral blood draw is taken from the enrolled subject at hour zero on day one of the study before treatment with oral thioridazine. Following treatment, blood draws are taken at 2, 4, 8 and 24 hours. These blood samples are analyzed using Clinical Laboratory Improvement Amendments (CLIA)-approved flow cytometry for CD34+ cell content. CD34+ cell levels will be reported as a percentage of total white blood cells (WBC) in the blood specimens and the difference between baseline and 8 hours will be reported (NCT01765803)
Timeframe: 8 hours following treatment

Interventionpercentage of total WBC count (Mean)
CD34+ cells at baselineCD34+ cells at 8 hoursDifference between baseline and 8 hours
Mellaril (Thioridazine)0.050.050

[back to top]

Toxicity

"Toxicity will be evaluated according to the grading system (0-5) NCI CTCAE (Common Terminology Criteria for Adverse Events) version 4.~Any subject who receives treatment on this protocol will be evaluable for toxicity." (NCT01765803)
Timeframe: Up to 1 month after treatment

Interventionparticipants (Number)
Grade 1 somnolenceReturned to baseline within 24 hours
Mellaril (Thioridazine)44

[back to top]